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I Zusammenfassende Darstellung 
1 Einleitung 
Tumor-spezifische Biomarker können in Verbindung mit ihren Kooperationspartnern nicht 
nur medizinisch zur Früherkennung bei Krebserkrankungen genutzt werden, sondern auch 
zum besseren Verständnis der Tumorentstehung und Progression beitragen. In diesem 
medizinisch-biologischen Umfeld ist die vorliegende Arbeit einzuordnen. 
In der folgenden Einleitung werden Probleme bei der Diagnose von Tumorerkrankungen 
mittels bekannter Biomarker benannt und Strategien für ein erfolgreiches Auffinden von 
potentiellen Tumormarker-Kandidaten aufgezeigt. Am Beispiel der Familie der S100-
Proteine, deren Mitglieder diskriminierend in spezifischen Tumorentitäten auftreten, werden 
potentielle Tumormarker-Kandidaten vorgestellt und diese durch die Identifizierung von 
Interaktionspartnern biologisch charakterisiert. 
1.1 Probleme in der Diagnostik von Tumorerkrankungen 
Trotz der Anwendungen neuester Erkenntnisse und Methoden aus Genomik, Proteomik und 
molekularer Medizin zeigen die Mortalitätsraten der häufigsten Tumorentitäten im Moment 
keine signifikante Reduzierung (Jemal et al. 2005). Somit ist der „Kampf gegen Krebs“ 
gegenwärtig nur bedingt erfolgreich. Eine der zurzeit besten Strategien in diesem Kampf ist 
eine frühe Diagnose und die Gewährleistung einer effektiven Behandlung. Ein weiterer 
Ansatz hierbei ist die Überwachung von Krebspatienten nach einer initialen, gewöhnlich 
chirurgischen Behandlung, um ein Rezidiv frühzeitig zu erkennen und eine zusätzliche 
Therapie festzulegen. Einen dritten wertvollen Ansatz in diesem Kampf stellt die 
Stratifizierung von Patienten hinsichtlich ihres Ansprechens auf unterschiedliche 
Behandlungsprozeduren dar, welche zu einer differenzierten, individuell orientierten 
Tumortherapie führen soll (Etzioni et al. 2003). Neben dem zunehmenden und teilweise 
erfolgreichen Einsatz von molekularbiologischen Erkenntnissen als Therapieansatz wie 
beispielsweise der Blockierung des BCR-ABL-Signalweges durch Imatinib (Druker et al. 
1996; Sawyers et al. 2002) können auch Biomarker aus Körperflüssigkeiten wie Serum, 
Plasma, Urin und/oder Mamilla-Aspirat sowie aus Gewebe hierbei wertvolle Instrumente 
sein. Gegenwärtig sind Biomarker aus Serum aber noch nicht ausreichend sensitiv und/oder 
spezifisch, um Krebserkrankungen frühzeitig zu diagnostizieren (Diamandis, van der Merwe 
2005). Die im Moment zur Verfügung stehenden Tumor-Biomarker wie beispielsweise PSA 
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(prostate serum antigen) zur Detektion von Prostatakarzinomen, CEA (carcinoembryonic 
antigen) bei der Detektion von Kolon-, Mamma-, Lungen-, Pankreaskarzinomen und cancer 
antigens (CA) wie CA125 beim Ovarialkarzinom, CA15.3 beim Mammakarzinom oder 
CA19.9 beim gastrointestinalem Karzinom werden zwar routinemäßig für eine frühe 
Diagnose sowie für Vorsorgeuntersuchungen benutzt, besitzen aber auf Grund geringer 
Sensitivität und/oder Spezifität keine ausreichendes Vorhersage-Potential (Diamandis 2004). 
Die geringe Spezifität dieser Biomarker führt nicht selten zu falsch-positiven Resultaten. 
Das biologische Verständnis der Tumorentstehung gilt es also zu verbessern, das im 
Zusammenhang mit der Entwicklung möglichst sensitiver und spezifischer Biomarker steht. 
1.2 Strategien für das Auffinden neuer Biomarker 
Viele Biomarker wurden in biologischen Flüssigkeiten von Tumorpatienten mit erhöhter 
Konzentration im Vergleich zu Kontrollpersonen gefunden. Daraus wurde die Hypothese 
abgeleitet, dass die wertvollsten Biomarker wahrscheinlich sekretorische Proteine, die ca. 20-
25 % aller humanen Proteine entsprechen, sein werden (Welsh et al. 2003). Es wird 
angenommen, dass eine Vielzahl an momentan noch nicht identifizierten bzw. ungenutzten 
Peptiden/Proteinen im Blut existiert, die potentielle diagnostische Biomarker darstellen 
(Liotta et al. 2003). 
Die Massenspektrometrie (MS) stellt derzeit die wichtigste analytisch-proteomische Methode 
in der Biologie dar (Aebersold, Mann 2003). Mittels dieser Methode können 
multiparametrische Analysen von komplexen biologischen Proben durchgeführt werden und 
dabei spezifische Proteinprofile detektiert sowie Proteine und Peptide identifiziert werden. 
Die Massenspektrometrie kann in der Tumor-Diagnostik zur Suche nach neuen Markern 
eingesetzt werden, indem beispielsweise biologische Flüssigkeiten wie Serum, Plasma etc. 
mit Hilfe chromatographischer oder elektrophoretischer Techniken fraktioniert und 
anschließend mittels MS analysiert werden, um neue Proteinmarker zu identifizieren. Eine 
Vielzahl an Studien von biologischen Flüssigkeiten wurden mit unterschiedlichen 
massenspektrometrischen Systemen wie MALDI-TOF (matrix assisted laser 
desorption/ionization – time of flight) oder SELDI-TOF (surface-enhanced laser 
desorption/ionization-time of flight) durchgeführt und hierbei erfolgreich potentielle 
Biomarker in unterschiedlichen Tumorentititäten identifiziert (Vlahou et al. 2001; Alexander 
et al. 2004; Zhang et al. 2004; Kooman 2005; Malik 2005; Chen et al. 2007). Es stellte sich 
dabei aber heraus, dass die Detektion und Identifizierung von Proteinmarkern aus 
biologischen Flüssigkeiten auf Grund der Komplexität dieser Proben limitiert ist (Kooman et 
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al. 2005). Plasma umfasst beispielsweise eine dynamische Breite an unterschiedlichen 
Proteinen von zehn Magnituden und ist mit einer einzelnen analytischen Technik ohne 
Fraktionierung, Protein-Konzentrierung oder -Depletion nicht bearbeitbar (Anderson and 
Anderson 2002); Serum beinhaltet Proteine, die einen Konzentrationsbereich von wenigen 
pmol/L bis zu hohen µmol/L (z.B. Albumin, 0,6 mmol/L) aufweisen (Service 2003). Es wird 
angenommen, dass massenspektrometrische Ansätze nicht sensitiv genug sind, um die in den 
Blutstrom abgegebenen potenziellen Proteinmarker, die mit Konzentrationen von weniger als 
einem Nanogramm pro Milliliter vorliegen, zu identifizieren (Diamandis, van der Merwe 
2005). So ist es auch nicht verwunderlich, dass viele der im Serum bzw. Plasma 
identifizierten Proteinmarker sogenannte high-abundance Proteine sind, die wenigstens 
teilweise Akute-Phase-Proteine repräsentieren (Zhang et al. 2003; Ye et al. 2003; Hlavaty et 
al. 2003; Cho et al. 2004). Diese Akute-Phase-Moleküle werden von der Leber und anderen 
Organen in die Blutzirkulation abgegeben und stellen keine spezifischen Tumor-Biomarker 
dar (Diamandis 2004).  
Es wird spekuliert, dass ein potentieller Proteinmarker-Kandidat an dem Ort, in dem der 
Krankheitsprozess ursprünglich stattfindet, in einer höheren Konzentration vorliegt als nach 
Verdünnung im peripheren Blut. Daher müsste ein Konzept zur Aufdeckung onkologischer 
Marker Gewebe-basierend sein (Zolg 2006). Eine detaillierte histopathologische Beurteilung 
der zu untersuchenden Gewebe ist entscheidend für erfolgreiche Proteinmarker-
Identifizierung in der anschließenden proteomischen Analyse. Durch die vor allem 
Tumorgewebe auszeichnende Heterogenität ist eine genaue Separierung einzelner, 
histologisch unterschiedlicher Gewebeareale essentiell, um einheitliche, von ungewünschten 
Gewebekomponenten befreite Proben zu erhalten, was durch den Einsatz Laser-basierender 
Mikrodissektion gewährleistet wird (von Eggeling et al. 2007). Auch wenn die Kompatibilität 
von Gewebe-Mikrodissektion und Massenspektrometrie in einer Reihe von Studien gezeigt 
wurde (Xu et al. 2002; Cheung et al. 2004; Zhang et al. 2005; Mustafa et al. 2007), wird diese 
Technik bei der proteomischen Untersuchung von Gewebe nicht routinemäßig angewandt. 
Dieser Fakt kann begründet sein durch (I) die Erfordernis von pathohistologischer Kompetenz 
bei der Beurteilung der Gewebe, (II) den zeitlichen Aufwand, den die Durchführung von 
Mikrodissektion erfordert sowie (III) die Kosten, die durch Anschaffung und Erhalt der 
Mikrodissektionstechnik entstehen. 
Ein massenspektrometrisches Verfahren, dessen Kompatibilität mit Mikrodissektion schon 
gezeigt wurde, ist die SELDI-MS (Abb. 1; Melle et al. 2003; Cheung et al. 2004; Krieg et al. 
2004; Guedj et al. 2006). 
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Abb. 1. Schematische Darstellung der Arbeitsweise der surface-enhanced laser desorption/ionization (SELDI) 
Massenspektrometrie (MS). Die Proteine aus einem Zelllysat binden entsprechend ihrer physikochemischen 
Eigenschaften auf den chromatographischen Spots eines ProteinChip array. Nach Waschen und Einbettung in 
eine Energie-absorbierende Matrix werden die Proteine mittels eines Laser-Impulses ionisiert und im MS mittels 
time-of-flight (TOF) vermessen. Hierbei werden niedermolekulare Proteine nach Durchquerung der 
elektromagnetischen Flugröhre früher am Detektor aufgezeichnet als höhermolekulare. 
Diese MS-Technik erfordert nur geringe Probenmengen und macht sie daher ideal zur 
Bearbeitung von mikrosezierten Präparaten. Die SELDI-Massenspektrometrie basiert auf 
sogenannten ProteinChip arrays, die unterschiedliche chromatographische Oberflächen 
besitzen (Hutchens, Yip 1993). Diese Oberflächen binden Proteine aus Zell-Rohextrakten 
entsprechend deren physikochemischen Eigenschaften, die anschließend direkt mittels 
Massenspektrometrie analysiert werden. Proteine, die so auf den Affinitäts-Oberflächen der 
ProteinChip arrays zurückgehalten werden, können leicht von Kontaminanten wie Salzen 
oder Detergensien, die aus entsprechenden Lysis- bzw. Lade-/Wasch-Puffern stammen, 
gereinigt werden und müssen im Vergleich zu anderen massenspektrometrischen Techniken 
nicht vorgereinigt werden. 
1.3 Die Familie der S100 Ca
2+
-bindenden Proteine und ihr Auftreten in Tumoren 
Die S100-Proteinfamilie umfasst mindestens 26 Mitglieder, deren Gene größtenteils im 
sogenannten epidermal differentiation complex auf Chromosom 1q21 lokalisiert sind. Die 
S100-Familie ist die Mitglieder-stärkste Untergruppe der Kalzium-bindenden Proteine mit 
EF-Hand-Domäne (Schäfer et al. 1995; Heizmann et al. 2002). Ihr Name leitet sich von ihrer 
Eigenschaft ab, bei neutralem pH in 100 % Ammoniumsulfat löslich zu sein (Moore 1965). 
Trotz ihrer hohen Sequenz-Homologie erscheint ihr Expressionmuster Zell-, Gewebe- sowie 
Kontext-spezifisch (Dowen, Crnogorac-Jurcevic 2006). Die S100 sind niedrig-molekulare, 
saure Proteine, die Homo- und Heterodimere bilden. Nach Ca2+-Bindung kommt es zu 
Konformationsänderungen, in deren Folge eine hydrophobe Region exponiert wird, die mit 
spezifischen Proteinen interagieren kann (Heizmann et al. 2002). 
Intensität
[µA] 
Molekulargewicht [Da] 
Zelllysat 
 Detektor
Laser 
TOF-MS 
ProteinChip array 
Vacuum
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S100-Proteine wurden mit unterschiedlichen zellulären Prozessen in Verbindung gebracht, 
inklusive Zellzyklus-Regulation, Zellwachstum und -differenzierung, Transkription sowie 
Zellbewegung und Invasivität (Heizmann, Cox 1998). Die funktionelle Komplexität der 
S100-Proteine wird durch verschiedene Charakteristika bestimmt. Neben der Zell- und 
Gewebe-spezifischen Expression lokalisieren S100-Proteine im Zytosol wie auch im Nukleus. 
Außerdem bindet S100-Protein Kalzium und andere zweiwertige Kationen mit verschiedener 
Affinität, was in unterschiedlichen Konformationsänderungen und dadurch unterschiedlichen 
Protein-Interaktionspartnern resultiert. 
Die Rolle der S100-Proteine in der Tumorgenese wird extensiv untersucht (Salama et al. 
2007). Differentielle Expressionen verschiedener S100-Proteine wurden in unterschiedlichen 
Tumortypen beschrieben und es scheint, dass diese Proteine in Abhängigkeit der untersuchten 
Tumoren onkogenetisches wie auch tumorsuppressives Potential besitzen (Dowen, 
Crnogorac-Jurcevic 2006). Dieses Phänomen spiegelt sich auch in ihrem Verhalten gegenüber 
Interaktionspartnern wider. So wurden unter anderen Proteininteraktionen zwischen Jab1, 
Cox-1 und den Tumorsuppressorproteinen BRCA1 sowie p53 und einer Reihe von S100-
Proteinen gezeigt (Donato 2003; Emberley et al. 2003; Kennedy et al. 2005; Tsai et al. 2006). 
Beispielsweise hemmen S100A4 wie auch S100B die Phosphorylierung von p53 was zur 
Inhibition der transkriptionellen Aktivität und dadurch zur Einschränkung der 
tumorsuppressiven Aktivität von p53 führt (Grigorian et al. 2001). Im Gegensatz dazu 
unterstützt S100A2 die transkriptionelle Aktivität von p53 (Mueller et al. 2005). Eine 
Vielzahl der S100-Proteine spielt eine Rolle bei der Zytoskelett-Dynamik und zeigt direkte 
Interaktionen mit Tubulin, Intermediär-Filamenten, Actin und Myosin (Santamaria-Kisiel et 
al. 2006). Einige dieser Prozesse scheinen bei der Metastasierung beteiligt zu sein (Davies et 
al. 1996; Kriajevska et al. 1998). Außerdem können Mitglieder der S100-Familie die 
Zellproliferation regulieren. So zeigt S100A1 eine Hemmung der Proliferation (Donato 2001). 
Interessanterweise besitzt S100A11 dahingehend eine duale Funktion, indem es die 
Zellproliferation von Keratinozyten einerseits intrazellulär inhibieren und andererseits 
autokrin stimulieren kann (Sakaguchi et al. 2005; Sakaguchi et al. 2008). Andere extrazellulär 
vorliegende S100-Mitglieder können als Leukozyten-Chemoattraktante sowie Makrophagen-
Aktivatoren wirken (Devery et al. 1994; Lau et al. 1995; Hiratsuka et al. 2006). 
Es scheint, dass jedes S100-Protein individuelle Rollen bei Tumorgenese und Metastasierung 
spielen kann. Die Expression der S100-Proteine ist nicht einheitlich und scheint in 
Abhängigkeit zu den untersuchten Tumortypen zu stehen. So zeigt S100B eine erhöhte 
Konzentration im Serum von Patienten mit Melanomen, die Tumorgrad-abhängig und mit 
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Metastasierung assoziiert ist (Bonfrer et al. 1998; Schlagenhauff et al. 2000). Eine 
Überexpression verschiedener S100-Proteine wie S100A4, S100A8, S100A9, S100A6 und 
S100A7 in unterschiedlichen Tumorentitäten, z.B. Kolorektal-, Prostata-, Magen- und 
Brustkarzinomen, die häufig mit einem erhöhten Metastasierungspotential korreliert, wurde 
beobachtet (Stulik et al. 1999; Komatsu et al. 2000; Nikitenko et al. 2000; Gongoll et al. 
2002; Cho et al. 2003; Emberley et al. 2003; Hermani et al. 2006; Rafii, Lyden 2006; Saleem 
et al. 2006; Yong, Moon 2007). Im Gegensatz dazu ist die Expression von S100A2 bei 
einigen Tumoren (z. B. Bronchialkarzinom) herunterreguliert, jedoch in papillären 
Karzinomen und im NSCLC (non-small cell lung carcinoma) überexprimiert (Feng et al. 
2001; Smith et al. 2004; Ito et al. 2005). S100A11 zeigt unterschiedliche, vom Tumortyp 
abhängige Wirkungen. Im Blasenkarzinom scheint die S100A11-Proteinexpression mit 
Tumorsuppression zu korrespondieren, wodurch hier eine verminderte Expression mit 
verschlechterter Prognose und einer verringerten Überlebensrate assoziiert ist (Memon et al. 
2005). Konträr dazu scheint S100A11 in Prostata-Tumoren eine Tumor-unterstützende 
Wirkung zu besitzen und die Expression in dieser Tumorentität geht mit einem höheren 
pathologischen Tumorgrad einher (Rehman et al. 2004). 
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2 Zielstellung der Arbeit 
Ziel der vorliegenden Arbeit war es, diskriminierende Proteinmarker, die möglichst 
Tumorentitäts-spezifisch auftreten, zu identifizieren und bioinformatisch zu validieren und 
dadurch zu entwickeln sowie mittels proteomischer, immunologischer und zellbiologischer 
Techniken zu charakterisieren. Dafür wurden vier Schwerpunkte bearbeitet. 
Der erste Schwerpunkt stellte die Charakterisierung verschiedener Tumorentitäten mittels 
proteomischer und immunologischer Analysen dar. Hierfür wurde eine methodische Prozedur 
entwickelt, die die Identifizierung und Beurteilung von Biomarkern erlaubt. Dabei wurden die 
mittels ProteinChip-basierender SELDI (surface-enhanced laser desorption/ionisation) 
Massenspektrometrie erzeugten Proteinprofile von epithelialen Tumorzellen aus Hals-Kopf-
Tumoren sowie kolorektalen Karzinomen nach exakter Mikrodissektion mit den 
Proteinprofilen von entsprechenden, ebenfalls mikrosezierten Tumor-distanten normalen 
Pharynx- und Kolon-Epithelien verglichen. Die für Tumor- und Normalgewebe jeweils 
spezifischen Signale wurden identifiziert und ihre räumliche Verteilung im Tumor durch 
Immunhistochemie (IHC) dargestellt. 
Der zweiter Schwerpunkt dieser Arbeit bestand darin, die zuerst im Gewebe identifizierten 
Proteinmarker hinsichtlich ihres Auftretens in Patientenseren zu untersuchen. Dafür erfolgten 
massenspektrometrisch Untersuchungen wie auch ELISA-Analysen. 
Die Untersuchung unterschiedlicher Tumorentitäten hinsichtlich ihrer proteomischen 
Ähnlichkeit/Übereinstimmung einerseits, sowie die Identifizierung von Proteinen, die 
andererseits zur Diskriminierung von unterschiedlichen Tumorentitäten geeignet sind, wurden 
als dritter Schwerpunkt dieser Arbeit formuliert. 
Als vierter Schwerpunkt erfolgte eine biologische und funktionelle Charakterisierung der in 
den Proteinprofiling-Experimenten gefundenen Biomarkern. Hierfür wurde ein Ansatz, der 
massenspektrometrische und immunologische Techniken vereinigte, entwickelt, um endogene 
Interaktionspartner der gefundenen Biomarker zu identifizieren. Diese Proteinkomplexe 
wurden anschließend hinsichtlich ihrer biologischen Funktion in Abhängigkeit spezifischer 
physiologischer Bedingungen wie der Einführung von DNA-Schäden oder der Depletion 
eines Interaktionspartners mittels RNA Interferenz verifiziert. 
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3 Ergebnisse 
3.1 Identifizierung und Charakterisierung von Biomarkern mittels der technischen 
Triade 
Im ersten Schwerpunkt wurden die methodischen Voraussetzungen für die proteomische 
Analyse von Tumorproben geschaffen (Melle et al., Cancer Res. 2004; 64: 4099-4104 – 
siehe Anhang 1.1). Bedingt durch die Komplexität von Serum wie auch Plasma hinsichtlich 
der Proteinzusammensetzung und der Dynamik in der Konzentration unterschiedlicher 
Proteine fokusierten wir unsere Untersuchungen auf Tumorgewebe. Da Tumorgewebe sich 
auf Grund seiner Zusammensetzung aus Tumorzellarealen, Tumorstroma und Tumornekrosen 
durch eine innewohnende Heterogenität auszeichnet, analysierten wir ausschliesslich Proben 
von mikroseziertem Gewebe. Hierfür wurde das Laser-Mikrodissektionssystem von P.A.L.M. 
benutzt. Dadurch konnten wir sicherstellen, dass das untersuchte Gewebematerial 
weitestgehend frei von Kontaminationen und ungewünschten Gewebekomponenten war, was 
außerordentlich wichtig für das Auffinden von zuverlässigen Biomarkern für die 
Krebsdiagnose ist (Craven and Banks 2001). Im Fall der in dieser Arbeit untersuchten 
epithelialen Tumoren der Pharynx wurden die epithelialen Tumorzellen von benachbarten 
Gewebekomponenten separiert. Im Gegensatz zu normalem Epithel ist die Abgrenzung der 
epithelialen Tumorzellkomplexe zum Tumorstroma und anderen Gewebeabschnitten 
unregelmäßig. Durch den Einsatz der Laser-basierenden Mikrodissektion konnten wir jedoch 
nahezu kontaminationsfreies Material gewinnen, welches ca. 3000-5000 Zellen pro Probe 
umfasste. Ähnliche Mengen an mikrosezierten Zellen wurden ebenfalls durch andere 
Arbeitsgruppen zur Darstellung von aussagekräftigen Proteinprofilen benutzt (Cazares et al. 
2002; Cheung et al. 2004). 
Die Proteinprofile der 101 mikrosezierten Gewebeproben (57 epitheliale Tumorgewebe und 
44 normale, Tumor-distante Pharynxepithel-Gewebe) wurden durch den Einsatz von 
ProteinChip arrays mit Anionenaustauscher- bzw. Kationenaustauscher-Oberfläche und der 
Analyse mittels SELDI-MS erzeugt. Die Cluster-Analyse der detektierten Signale und die 
Ermittlung der P-Werte für die Proben aus normalem und Tumorgewebe erfolgten mittels des 
Biomarker Wizzard Program (version 3.0). Für die P-Wert Kalkulation wurden die Spektren 
mit dem Mann-Whitney U test für nicht-parametrische Datensätze analysiert. Damit konnten 
wir 96 Proteinsignal-Cluster nach Normalisierung im Messbereich zwischen 2 und 20 Kilo-
Dalton (kD) detektieren. Hierbei wurden 15 Signale gefunden, mit denen Tumor- und 
normales Gewebe signifikant unterschieden werden können. Da ein diskriminierendes Signal 
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nur als nutzbarer Proteinmarker betrachtet werden kann, wenn es identifiziert ist (Diamandis 
2006), wurden die beiden Signalmassen mit den besten P-Werten für eine weitere 
Identifizierung ausgewählt. Diese zwei interessanten Signale, 10,84 kD (P = 3,34x10-5) und 
13,23 kD (P = 4,6x10-5), lagen im epithelialen Tumorgewebe im Vergleich zu normalem 
Pharynxgewebe mit herunterregulierter Proteinexpression vor. Als Kontrolle zur Beurteilung 
der angewandten Methoden wurde ein Signal (11,87 kD) mit nicht-signifikantem P-Wert (P = 
0,379) ebenfalls identifiziert. 
Zur Identifizierung wurden Proteinlysate von histologisch beurteilten Tumorgeweben und 
Biopsien von normalen, Tumor-distanten Pharynxepithelien mittels zwei-dimensionaler 
Gelelektrophorese (2DE) aufgetrennt. Mehrere Proteinspots mit differentieller Expression 
konnten in den mit Coomassie gefärbten Gelen visuell detektiert werden. Auf Grund der 
Bindung der drei zu identifizierenden Proteine an ProteinChip arrays mit 
Anionenaustauscher-Oberfläche in den vorangegangenen Proteinprofiling-Experimenten 
konnten wir einen isoelektrischen Punkt der Proteinkandidaten von < 7,5 erwarten. Aus 
diesem Grund konzentrierten wir uns in den 2DE-Gelen auf Proteinspots mit einem 
molekularen Gewicht im Bereich von 5 – 20 kD und einem isoelektrischen Punkt im Bereich 
von 3 – 7,5. Proteinspots, die diese Kriterien erfüllten, wurden aus dem Gel geschnitten und 
einem tryptischen Verdau unterzogen. Die beim Verdau entstandenen Fragmente wurden 
mittels SELDI-MS analysiert und die so gewonnenen peptide mass fingerprints (PMF) zur 
Suche in Protein-Datenbanken benutzen. Der erfolgreiche Einsatz dieser Technik hinsichtlich 
der Generierung von PMF konnte schon in einer früheren Arbeit gezeigt werden (Melle et al. 
2003). Die Suche in einer Datenbank deckte S100A8 (Calgranulin A), S100A9 (Calgranulin 
B) bzw. S100A11 (Calgizzarin) als die besten Kandidaten auf. Diese Ergebnisse konnten 
mittels Tandem-MS-Analyse bestätigt werden. S100A8, S100A9 und S100A11 gehören zur 
Familie der S100 Ca2+-binde Proteine (Donato 2001). Zur Überprüfung, dass S100A8, 
S100A9 bzw. S100A11 mit den in der Proteinprofil-Analyse gefundenen Signale von 10,84 
kD, 13,23 kD bzw. 11,87 kD übereinstimmen, wurden Immundepletions-Experimente mit 
spezifischen Antikörpern gegen S100A8, S100A9 bzw. S100A11 und Proteinlysaten von 
mikrosezierten Pharynxepithelium, die als Ausgangsmaterial dienten, durchgeführt. Hierbei 
zeigte sich in der Analyse mittels SELDI-MS, dass die Signale, die zu den drei identifizierten 
Proteinen korrespondieren, signifikant reduziert wurden. Zur weiteren Bestätigung der 
Identität und zur Lokalisierung dieser Proteine im Phayrnxgewebe führten wir 
immunhistochemische Untersuchungen durch. Hierbei zeigte sich eine identische Immun-
Reaktivität von S100A8 und S100A9 im normalen, Tumor-distanten Epithel. Im Vergleich 
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dazu konnten im Tumorgewebe keine Signale, die zu S100A8 bzw. S100A9 korrespondieren, 
detektiert werden. Dieses identische Verhalten von S100A8 und S100A9 ist nicht 
verwunderlich, da beide Proteine unter physiologischen Bedingungen ein ähnliches 
Proteinexpression-Niveau zeigen sowie Heterodimere bilden können (Thorey et al. 2001; 
Dell´Angelica et al. 1996). S100A11, das als Kontrolle diente, zeigte in Tumor wie auch in 
normalen epithelialen Geweben positive Immunreaktionen. Als weitere Überprüfung, dass 
S100A8, S100A9 und S100A11 identisch zu den in der Proteinprofil-Analyse gefundenen 
Signalen sind, wurden IHC-positive bzw. –negative Zellareale mittels Mikrodissektion 
separiert und entsprechende Proteinlysate hinsichtlich der drei identifizierten Signale 
massenspektrometrisch untersucht. Hierbei konnten in Lysaten aus positiven Arealen Signale 
detektiert werden, die den in der initialen Proteinprofil-Analyse gefundenen Signalen 
entsprechen. Keine entsprechenden Signale wurden in Lysaten aus IHC-negativen 
Zellfraktionen gefunden. 
Das in dieser Untersuchung gezeigte Ergebnis einer verminderten Proteinexpression von 
S100A8 und S100A9 steht im Kontrast zu früher publizierten Studien, die eine erhöhte 
Expression der beiden Proteine hinsichtlich ihres Gen-Niveaus wie auch ihres Protein-
Niveaus in Tumoren im Vergleich zu korrespondierenden normalen Geweben zeigten (Stulik 
et al. 1999; Chaurand et al. 2001; Mueller et al. 2003). Diese Diskrepanz kann erklärt werden 
durch den Fakt, dass (I) unsere Analyse auf einer anderen Tumorentität basiert, (II) dass das 
mRNA-Niveau auf Grund translationaler Kontrollmechanismen nicht notwendigerweise mit 
dem Niveau der Proteinexpression korrelieren muss und (III) dass wir im Gegensatz zu den 
oben erwähnten Studien mikroseziertes Material benutzten und unsere Ergebnisse mit IHC 
bestätigten. Interessanterweise ist zu erwähnen, dass in einer Genexpressions-Studie zu Hals-
Kopf-Tumoren eine verringerte Expression von S100A9 mittels IHC bestätigt wurde 
(Gonzalez et al. 2003). 
Durch den Einsatz der hier aufgezeigten „technischen Triade“, die sich aus 
Gewebemikrodissektion zur Gewinnung von definiertem Probenmaterial, Analyse dieses 
Materials zur Identifizierung spezifischer Proteinmarker mittels SELDI-MS, 2DE sowie 
Tandem-MS und Untersuchung dieser Marker mittels IHC zusammensetzt, ist es möglich, 
Tumormarker zu ermitteln und zu charakterisieren (Abb. 2; Melle et al., Cancer Res. 2004; 
64: 4099-4104 – siehe Anhang 1.1). 
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Abb. 2. „Technische Triade“ zur proteomischen Identifizierung und Charakterisierung von Tumormarkern. 
Beginnend mit der Mikrodissektion wird Probenmaterial gewonnen, das mittels SELDI-MS analysiert wird. 
Proteinmarker werden mittels 2DE, Tandem-MS und Immundepletion identifiziert und anschliessend durch IHC 
charakterisiert. Mikrodissektion von immunhistochemisch behandelten Gewebearealen und Re-Analyse dieser 
mittels ProteinChip arrays und SELDI-MS schließen den Kreis. (modifiziert nach Melle et al. 2004) 
Diese „technische Triade“ wurde von uns in zahlreichen weiteren Untersuchungen 
verschiedener Tumorentitäten erfolgreich validiert (Melle et al. 2005b; Melle et al. 2006b; 
Melle et al. 2007a; Melle et al. 2007b). In einer dieser Untersuchungen wurden jeweils 
mikrosezierte Gewebeproben aus epithelialen Tumorzellen von kolorektalen Karzinomen 
(CRC) (n = 13) bzw. Adenomen (n = 30) und normalen, Tumor-distanten Kolongewebe (n = 
19) miteinander verglichen (Melle et al., Int. J. Oncol. 2006; 28: 195-200 – siehe Anhang 
1.2). In dieser Studie detektierten wir nach Normalisierung 158 Proteinsignal-Cluster im 
Messbereich zwischen 2,5 – 200 kD. Unter den 18 signifikant differentiell exprimierten 
Signalen konnte S100A11 (S100C; Calgizzarin) im kolorektalen Karzinom mit einer 
signifikant erhöhten Proteinexpression im Vergleich zu kolorektalem Adenom bzw. 
normalem Kolonepithelium identifiziert werden. Auffällig ist, dass hier S100A11 im 
Vergleich zur oben erwähnten Studie zu Hals-Kopf-Tumoren (Melle et al. 2004), in der 
S100A11 nicht-differentiell exprimiert gefunden wurde, zwischen kolorektalem Karzinom, 
kolorektalem Adenom und normalem Kolongewebe diskriminieren kann. 
3.2 Validierung von Proteinmarkern aus Tumorgewebe im Serum 
Eine Detektion früher Tumorstadien ist durch die Analyse nicht-invasiv gewonnenen 
Materials wie Serum vorstellbar. Auch wenn Serum breit verfügbar und einfach zu sammeln 
und zu asservieren ist, könnte die Konzentration an Tumor-spezifischen Proteinen, vor allem 
in frühen Phasen, zu gering sein. Im Gegensatz dazu können im Gewebe geringste, Tumor-
relevante Veränderungen im Proteinprofil detektiert werden. Aus diesem Grund fokusierten 
wir im zweiten Schwerpunkt auf die Verbindung der Vorteile von Serum- und Gewebe-
Gewebe- 
Mikrodissektion 
Immunhistochemie 
SELDI-MS, 2DE, 
Tandem-MS 
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Analyse, indem wir in mikroseziertem Gewebe differentiell exprimierte Proteine aufdeckten 
und nach diesen anschließend in Seren mittels Antikörper-basierenden Tests suchten (Melle 
et al., Gastroenterology 2005; 129: 66-73 – siehe Anhang 1.3). Hierzu wurde zu Beginn das 
Proteinprofil von 39 kolorektalen Karzinomen (CRC) und 40 normalen, Tumor-distanten 
Kolonepithelgeweben mittels ProteinChip array-basierender SELDI-Massenspektrometrie 
ermittelt. Nach Normalisierung und bioinformatorischer Bearbeitung mittels des Biomarker 
Wizzard Program ergaben sich hierfür im Messbereich von 2 – 20 kD 126 Proteinsignal-
Cluster, die 13 Signale enthielten, die zwischen epithelialen Tumorzellen aus kolorektalen 
Karzinomen und normalen Kolonepithelien diskriminieren konnten. Drei Signale mit 
bemerkenswert geringen P-Werten [3,37 kD (P = 4,39x10-5); 3,44 kD (P = 1,88x10-5); 3,49 
kD (P = 9,91x10-5)], die in kolorektalen Karzinomproben überexprimiert vorlagen, ähnelten 
in ihrem Proteinmuster und ihrem Molekulargewicht den zur Familie der Defensine zählenden 
α-Defensine 1-3 (HNP1-3, human neutrophil protein 1-3), die in früheren Arbeiten mittels 
SELDI oder Tandem-MS beschrieben bzw. identifiziert wurden (Vlahou et al. 2001; Diamond 
et al., 2001; Zhang et al. 2002). Die Identität dieser drei Signale als HNP1-3 konnte von uns 
mittels Immundepletions- und immuno capturing-Experimenten bestätigt werden. HNP1-3 
sind kleine Peptide, die zu den Defensinen gehören und in intestinalen Epithelzellen unter 
verschiedensten Bedingungen exprimiert werden. Neuere Studien zeigen die Expression von 
HNP1-3 in epithelialen Zellen des Ileum und des Kolon bei entzündlichen Erkrankungen, 
ohne diese im normalen intestinalen Gewebe detektieren zu können (Ogawa et al. 2000; 
Cunliffe et al. 2002). Da wir in unserer Studie mikroseziertes Material benutzten und hierbei 
entzündlich infiltrierte Abschnitte, die Neutrophile enthalten können, ausschlossen, konnten 
wir nachweisen, dass die im kolorektalem Karzinom überexprimiert gefundenen HNP1-3 
direkt aus dem Tumorgewebe stammen, da die mikrosezierten Tumorgewebeproben nicht 
mehr Neutrophile beinhalteten als das parallel analysierte und ebenfalls mikrosezierte 
normale Kolongewebe. 
Immunohistochemische Analysen mit einem Antikörper gegen HNP1-3 zeigten im Vergleich 
zu normalen Kolongeweben starke Reaktionen in kolorektalen Tumorgeweben und in invasiv 
wachsenden Karzinomen und in der Re-Analyse dieser IHC-positiven Zellareale konnten im 
Gegensatz zur Re-Analyse der IHC-negativen Gewebeareale Signale detektiert werden, die zu 
HNP1-3 korrespondieren. Zur Suche nach HNP1-3 in Seren von Patienten mit kolorektalen 
Tumoren und normalen Kontrollen benutzten wir zwei Proben-Gruppen (n = 48; n = 42), in 
denen unabhängig die HNP1-3 – Konzentration mittels ELISA quantifiziert wurden. In der 
ersten Probengruppe konnte eine signifikant höhere Konzentration von HNP1-3 in Seren von 
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Tumorpatienten im Vergleich zu normalen Kontrollen ermittelt werden (P = 2,14x10-5). Der 
Median für die Kontrollen lag bei 8,1 ng/ml; der Median für Patienten mit Kolonkarzinom lag 
bei 29,4 ng/ml. Die entsprechende ROC (engl.; receiver operating curve) zeigte eine 
Sensitivität von 100% und eine Spezifität von 69%. Der cut-off lag bei 14,8 ng/ml. Die 
unabhängige Validierung der zweiten Probengruppe zeigte die gleiche Verteilung wie die 
erste Probengruppe und resultierte in einem P-Wert von 5,60x10-3. Hierbei lag der Median für 
die Kontrollen bei 5,6 ng/ml und der für Patienten bei 14,99 ng/ml. Die ROC resultierte in 
einer Sensitivität von 100% und einer Spezifität von 65,2%. Der cut-off lag hier bei 12,3 
ng/ml. HNP1-3 konnten bei einer Analyse der Seren mittels SELDI-MS nicht diskriminierend 
detektiert werden (unveröffentlichte Resultate). Mit dieser Studie zeigten wir erstmals die 
Effizienz von Gewebe-basierenden ProteinChip-Analysen zur Detektion und Identifizierung 
von Proteinmarkern aus Seren. 
In weiteren Untersuchungen konnten wir diskriminierende Proteinmarker, die in Geweben 
von Pankreaskarzinomen bzw. in normalen Epithelien der Pharynx mittels SELDI-MS 
gefunden wurden, ebenfalls in entsprechenden Seren nachweisen (Melle et al. 2007b; 
unveröffentlichte Resultate). So konnten wir S100A8, das in epithelialen Tumorzellen des 
Pharynx herunterreguliert gefunden wurde (Melle et al. 2004), in Kontrollseren mit erhöhter 
Konzentration im Vergleich zu Seren von Patienten mit Hals-Kopf-Tumoren detektieren 
(Abb. 3; unveröffentlichte Resultate).  
Abb. 3. Box plot der Serumkonzentration von S100A8 für Kontrollen (n = 31) und Patienten (n = 31) mit Hals-
Kopf-Tumoren. Die y-Achse stellt die Konzentration in ng/ml dar. 
3.3 Proteomischer Vergleich verschiedener Tumorentitäten 
Um einzelne Tumorentitäten zu charakterisieren und dabei mittels dem oben vorgestellten 
proteomischem Ansatz möglichst Entitäts-spezifische Proteinmarker zu detektieren, wurden 
im dritten Schwerpunkt der vorliegenden Arbeit Proteinprofile von epithelialen 
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Tumorzellen aus kolorektalen Karzinomen (CRC) mit denen aus hepatozellulären 
Karzinomen (HCC) und/oder denen aus Leber-Metastasen von kolorektalem Karzinom 
(MTS) verglichen (Melle et al., PLoS ONE 2008; 3: e3767 – siehe Anhang 1.4). Die 
Analyse der mittels SELDI-basierender Massenspektrometrie erzeugten Proteinprofile der 
mikrosezierten MTS (n = 17) mit den bereits publizierten Proteinprofilen von mikrosezierten 
kolorektalen Karzinomen (n = 14) (Melle et al. 2006a) und hepatozellulären Karzinomen (n = 
46) (Melle et al. 2007a) zeigte 372 Proteinsignal-Cluster nach Normalisierung im 
Messbereich zwischen 2,5 – 200 kD. Nach der Evaluierung mit dem CiphergenExpress 
Progamm detektierten wir für CRC, HCC und MTS eine Vielzahl von signifikant 
unterschiedlichen Signalen (n = 49). Zwei Signale mit bemerkenswert niedrigen P-Werten (P
= 3,00x10-9 bzw. P = 1,82x10-6), die in MTS wie auch CRC eine im Vergleich zu HCC 
signifikant erhöhte Proteinexpression zeigten, wurden als S100A6 bzw. S100A11 
identifiziert. Beide Proteine können CRC gegen HCC sowie im Fall von S100A6 MTS gegen 
HCC sehr gut diskriminieren. Diese Ergebnisse konnten wir in immunhistochemischen 
Experimenten bestätigen. Mit diesen Untersuchungen konnten wir frühere Studien bestätigen, 
die S100A6 wie auch S100A11 mit verschiedenen epithelialen Tumoren und mit 
Metastasierung in Verbindung bringen (Maelandsmo et al. 1997; Komatsu et al. 2000; Yao et 
al. 2007). Eine Unterscheidung von CRC und MTS war mit keinem der beiden Proteinen 
möglich, was sich auch in der Ähnlichkeit der Proteinprofile der primären kolorektalen 
Karzinome und der davon abstammenden Leber-Metastasen widerspiegelt. Die Analyse der 
Proteinprofile von Metastasen aus unterschiedlichen Typen metastasierender Tumore könnte 
zu einem für viele Metastasisgewebe allgemeinen „metastatischen Proteinprofil“ führen. Mit 
S100A6 liegt ein vielversprechender Kandidat zur Unterscheidung von primären HCC und 
CRC-MTS vor, da die Diskriminierung zwischen primärem hepatozellulären Karzinom und in 
der Leber lokalisierten Metastasen kompliziert und fehlerbehaftet ist (Helmberger et al. 2002). 
In einer weiteren dem dritten Schwerpunkt zu zuordnenden, systembiologischen Studie 
wurden im Gegensatz zu den oben aufgeführten Untersuchungen nach Signalen in den 
Proteinprofilen verschiedener Tumorentitäten gesucht, die zur Konvergenz dieser 
proteomischen Muster beitragen (Müller et al.; Bioinformatics 2006; 22: 1293-1296 – siehe 
Anhang 1.5). Dafür wurden die in früheren Arbeiten ermittelten Proteinprofile epithelialer 
Tumorzellen aus Hals-Kopf-Tumoren der Pharynx und aus kolorektalen Karzinomen sowie 
die der entsprechenden, Tumor-distanten normalen Epithelgewebe mittels einer Vielzahl an 
statistischen und bioinformatorischen Programmen analysiert (Melle et al. 2003; Melle et al. 
2004; Melle et al. 2005a). Hierbei konnte gezeigt werden, dass epitheliale Tumore aus 
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Pharynx und Kolon hinsichtlich ihres proteomischen Musters größere Ähnlichkeiten 
zueinander aufweisen als gegenüber ihren ursprünglichen Geweben. Dabei wurden die 
Proteinprofile in die folgenden acht Probengruppen eingeteilt: NCOL (normales 
Kolonepithel-Gewebe, n = 18), TuCOL (kolorektales Karzinom-Gewebe, n = 29), NHN 
(normales pharyngeales Epithel, n = 28), TuNH (Hals-Kopf-Tumorgewebe, n = 31), NALL 
(normals Kolonepitel und Pharynxepithel-Gewebe, n = 46), TuALL (kolorektales Karzinom- 
und Hals-Kopf-Tumorgewebe, n = 60), COLALL (normales Kolonepithel- und kolorektales 
Karzinom-Gewebe, n = 47) und HNALL (normales pharyngeales Epithel und Hals-Kopf-
Tumorgewebe, n = 59). In diesen Gruppen wurden mittels t-test, decision trees (engl.), 
random forest classification (engl.) und support vector machines (engl.) nach 
charakteristischen Merkmalen gesucht indem die Probengruppen wie folgt verglichen wurden: 
NALL versus TuALL, NCOL versus TuCOL, NHN versus TuHN, COLALL versus HNALL, 
NCOL versus NHN und TuCOL versus TuHN. Beim Vergleich von NCOL verus NHN 
wurde der klarste decision tree aller durchgeführten sechs Vergleiche gefunden. Um diese 
beiden Gruppen exakt voneinander zu trennen, war nur ein sogenannter split point 
ausreichend, der zum Signal bei 10848,5 Da korrespondierte. Dieses Signal wurde von uns in 
einer frühere Studie als S100A8 identifiziert (Melle et al. 2004). Für die anderen fünf 
Vergleiche wurden komplexere decision trees für eine Trennung zweier Gruppen gefunden, 
was eine geringere Unterscheidung dieser Paare impliziert. Mit allen vier Gewebetypen 
(NHN, NCOL, TuHN, TuCOL), hier als Klassen bezeichnet, führten wir eine random forest 
(RF) classification durch, bei der ohne Ausnahme alle „Normal“-Proben ihrem 
entsprechenden Gewebetyp korrekt zugeordnet wurden. Abweichend davon wurden jeweils 
zwei Proben zwischen TuCOL-Gruppe und TuHN-Gruppe falsch zugeordnet. Häufig 
auftretende Verwechslungen traten zwischen „Normal“- und „Tumor“-Proben innerhalb des 
selbem Gewebes auf. Aus dieser Klassifizierung wurde die Wichtigkeit der Merkmale 
(entspricht den Proteinsignalen), die den random forest aufbauen, abgeleitet. Diese 
Kalkulation setzte sich aus 50 Merkmalen, die für spezifische Signale in den Proteinprofilen 
stehen, zusammen. Die beiden herausragendsten Merkmale, die bedeutender als die übrigen 
Merkmale sind, korrespondieren zu Signalen mit einem Molekulargewicht von 13245,3 Da 
bzw. 10848,5 Da. Das letztbenannte Merkmal von 10848,5 Da spielte hierbei eine wichtige 
Rolle in der Identifizierung von jeder der vier Klassen. Die RF-Analysen für jeweils zwei 
Klassen zeigten eine perfekte Klassifizierung für die Proben der „Normal“-Gewebe (NHN 
versus NCOL). Im Gegensatz dazu kam es bei allen anderen Fällen aber zu 
Falscheinteilungen der Proben. Mittels Analysen mit support vector machines (SVM) 
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ermittelten wir die maximale Exaktheit einer Vorhersage zur Verteilung von Proben in 
spezifische Gruppen. Hierbei wurden 50 Paare von Proteinen ermittelt, deren 
Expressionssignale die Proben aus NCOL versus NHN mit 100 %iger Genauigkeit 
vorhersagen. Die Vorhersage-Exaktheit für die Tumorproben (TuCOL versus TuHN) betrug 
93,3 %. Die Genauigkeit der Vorhersage zu TuCOL versus NCOL betrug 87,2 %, die zu 
TuHN versus NHN 84,8 %; die Vorhersage-Exaktheit zu Tumor- versus „Normal“-Gewebe 
betrug 78,3 %. 
Das in der RF-Klassifizierung ermittelte, bedeutende Merkmal, das Signal mit 10848,5 Da, 
stand für die höchsten Distanzen zwischen NCOL und NHN (39 mean square distance [msd] 
und zwischen TuHN und NHN (25 msd). Die höchsten Konvergenzen zeigten NCOL und 
TuCOL (1 msd) sowie TuCOL und TuHN (8 msd) hinsichtlich dieses Signals. 
3.4 Biologische Charakterisierung diskriminierender Proteinmarker 
Neben der Detektion und Identifizierung von Proteinmarkern, die zwischen Tumor- und 
Normalgewebe diskriminieren können, ist es ebenfalls von herausragender Bedeutung, diese 
Proteine hinsichtlich ihrer biologischen Funktion zu untersuchen. Eine Möglichkeit, Proteine 
zu charakterisieren und dadurch Einblicke in ihre physiologische Rolle zu erhalten, ist die 
Identifizierung von Interaktionspartnern (Coulombe et al. 2004). Die Aufklärung der 
Zusammensetzung molekularer Maschinen kann dabei zum Verständnis zellulärer 
Mechanismen beitragen und war Inhalt des vierten Schwerpunkts der vorliegenden Arbeit. 
Zu diesem Zweck entwickelten wir einen sogenannten „Protein-Protein-Interaktionstest“ 
(PPIT), der auf massenspektrometrischer Analyse mittels SELDI-MS und immunologischen 
Techniken basiert (Abb. 4; Lehmann et al., J. Proteome Res. 2005; 4: 1717-1721 – siehe 
Anhang 1.6). Um die Tendenz der Detektion von falsch-positiven Proteininteraktionen zu 
vermeiden, wurden ausschließlich endogen exprimierte Proteine analysiert. Hierbei 
untersuchten wir als Modellsystem mit S100A8 ein Mitglied der S100 Ca2+-binde Familie 
hinsichtlich möglicher interagierender Proteinpartner. S100A8 wurde in einer früheren Studie 
als differentiell unterschiedlich exprimiert in Hals-Kopf-Tumoren beschrieben (Melle et al. 
2004). Neben einem Signal, das zum Molekulargewicht (MW) von S100A8 korrespondiert, 
wurden in der SELDI-basierenden massenspektrometrischen Analyse der mittels eines 
spezifischen anti-S100A8 Antikörpers aus HaCaT-Keratinozyten-Lysat präzipitierten Proteine 
weitere spezifische Signale detektiert. Diese Signale wurden nicht in einem Kontroll-
Experiment mit einem unspezifischen Antikörper gefunden. 
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Abb. 4. Schematische Darstellung des Protein-Protein-Interaktionstests (PPIT). Dieser Test setzt sich aus drei 
experimentellen Schritten zusammen: Präzipitation, Elution und Analyse der potentiellen Interaktionspartner. (A) 
Mittels eines spezifischen Antikörpers, der an Interaction Discovery Mapping (IDM) Beads gekoppelt wurde, 
wurde das Antigen zusammen mit endogen exprimierten, interagierenden Partnern aus einem Zelllysat gefällt. 
(B) Der/Die präzipitierte(n) Proteinkomplex(e) wurde(n) von den Beads eluiert. Dabei wurden die Bindungen 
zwischen interagierenden Proteinen, inklusive der Bindung zwischen Antikörper und Antigen aufgebrochen. (C) 
Das Eluat wurde anschließend parallel mittels zwei Verfahren bearbeitet. (1) Ein Teil des Eluats wurde benutzt, 
um die Molekulargewichte (MW) der Bestandteile der(s) präzipitierten Proteinkomplexe(s) mittels SELDI-MS 
zu ermitteln. (2) Der andere Teil des Eluats wurde, z.T. nach vorangegangener Auftrennung im SDS-
Polyacrylamid-Gel sowie anschließender Detektion und Bearbeitung spezifischer Proteinbanden, tryptisch 
verdaut und die dabei entstandenen Fragmente im SELDI-Massenspektrometer vermessen. Die so ermittelten 
peptide mass fingerprints (PMF) wurden zur Suche in Datenbanken benutzt. Mit Antikörper-basierenden 
Experimenten wie Coimmunpräzipitation (Co-IP) und/oder immunocapturing assays wurde der bei dieser Suche 
gefundene Kandidat als potentieller Interaktionspartner bestätigt oder ausgeschlossen. 
Ein spezifisches Signal bei 13,22 kD korrespondierte sehr gut zum MW von S100A9, einem 
bekannten Interaktionspartner von S100A8 (Dell´Angelica et al. 1996). Ein weiteres 
spezifisches Signal bei 11.065 kD wurde mittels PPIT als S100A10 identifiziert. Bei der 
anschließenden Suche nach Interaktionspartnern von S100A10 mit einem entsprechenden 
spezifischen Antikörper wurde in einem PPIT S100A7 als interagierendes Protein von 
S100A10 aufgedeckt. Mittels dieser „proof of principle“ Studie konnte wir erstmals zeigen, 
dass mit Hilfe von SELDI-MS, eingebunden in einen sogenannten „Protein-Protein-
Interaktionstest“, Proteininteraktionen detektiert und mittels immunologischer Verfahren die 
daran beteiligten Faktoren identifiziert werden können. Eine Reihe weiterer Protein-Protein-
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Interaktionen konnte durch den Einsatz dieses Verfahrens erstmals beschrieben werden 
(Arndt et al. 2007; Escher et al. 2007; Fegers et al. 2007; Kob et al. 2007; Marx et al. 2007). 
Bei der Suche nach Interaktionspartnern von S100A11, das in kolorektalen Karzinomen 
überexprimiert vorliegt (Melle et al. 2006a), wurden weitere Proteininteraktionen detektiert. 
In dieser Studie konnten wir mittels eines PPIT feststellen, dass Rad54B spezifisch mit 
S100A11 interagiert (Murzik et al.; Mol. Biol Cell 2008; 19: 2926-2935 – siehe Anhang 
1.7). Neben dieser Proteininteraktion konnte eine schon beschriebene Interaktion zwischen 
S100A11 und Aktin detektiert werden (Xhao et al. 2000). Um eine biologische Funktion 
dieses Komplexes zu ermitteln, wurden Immunfluoreszenz-basierende Untersuchungen mit 
anschließender konfokaler Laser-scanning Mikroskopie durchgeführt, da beide Proteine im 
Zellkern lokalisiert sein können (Broome et al. 1999; Wesoly et al. 2006). Hierbei konnten 
wir feststellen, dass beide Proteine in einem Foci-ähnlichen Muster im Zellkern von HaCaT-
Keratinocyten kolokalisieren. Rad54B ist eine DNA-abhängige ATPase, die an der 
homologen Rekombinations-Reparatur von DNA beteiligt ist (Miyagawa et al. 2002; Wesoly 
et al. 2006). Homologe Rekombination (HR) ist ein Haupt-Reparaturweg von Doppelstrang-
Brüchen (DSB) in der DNA (Wolner et al. 2003). Die Induktion von DNA-Schäden mittels 
Bleomycin (BLM) verursachte schon 30 min nach Schadensinduktion eine sichtbare Zunahme 
der Kolokalisierung zwischen S100A11 und Rad54B an Stellen der DNA-DSB-Reparatur. 
Diese Reparaturstellen wurden durch Immunfluoreszenz gegen γH2AX-Foci detektiert. Die 
Phosphorylierung von H2AX und die Bildung von γH2AX-Foci an DSB ist eine der ersten 
zellulären Antworten nach Induktion von DNA-Schäden (Rogakou et al. 1998). Die S100A11 
– Rad54B-Kolokalisierung erreichte drei Stunden nach BLM-Behandlung ihr höchstes Niveau 
und verringerte sich danach wieder auf das Niveau vor der DNA-Schadensinduktion, welches 
nach ungefähr 24 Stunden erreicht wurde. Der Komplex aus S100A11 und Rad54B 
kolokalisiert direkt mit DNA-Schadensstellen wie wir in einem Immunfluoreszenz-
basierenden Experiment zeigten, das gleichzeitig S100A11, Rad54B und γH2AX detektierte. 
Hierbei kolokalisierten S100A11, Rad54B und γH2AX in Foci im Nukleoplasma von HaCaT-
Zellen. Der Einfluss von S100A11 hinsichtlich der Erkennung von DNA-Schadensstellen 
durch Rad54B wurde mittels RNA-Interferenz-Experimenten geklärt. Dafür wurde S100A11 
mittels einer spezifischen siRNA depletiert und die Foci-Formierung in mit BLM behandelten 
HaCaT-Keratinozyten untersucht. Eine signifikante Reduktion des S100A11 Proteinniveaus 
wurde 72 Stunden nach der Transfektion mit der spezifischen S100A11 siRNA in Immunblot-
Untersuchungen gefunden. Im Gegensatz zu mit BLM behandelten HaCaT-Zellen, die mit 
einer unspezifischen, so genannten non-silencing siRNA transfiziert wurden und in denen 
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Rad54B in Foci erschien, zeigten die mit der spezifischen S100A11 siRNA transfizierten 
Zellen eine diffuse nukleoplasmatische Lokalisierung von Rad54B. In den HaCaT-Zellen, die 
mit der unspezifischen siRNA transfiziert wurden, konnte weiterhin eine Kolokalisierung des 
S100A11/Rad54-Komplexes mit γH2AX in Foci an DNA-Schadens-Reparaturstellen 
gefunden werden. Daraus lässt sich schließen, dass das Auftreten von Rad54B-Foci an DNA-
Schadensstellen vom Protein-Status von S100A11 abhängt und nicht von der Induktion von 
DNA-Schäden mittels BLM. 
Zusätzlich konnten wir eine erhöhte Proteinexpression von p21 nach Induktion von DNA-
Schäden mittels BLM in HaCaT-Zellen finden. Überraschenderweise wurde das p21-
Proteinniveau signifikant reduziert, wenn S100A11 mittels einer spezifischen siRNA 
herunterreguliert wurde. Diese Daten können in Einklang mit einer kürzlich erschienen Studie 
gebracht werden, die eine Induktion von p21 nach dem Transfer von S100A11 in den Zellkern 
zeigte (Sakaguchi et al. 2003). Gleichzeitig verschlechterte sich die Proliferationskapazität der 
HaCaT-Zellen mit durch RNA-Interferenz herunterregulierten S100A11. Der Anteil der 
apoptotischen Zellfraktion von S100A11 knock-down Zellen erhöhte sich signifikant im 
Vergleich zu Kontrollzellen. Hierbei scheint die Funktion von p21 als Inhibitor der Apoptose, 
eingeschränkt zu sein (Gartel, Tyner 2002). Es scheint, dass S100A11 einerseits 
Verantwortung für die Akkumulation von Rad54B an Orten der DNA-DSB-Reparatur trägt 
und andererseits eine Rolle bei der p21-vermittelten Zellzyklus-Regulation spielt.  
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4 Zusammenfassung und Ausblick 
Trotz des enormen Aufwandes, der mittels des Einsatzes der neuesten Ergebnisse und Ansätze 
aus Genomik, Proteomik und molekularer Medizin unternommen wird, zeigen sich bei früher 
Diagnose und adäquater Behandlung der häufigsten Tumorentitäten nur hinter den 
Erwartungen zurückliegende Erfolge. Die momentan benutzten Tumormarker, die vor allem 
bei Analysen von Serum und anderen Körperflüssigkeiten gefunden wurden, besitzen 
hinsichtlich ihrer Eignung zur Früherkennung oder Prognose spezifischer Tumorentitäten nur 
eingeschränktes Potential. 
Der erster Schwerpunkt der vorliegenden Arbeit war es, einen technischen Ansatz zu 
entwickeln, mit dem differentiell exprimierte Proteine aus Gewebe identifiziert werden, die 
zwischen Tumorgewebe und Tumor-distanten Gewebe diskriminieren können. Hierfür wurde 
als zentrale proteomische Technik die SELDI (engl.; surface-enhanced laser 
desorption/ionization) Massenspektrometrie (MS) benutzt. Diese Technik wird als „cancer 
biomarker discovery tool“ angesehen (Diamandis 2004), die bei der Detektion Tumor-
spezifischer Proteinmuster und Identifizierung von Tumormarkern aus Körperflüssigkeiten 
schon zum Einsatz kam. Hierbei zeigte sich aber, dass die mit SELDI-MS in Serum 
detektierten diskriminierenden Signale Proteinen entsprachen, die in Konzentrationsbereichen 
vorlagen, die nicht mit den erwarteten Konzentrationen eines vom Primärtumor in den 
Blutstrom abgegebenen Proteins in Einklang zu bringen waren und wahrscheinlich 
sekundären Krankheitserscheinungen, die nicht direkt mit Tumorgenese in Verbindung 
stehen, zu zuordnen sind. Da momentan noch keine massenspektrometrische Technik 
beschrieben wurde, um solch niedrig konzentrierten Proteine in Körperflüssigkeiten 
ausreichend sicher detektieren zu können, wurde mit Tumorgewebe die unmittelbare Quelle 
potentieller Tumormarker als Untersuchungsmaterial ausgewählt. Um Kontaminationen mit 
ungewünschten Gewebearealen zu vermeiden und einzuschränken, wurden die zu 
untersuchenden Gewebeproben mittels Laser-Mikrodissektion gewonnen. Nach der SELDI-
MS - Analyse dieser Probe ergab sich ein Gewebe-spezifisches Proteinmuster, das sich aus 
differentiell exprimierten Proteinen zusammensetzte. Zur Identifizierung solcher 
diskriminierenden Signale wurden die Proteinlysate mittels zwei-dimensionaler 
Gelelektrophorese aufgetrennt, die „petide mass fingerprints“ (PMF) einzelner, tryptisch 
verdauter Proteinspots aus dem Gel mittels SELDI-MS ermittelt und zur Suche in einer 
Protein-Datenbank benutzt. Die hierbei erhaltenen Kandidaten wurden mittels 
immunologischen Techniken und SELDI-Analyse bestätigt oder verworfen. Um die so 
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gefundenen potentiellen Tumormarker-Kandidaten weiter zu charakterisieren, wurden 
immunhistochemische Untersuchungen durchgeführt. Dabei konnte die Lokalität dieser 
Proteine im Gewebe aufgeklärt werden, die Rückschlüsse auf mögliche physiologische 
Funktionen erlauben. 
Die in dieser Arbeit entwickelte technische Triade, bestehend aus Gewebe-Mikrodissektion, 
SELDI-MS-Analyse und Immunhistochemie (IHC), wurde zur Identifizierung und 
Charakterisierung differentiell exprimierter Proteine aus unterschiedlichen Tumorentitäten 
benutzt. Mittels dieser technischen Triade wurden die Ca2+-bindenden Proteine S100A8 und 
S100A9 als diskriminierende Proteine bei einer Untersuchung von Hals-Kopf-Tumoren 
identifiziert. Es wurde gezeigt, dass mittels oben benannter Proteine Tumor-distantes, 
normales Pharynxepithel von epithelialen Tumorzellen der Pharynx genau unterschieden 
werden kann. S100A8 wie auch S100A9 wurden bisher mit einer signifikant erhöhten 
Proteinexpression in verschiedenen Tumorentitäten (z. B. Kolon-, Prostata-, Magenkarzinom) 
beschrieben. In der hier vorliegenden Arbeit konnte das erste Mal eine verminderte S100A8- 
bzw. S100A9-Proteinexpression mit einer Tumorentität in Verbindung gebracht werden. Mit 
S100A2 und S100A11 gibt es zwei weitere Mitglieder der S100-Proteinfamilie, die ein 
ähnliches Charakteristikum zeigen, indem sie in spezifischen Tumorentitäten überexprimiert 
und in anderen spezifischen Tumorentitäten mit zum entsprechenden Normalgewebe 
verringerter Proteinexpression vorliegen. Das Expressionsverhalten von S100A8 bzw. 
S100A9 in weiteren Tumorentitäten muss Gegenstand zukünftiger Untersuchungen sein. 
Der zweiter Schwerpunkt der vorliegenden Arbeit war die Validierung der im Gewebe 
mittels technischer Triade gefundenen potentiellen Proteinmarker im Serum. Hierbei konnten 
die α-Defensine 1-3 (HNP1-3), die im Kolonkarzinom im Vergleich zu Tumor-distanten, 
normalen Kolonepithel differentiell überexprimiert gefunden wurden, ebenfalls in ELISA-
Tests mit Seren von Kolonkarzinom-Patienten mit signifikant erhöhter Konzentration im 
Vergleich zu Kontrollseren detektiert werden. Hierbei ist anzumerken, dass Signale, die zu 
HNP1-3 korrespondieren, auf Grund ihrer geringen Proteinkonzentration in Seren mittels 
SELDI-MS nicht detektiert werden konnten und somit die Identifizierung der HNP1-3 als 
potentieller Tumormarker-Kandidat für Kolonkarzinome ausschließlich durch die initiale 
Untersuchung am Gewebe erfolgreich war. Momentan ist unsere Arbeitsgruppe in ein durch 
das BMBF gefördertes Projekt maßgeblich involviert, das in Zusammenarbeit mit 
universitären und Industrie-Partnern die Entwicklung und Validierung von Antikörper-Chips 
zur Detektion von Kolonkarzinomen, die unter anderem auf der Vermessung der HNP1-3 - 
Konzentration basieren, beinhaltet. 
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Kürzlich wurde als Kongressbeitrag ebenfalls das geplante Konzept einer anderen 
Arbeitsgruppe zur Validierung von Tumormarkern aus Serum, die in vorangehenden 
Analysen in Gewebe detektiert werden sollen, vorgestellt (Meyer, Stühler 2007; Cottingham 
2007). 
In dieser Arbeit wurde des Weiteren die Proteinkonzentration von S100A8, das wie oben 
erwähnt als diskriminierendes Protein in Pharynxkarzinomen gefunden wurde, in Seren von 
Patienten mit Hals-Kopf-Tumoren und Kontrollen validiert. Hierbei wurden die Ergebnisse 
der vorangegangenen Untersuchungen in Pharynxgewebe bestätigt, indem gezeigt wurde, dass 
die S100A8-Proteinkonzentration in Normalseren gegenüber Patientenseren signifikant erhöht 
vorliegt. Zukünftige Studien mit einer größeren Anzahl an Seren, die in spezifische Gruppen 
hinsichtlich Tumorgrad, Normalkontrollen ohne Befund, Tumor-negative Kontrollen mit 
Befund etc. eingeteilt sind, müssen zeigen, ob S100A8, ähnlich S100B für Melanome (Salama 
et al. 2007), als potentieller, diagnostischer und/oder prognostischer Tumormarker-Kandidat 
dienen kann. 
In der vorliegenden Arbeit wurden im dritten Schwerpunkt außerdem die Proteinprofile 
verschiedener Tumorentitäten miteinander verglichen. Hierbei wurde gezeigt, dass Karzinome 
des Kolon und Pharynx hinsichtlich ihres Proteinprofiles eine größere Ähnlichkeit besitzen als 
zum entsprechenden Tumor-distanten Normalgewebe. Gleichzeitig wurden in dieser Arbeit 
mit S100A6 und S100A11 zwei Proteinmarker ermittelt, mit denen zwei unterschiedliche 
Tumorentitäten, hepatozelluläres Karzinom (HCC) und kolorektales Karzinom (CRC), 
unterschieden werden können. Es scheint, dass mit S100A6 zusätzlich ein potentieller 
Proteinmarker-Kandidat existiert, mit dem Leber-Metastasen aus kolorektalem Karzinom 
(MTS) und HCC diskriminiert werden können. Zukünftige Arbeiten hierzu sollen einerseits 
zu einem einheitlichen Tumor-Proteinprofil und andererseits zu einem spezifischen, vom 
jeweiligen Primärtumor unabhängigen Metastasen-Proteinprofil führen. Außerdem sollen 
proteomische Ähnlichkeiten zwischen Metastase und jeweiligen Primärtumor erarbeitet 
werden. Dadurch erwarten wir zweierlei: (I) die Unterscheidung der Metastasen von einem 
möglicherweise parallel dazu auftretenden primären Tumor im selben Gewebe und (II) 
Rückschlüsse auf die Identität des metastasierenden Primärtumors. 
Ein Weg, um die in „protein profiling“-Experimenten identifizierten Proteinmarker-
Kandidaten zu charakterisieren und einen Einblick hinsichtlich ihrer biologischen Funktion zu 
erhalten, ist die Identifizierung von mit diesen Proteinmarkern interagierenden Proteinen. 
Hierzu wurde im vierten Schwerpunkt dieser Arbeit ein sogenannter „Protein-Protein-
Interaktionstest“ (PPIT) etabliert. Mit diesem wurden ausschließlich in vivo existierende 
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Protein-Interaktionen aufgedeckt. Hierbei wurden in einer „proof of principle“-Studie 
Interaktionspartner von S100-Proteinen identifiziert. In dieser Arbeit wurde des Weiteren 
Rad54B, eine DNA-abhängige ATPase, die an der homologen Rekombinationsreparatur 
beteiligt ist, als Interaktionspartner von S100A11 identifiziert und diese Proteininteraktion 
charakterisiert. Dabei konnte gezeigt werden, dass Rad54B mit S100A11 an DNA-
Doppelstrang-Brüchen kolokalisiert. In Zellkulturen, in denen S100A11 mittels RNA-
Interferenz depletiert wurde, konnte Rad54B Orte mit Doppelstrang-Brüchen nicht erkennen, 
was scheinbar zu einer Verminderung der DNA-Schadensreparatur führte, da das Potential 
dieser Zellen Kolonien zu bilden im Vergleich zu Kontrollen signifikant eingeschränkt war. 
Gleichzeitig war in den S100A11 depletierten Zellen eine Abnahme der p21-
Proteinexpression zu verzeichnen, die sich auch in einer erhöhten Anzahl an apoptotischen 
Zellen und in einer reduzierten Proliferationskapazität widerspiegelte. Zukünftige 
Experimente müssen zeigen, ob und wenn ja, welche Rolle S100A11 bei der Regulation des 
Zellzykluses spielt. 
Die in der vorliegenden Arbeit dargestellten Experimente haben potentielle Tumormarker-
Kandidaten aufgedeckt. Umfassende Studien mit einer erweiterten Probenzahl inklusive 
Proben von Patienten ohne entsprechende Tumorentität sollen eine mögliche Spezifität dieser 
Tumormarker-Kandidaten validieren sowie Untersuchungen zum Inhalt haben, ob diese 
Marker neben Gewebe zusätzlich auch in nicht-invasiv zu entnehmenden Material wie Serum 
auftreten und hier ebenfalls diskriminierend sind, wie die in dieser Arbeit aufgeführten ersten 
Ergebnisse vermuten lassen. Des Weiteren sollen in zukünftigen Experimenten weitere 
Interaktionspartner von in vorangegangenen Proteinprofil-Untersuchungen detektierten 
Markern sowie von weiteren Mitgliedern der S100-Proteinfamilie identifiziert und diese 
Proteinkomplexe zell- und molekularbiologisch charakterisiert werden, um so Rückschlüsse 
auf ihre biologischen Funktionen zu gewinnen. 
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ABSTRACT
Biomarkers are needed to elucidate the biological background and to
improve the detection of cancer. Therefore, we have analyzed laser-
microdissected cryostat sections from head and neck tumors and adjacent
mucosa on ProteinChip arrays. Two differentially expressed proteins
(P 5 3.34 3 1025 and 4.6 3 1025) were isolated by two-dimensional gel
electrophoresis and identified as S100A8 (calgranulin A) and S100A9
(calgranulin B) by in-gel proteolytic digestion, peptide mapping, tandem
mass spectrometry analysis, and immunodepletion assay. The relevance of
these single marker proteins was evaluated by immunohistochemistry.
Positive tissue areas were reanalyzed on ProteinChip arrays to confirm
the identity of these proteins. As a control, a peak with low P was
identified as calgizzarin (S100A11) and characterized in the same way.
This technical triade of tissue microdissection, ProteinChip technology,
and immunohistochemistry opens up the possibility to find, identify, and
characterize tumor relevant biomarkers, which will allow the movement
toward the clonal heterogeneity of malignant tumors. Taking this ap-
proach, proteins were identified that might be responsible for invasion
and metastasis.
INTRODUCTION
Despite enormous efforts, in only a few tumor diseases have rele-
vant markers been established that can be used for early diagnosis or
improved therapy in cancer (1, 2). This remains the case, although
many new parallel genomic and proteomic techniques have been
introduced in the last 5 years. The strategy of how to search for
biomarkers therefore has to be reconsidered. One point might be that
the in situ situation in tumors is neglected because results from
starting material such as serum and nonmicrodissected tissue cannot
be traced back to the biological properties or the heterogeneity of the
tumor itself. Hence, microdissection, proteomic techniques, and im-
munohistochemistry (IHC) for the characterization have to be com-
bined in a technical triade.
In this study, the proteomic technique surface-enhanced laser des-
orption/ionization-mass spectrometry (MS)-based ProteinChip tech-
nology has been used (3–5). First described by Hutchens and Yip (6),
the technology makes use of affinity surfaces to retain proteins based
on their physicochemical characteristics, followed by direct analysis
by time of flight-MS. Proteins being retained on chromatographic
surfaces can be easily purified from contaminants such as buffer salts
or detergents, thus eliminating the need for preseparation techniques,
as required with other MS techniques. Furthermore, the low sample
requirements of this technique are ideal for small biopsies or micro-
dissected tissue, which are required to produce the homogeneous
tissue samples typically used in cancer research (7–10). Microdis-
sected tissue material, free of contaminating and unwanted tissue
components, is extremely important for finding reliable biomarkers in
cancer diagnosis (11) and in elucidating clonal heterogeneity of tu-
mors. In the case of epithelial tumors, the epithelial cells are separated
from all surrounding tissue constituents. In normal tissue, the lining
epithelium consists of only one or a few cell rows, whereas in tumor
tissues, the boundaries to normal pharyngeal tissue are irregular and
therefore can only be isolated with an extremely precise technique
such as laser-based microdissection. The compatibility of laser-based
microdissection with ProteinChip technology has been shown in a
number of small studies (4, 8, 9, 12), but until now, only very few
studies with a statistically relevant number of cases have been per-
formed (10, 13).
When specific changes between the protein profile of microdis-
sected tumor and normal pharyngeal epithelium tissue are found by
ProteinChip technology, single peaks can be isolated and identified.
Isolation and identification can be performed by either two-dimen-
sional electrophoresis (14) or ProteinChip technology (15), where the
isolated protein is digested by proteolytic enzyme cleavage, and the
mass values of the fragments generated are used for peptide mapping
to identify the protein of interest by a database search. Furthermore,
for confirmatory identification, selected peptides can be sequenced by
collision-induced dissociation using a ProteinChip Interface coupled
to a tandem mass spectrometer (16, 17). Although successful identi-
fications of surface-enhanced laser desorption/ionization-detected
protein markers are frequently reported for other biological samples
(18–21), those from microdissected materials are very rare (10). After
identification, IHC with a specific antibody opens up the possibility to
determine tissue distribution and localization of the identified pro-
teins. By locating expression to specific tissue areas, insight into
clonal heterogeneity and functional differentiation of the tumor can be
obtained.
In the study presented here, pure microdissected populations of
normal pharyngeal epithelium and tumor squamous epithelial cells
were analyzed using ProteinChip arrays. The two differentially ex-
pressed peaks with the best P values, along with a control peak
showing a low P, were identified using two-dimensional electrophore-
sis and in-gel digestion, peptide mapping, and tandem MS. The
assumption that these proteins are identical to the differentially ex-
pressed peaks found by ProteinChip analysis was confirmed with an
immunodepletion assay. The localization of these proteins in tissue
was subsequently verified on cryostat sections of the squamous cell
carcinomas of the head and neck (HNSCC) by IHC, using the corre-
sponding monoclonal antibodies or antiserum, respectively. Positive
tissue areas were microdissected in corresponding serial unstained
tissue sections and reanalyzed using ProteinChip arrays to show that
these proteins are matching to the differentially expressed peaks found
in the prior analysis. Thereby, the relevance of statistically significant
proteins could be traced back to the in situ situation in the tumor.
MATERIALS AND METHODS
Laser Microdissection of Tissue Sections. All 57 head and neck tumor
samples and matched normal mucosa (n 5 44) were obtained after surgical
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resection at the ENT Department of the Friedrich-Schiller-University (Jena,
Germany); these were collected fresh, snap-frozen in liquid nitrogen, and
stored at 280°C. Tumor specimens were categorized according their Union
International Contre Cancer-Tumor-Node-Metastasis classification. All were
classified as squamous cell carcinoma G2, M0.
Laser microdissection was performed with a laser microdissection and
pressure-catapulting microscope (Palm, Bernried, Germany) as described else-
where (10). In brief, we microdissected on native air-dried cryostat tissue
sections ;3000–5000 cells each in a maximum of 20–30 min. Proteins were
extracted by a lysis buffer [100 mM sodium phosphate (pH 7.5), 5 mM EDTA,
2 mM MgCl2, 3 mM 2-b-mercaptoethanol, 0.1% 3-[(3-cholamidopropyl)di-
methylammonio]-1 -propanesulfonic acid, 500 mM leupeptin, and 0.1 mM
phenylmethylsulfonyl fluoride] for 30 min on ice. After centrifugation (15 min;
15,000 rpm), the supernatant was immediately analyzed or frozen in liquid
nitrogen for a maximum of 1 day.
Profiling of Microdissected Normal Pharyngeal Epithelium and Tumor
Tissue. The protein lysates from both microdissected tissues were analyzed on
a strong anion exchange array (SAX2; Ciphergen Biosystems, Inc., Fremont,
CA) as described elsewhere (10). In brief, array spots were preincubated by a
washing/loading buffer containing 100 mM Tris-buffer (pH 8.5), with 0.05%
Triton X-100 followed by an application of 2 ml of sample extract on Protein-
Chip arrays, which were incubated at room temperature for 90 min in a
humidity chamber. After washing twice and application of 23 0.5 ml sinapinic
acid (saturated solution in 0.5% trifluoroacetic acid/50% acetonitrile), mass
analysis was performed in a ProteinChip Reader (model PBS II; Ciphergen
Biosystems, Inc.) according to an automated data collection protocol. Cluster
analysis of the detected signals and the determination of the respective P
values for normal and tumor tissue were carried out with the Biomarker
Wizard Program (Version 3.0; Ciphergen Biosystems, Inc.). For P calculation,
spectra with at least 10 signals in the range between 2 and 20 kDa exhibiting
a signal-to-noise ratio of at least 5 were selected and analyzed with the
Mann-Whitney U test for nonparametric data sets.
Identification of Differential-Expressed Protein Peaks. Samples for
two-dimensional electrophoresis were prepared directly from surgical material
of ProteinChip System-analyzed HNSCC and corresponding normal tissue.
Proteins were isolated and two-dimensional electrophoresis was performed as
described elsewhere (10). In brief, isoelectric focusing was carried out on a
PROTEAN IEF Cell (Bio-Rad) using 17-cm immobilized pH gradient strips.
Vertical SDS-PAGE was performed in a cooled PROTEAN II Multi Cell
(Bio-Rad) using linear gradient gels with total acrylamide concentrations
ranging from 7 to 20%. Analytical gels were silver stained using the Vorum
protocol (22), and semipreparative gels were stained with Coomassie brilliant
blue G-250.
Protein patterns of the two-dimensional gels from normal pharyngeal epi-
thelium and tumor tissue were compared, and consistent differentially ex-
pressed proteins with a size of ;5–20 kDa were excised. In-gel digestion of
proteins was performed as described elsewhere (10). In brief, excised gel
pieces were destained and dried. After rehydration and digestion with 10 ml of
a trypsin solution (0.04 mg/ml; Roche) at 37°C for 7 h, supernatants were
applied directly on a ProteinChip array with a hydrophobic surface (H4;
Ciphergen Biosystems, Inc.). After addition of the matrix (CHCA; Ciphergen
Biosystems, Inc.), peptide fragment masses were analyzed using the PBS II
instrument. The spectra for the peptide mapping experiments were internally
calibrated using three common trypsin autolysis products. Proteins were iden-
tified using the fragment masses generated through trypsin digestion by search-
ing in a publicly available database.6
The criteria for positive identification of proteins were as follows: (a)
probability index should be 1.0e 1000; (b) Z score for the protein should be
.2; and (c) molecular weight and isoelectric point of identified proteins should
match estimated values obtained from two-dimensional gel electrophoresis.
Tandem MS data were acquired on a Micromass QTOF II (Manchester,
United Kingdom) tandem quadrupole-time of flight mass spectrometer
equipped with a Ciphergen PCI 1000 ProteinChip Interface. The system was
externally calibrated in tandem MS mode using the parent ion and selected
fragments of adrenocorticorticotropic hormone human fragment 18–39 (m/
z 5 2465.1983). Tandem MS spectra were used for database searches with
MASCOT,7 using National Center for Biotechnology Information and
SwissProt databases.
For immunodepletion, 2 ml (40 ng) of antihuman monoclonal antibody for
calgranulin A(S100A8) (S13.67; BMA Biomedicals; Augst, Switzerland),
calgranulin B (S100A9) (S36.48; BMA Biomedicals), or an anti-calgizzarin
(S100A11) serum (gift of Dr. Jean-Christophe Deloulme), respectively, were
incubated with 10 ml of protein A-agarose (Sigma) for 15 min on ice. A pellet
was generated by centrifugation, and the supernatant was discarded. The pellet
was washed twice with a buffer containing 20 mM HEPES (pH 7.8), 25 mM
KCl, 5 mM MgCl2, 0.1 mM EDTA, and 0.05% NP40. Afterward, 5 ml of a
lysate from a laser-dissected tumor or normal tissue were incubated with this
pellet for 45 min on ice. As a negative control, 5 ml of the lysate were
incubated with protein A-agarose without antibody for 45 min on ice. After
incubation, samples were cleared by centrifugation, and 3 ml of each super-
natant were analyzed by ProteinChip arrays with a hydrophobic surface.
Characterization of Proteins by IHC. Eight-mm cryostat sections of
frozen head and neck cancer tissue containing both normal and pharyngeal
epithelium and HNSCC were placed on charged slides, dried for ;60 min at
20°C, and fixed as described by Melle et al. (10). After fixation, slides were
treated with 10% methanol in Tris-buffered saline containing 1% H2O2 to
inhibit endogenous peroxidatic activity. Subsequently, they were rinsed twice
with Tris-buffered saline and incubated with the corresponding monoclonal
antibody against calgranulin A (S100A8; clone S13.67; BMA Biomedicals),
calgranulin B (S100A9; clone S36.48; BMA Biomedicals), or with an anti-
calgizzarin (S100A11) serum, respectively. A Jenchrom pxbl-kit (MoBiTec,
Go¨ttingen, Germany) was used according to manufacturer’s instructions to
visualize the location of the antibody. Negative controls were incubated only
with the labeled secondary antibody. Sections cut in parallel to the IHC-treated
sections were stained by H&E for better identification of different tissue areas.
IHC staining was evaluated by a pathologist and an anatomist.
The laser scanning microscopy was performed with a LSM 310 (Carl Zeiss,
Oberkochen-Jena, Germany) in the transmission mode using an Argon-ion
laser. In most cases, Zeiss objective NEOFLUAR 403/1.30 oil was used in
combination with pinhole 20 at a scanning time of 60 s (23, 24).
RESULTS
Profiling of Microdissected Normal Pharyngeal Epithelium and
Tumor Tissue. For this study, areas corresponding to ;3000–5000
cells/tissue probe were excised, and 101 tissue sections (57 tumor and
44 normal pharyngeal epithelium tissues) were successfully dissected
by a pathologist. All protein lysates from the microdissected tissues
were applied to SAX2 arrays and analyzed on a PBS II instrument. In
the low range (2–20 kDa), up to 96 peaks were detected with nor-
malized intensities.
After evaluation with Biomarker Wizard Program, the peak
masses with the two best P values and down-regulated in epithelial
tumor tissue, 10.84 kDa (P 5 3.34 3 1025) and 13.23 kDa
(P 5 4.6 3 1025), were selected for additional characterization and
identification. As a control, one peak (11.78 kDa) with no significant
P (P 5 0.379) was investigated in parallel. First, we used the TagIdent
tool from ExPASy8 by entering the mass of these unknown proteins.
This tool searches for proteins similar in size and in isoelectric point
in the SWISS-Prot and TrEMBL Translation of EMBL (European
Molecular Biology Laboratory) databases, which can give some in-
dication about possible candidates. The latter identified calgranulin A
(accession number P05109), calgranulin B (accession number
P06702), and calgizzarin (accession number P31949) were among the
proteins listed.
Identification of Differential-Expressed Protein Peaks. Histo-
logically assessed tumor pieces and biopsies from normal tissue were
subjected to two-dimensional electrophoresis to identify the detected
peaks at 10.84, 13.23, and 11.78 kDa. Numerous protein spots show-
6 Internet address: http://129.85.19.192/profound_bin/WebProFound.exe.
7 Internet address: http://www.matrixscience.com.
8 Internet address: http://www.expasy.ch/tools/tagident.
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ing differential expression in both specimens were observed. Because
of the binding of the unknown protein species to a strong anion
exchange surface at pH 8.5 in our ProteinChip analysis, we expected
the isoelectric point of this protein candidate to be ,8.5. We therefore
decided to concentrate on 19 spots in range of 5–20 kDa exhibiting an
isoelectric point in the range of 4.5–7 in our two-dimensional elec-
trophoresis. Selected spots were cut out from the second dimension
gels and subsequently subjected to in-gel digestion with trypsin and
protein identification. An empty gel piece underwent the same treat-
ment as a control. The digest solution was spotted on a hydro-
phobic H4 array and the masses of the fragments determined by the
PBS II instrument. Database searches revealed calgranulin A,
calgranulin B, and calgizzarin with high Z-score (2.34, 2.37, and
2.31, respectively) and good sequence coverage (Profound)6 as the
best candidates (Table 1).
These results were further confirmed by tandem MS analysis. The
H4 array with the tryptic digests was transferred to a tandem MS
equipped with a surface-enhanced laser desorption/ionization Protein-
Chip Interface. The peptides generated were selected and fragmented
into smaller ions by collision-induced dissociation. Sequences of the
peptides are given in Table 2. These results confirmed the identifica-
tion of the proteins as calgranulin A, calgranulin B, and calgizzarin.
To confirm that calgranulin A, calgranulin B, and calgizzarin are
matching to the differentially expressed peaks at 10.84, 13.23, and
11.78 kDa found by ProteinChip analysis, an immunodepletion assay
was performed with microdissected tumor and normal pharyngeal
epithelium tissue. Analysis of the supernatant of the immunodepletion
assay by ProteinChip arrays showed that the peaks corresponding to
calgranulin A, calgranulin B, and calgizzarin were significantly re-
duced. In the negative control (immunodepletion process with no
antibody), the corresponding peaks were clearly detectable (Fig. 1).
Characteriziation of Proteins by IHC. To further confirm iden-
tification and to localize calgranulin A, calgranulin B, and calgizzarin
in tissue sections, we examined their expression in five head and neck
cancer tissue sections, using both IHC and ProteinChip technology.
Negative controls without the primary or with no antibody all dem-
onstrated negative results.
Table 1 Identified proteins by two-dimensional electrophoresis and SELDI-MSa (mass accuracy better than 200 ppm)
Protein Swissprot Z-score
Molecular mass
(kDa)
Isoelectric
point
Sequence
coverage (%) Masses matched (Da)
Calgranulin A (S100A8) P05109 2.34 10.89 6.5 62 963.0; 1111.1; 1421.6; 1549.8; 1563.7; 1877.17; 2391.3
Calgranulin B (S100A9) P06702 2.37 13.30 5.7 84 971.3; 1455.6; 1614.6; 1630.7; 1807.1; 2193.2; 2613.2
Calgizzarin P31949 2.31 11.86 6.6 48 771.4; 1142.0; 1480.1; 1850.4; 1866.3; 2892.3; 2907.8
a SELDI-MS, surface-enhanced laser desorption/ionization-mass spectrometry.
Table 2 Results obtained from the CID-MS/MS analysis of selected peptides derived
from calgranulin A, calgranulin B, and calgizzarin, respectively
Peptide (m/z) Sequence Residues
Calgranulin A
963.50 GNFHAVYR 24–31
1421.69 LLETECPQYIR 37–47
Calgranulin B
1455.69 LGHPDTLNQGEFK 26–38
Calgizzarin
1141.60 NQKDPGVLDR 53–62
Fig. 1. A, normalized ProteinChip array profiles of the immunodepletion assay of head and neck cancer tissue with calgranulin A, calgranulin B, and calgizzarin and corresponding
negative controls. The peaks at 10.83, 13.18, and 11.87 kDa representing calgranulin A, calgranulin B, and calgizzarin were detectable in the negative control but not in the
corresponding depleted probe. B, normalized ProteinChip array profiles of microdissected immunohistochemical positive and negative tissue areas. The signals with a molecular mass
of 10.84 and 13.23 kDa representing calgranulin A and calgranulin B were detectable in protein lysates from positive areas and were absent in the negative areas. The peak right of
calgranulin A might be a phosphorylated form (p). In case of calgizzarin (11.87 kDa), both normal and tumor epithelial tissues were positive in immunohistochemistry (IHC; Fig. 2).
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Calgranulin A and calgranulin B showed an identical reactivity in
tissue, with a strong immune reactivity in the normal epithelium,
except in the basal and parabasal cells. In tumor tissue, no expression
could be detected for either protein (Fig. 2, A and C). Normal and
tumor tissue components such as collagenic fibers, fibrocytes, fibro-
blasts, and macrophages were positive, whereas glandular ductal cells
and endothelial cells were negative for calgranulin A/B. Calgizzarin
showed a positive immune reaction with all layers of normal and
tumor epithelium (Fig. 2, B and D). In contrast to calgranulin A/B,
endothelial cells and glandular ductal cells were positive. Table 3
summarizes all immunohistological results for calgranulin A/B and
calgizzarin.
To ensure that the localized calgranulin A, calgranulin B, and
calgizzarin are identical to the peaks found by ProteinChip analysis,
IHC-positive and -negative cell areas were obtained by tissue laser
microdissection. In protein lysates from the positive fraction, a signal
identical in mass to the peak obtained with the initial ProteinChip
analysis was detected. In the protein lysate from the negative fraction,
this peak was not visible (Fig. 1).
DISCUSSION
New biomarkers or biomarker patterns found by genomic or pro-
teomic high-throughput techniques will enable scientists and medical
staff to make a more reliable early diagnosis of certain human dis-
eases, especially malignant tumors, and facilitate the prediction of
their progression. In this way, biomarkers may contribute to a more
differentiated, individually orientated tumor therapy. Despite enor-
mous efforts, until now only in a few tumor disease relevant markers
have been established (1).
One of the most promising proteomic tools for the detection of new
proteomic cancer biomarkers is Ciphergen’s ProteinChip technology
(for examples, see Refs. 25, 26). Until now, this technique has been
predominantly used for body fluid analyses because they are fast and
easy to analyze by direct application onto ProteinChip arrays. Nev-
ertheless, it is known that inter- and intraindividual changes in serum
depending on sex, hormone level, nutrition state, or inflammation are
high and can change the protein profile drastically. Hence, biomarkers
involved in the genesis and progression of cancer must be present at
a high level to be observed above normal changes. Despite these
concerns, a large number of studies using body fluids as starting
material have been published [serum (25, 27); urine (28); nipple
Table 3 Protein expression of calgranulin A, calgranulin B, and calgizzarin in
different normal and tumor tissue components
Calgranulin A, B Calgizzarin
Normal epithelium
Basal layer 2 1
Parabasal layers 2 1
Superficial layer 1 1
Epithelial tumor cells 2 1
Other tissue or hematological components
Collagenic fibers 1 1
Fibrocytes/fibroblasts 1 1
Glandular ductal cells 2 1
Macrophages 1 1
Leukocytes 1 1
Endothelial cells 2 1
Fig. 2. Immunohistochemistry (IHC) of cal-
granulin A/B and calgizzarin visualized by laser
scanning microscopy. Positive reaction is depicted
in blue with a magnification of 3180. A and C,
IHC of calgranulin A; B and D, IHC of calgizzarin.
A, normal pharyngeal epithelium with expression
of calgranulin A in epithelial cells, except in basal
and parabasal cells (arrow). All connective tissue
constituents were negative. B, expression of calgiz-
zarin in all normal epithelial cells and stromal cells
(fibrocytes). C, pharyngeal tumor tissue with no
expression of calgranulin A in epithelial tumor
cells (arrows). Positive expression could be found
in connective tissue cells, fibrocytes, macrophages,
and as deposition on collagenic fibers. D, pharyn-
geal tumor tissue with expression of calgizzarin in
epithelial tumor cells (black arrow), in constituents
of connective tissue and in glandular ducts (white
arrows).
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aspirate fluid (29); and pancreatic juice (26)]. However, if after
bioinformatic processing markers can be found, they would be ideal
for screening high-risk individuals or even individuals without ele-
vated risk, which is discussed by the latest study on ovarian cancer
(30) or others (18, 19, 21).
In contrast to serum, the analysis of tissues is more time consuming
because here microdissection is necessary to separate tumorous from
healthy cells, although the chance to find a reliable tumor marker
might be higher than in serum. There is certainly a higher chance of
obtaining more information about the biological mechanisms leading
to the genesis and progression of cancer. Studies using tissue as a
starting material have been underrepresented until now, and in most
cases, a low number of samples were analyzed, which might be
because even laser-based microdissection is tedious and has to be
done by an experienced pathologist. To date, prostate cancer (4, 12,
31), melanomas (8, 32), lung tumors (13), renal cell carcinomas (9,
32), and HNSCC (10) have been assessed in this way.
After a significant protein has been detected by profiling experi-
ments with ProteinChip arrays, two questions have to be addressed:
first, how the protein can be enriched and identified, and second,
whether this identified protein can be found and localized in the
starting tissue. Localization may give insight to the heterogeneity of
tissue and the tumor itself.
In our study, we addressed the first question by detecting differen-
tially expressed proteins in microdissected tissue using ProteinChip
technology and subsequent enrichment and identification of the pro-
teins of interest by two-dimensional electrophoresis, in-gel digestion,
peptide mapping, tandem MS, and immunodepletion assay. After
profiling, the obtained masses of proteins were used for database
searches, which gave some indication about possible candidates.
Two-dimensional electrophoresis offers the opportunity to enrich and
isolate putative candidates and to digest them with trypsin. The
generated peptides could then be analyzed on the PBS II ProteinChip
Reader and database searches pointed with a high probability to
calgranulin A, calgranulin B and calgizzarin. To confirm that the
isolated and digested proteins are identical to the differentially ex-
pressed peaks found with ProteinChip arrays, we performed an im-
munodepletion assay with the same starting material and correspond-
ing antibodies. The respective peaks were absent in the analyzed
supernatant and must therefore be depleted by the antibody. The
identification was further confirmed by tandem MS analysis of se-
lected peptides from the digest. The second question about the local-
ization of calgranulin A, calgranulin B, and calgizzarin in tissue was
then addressed by IHC. These proteins could be found in different
normal and tumor tissue components. The reanalysis of calgranulin
A-, calgranulin B-, and calgizzarin-positive and -negative tissue areas
by microdissection and profiling confirms moreover their identities to
the differentially expressed peaks. This process enabled the tissue
heterogeneity of samples to be partly solved by laser microdissection,
dividing epithelial tissue from connective tissue. The clonal hetero-
geneity of the tumor itself concerning the transcriptome and the
proteome is morphologically hard to recognize and therefore cannot
be completely solved by microdissection, unless by repeated cycles of
microdissection, protein profiling, and immunohistochemical analyses
with different antibodies.
In contrast to publications that show the protein profiles of specific
tissues exclusively without an identification and characterization (12,
25, 30), we were able to identify significant signals in protein profiles
from microdissected tissues. Calgranulin A, calgranulin B, and cal-
gizzarin belong to the group of S100 proteins involved in the Ca21
signaling network and regulate intracellular activities such as cell
growth and motility, cell cycle progression, transcription, and cell
differentiation (33, 34). This group of proteins has received increased
attention because of their involvement in several human diseases such
as rheumatoid arthritis, acute inflammatory lesions, cardiomyophathy,
Alzheimer’s disease, and cancer (35–38). It is unique that the indi-
vidual members of S100 proteins are located in specific cellular
compartments from which they are able to relocate upon Ca21 acti-
vation, transducing the Ca21signal in a temporal and spatial manner
by interacting with different targets specific for each S100 protein
(39). Another important aspect exclusive to the S100 protein family is
that most genes of the members are located in a gene cluster on human
chromosomal region 1q21 (40).
This region is characterized by several rearrangements that oc-
curred during tumor development (41). This circumstance might be
linked to the deregulation of some S100 gene expression in various
tumor types and might be associated with tumor development and
metastasis (33).
The proteins identified here have been described earlier in gene
expression studies, e.g., in breast carcinoma (42), in murine epithelial
skin tumors (43), and in a mouse model of a gastric B-cell mucosa-
associated lymphoid tissue lymphoma (44) with increased gene ex-
pression of S100A8 (MRP8; calgranulin A), S100A9 (MRP14; cal-
granulin B), and S100A11 (S100C; calgizzarin), respectively. Also,
protein expression studies have detected an increased level of these
S100 proteins in different tumor tissues compared with their corre-
sponding abundance in normal tissues (45–47). These observations
are only consistent with our nonsignificant results concerning
S100A11, calgizzarin. In our study, we detected signals of S100A11
by IHC that were distributed in both tissue types with a slightly
stronger signal in HNSCC than in normal tissues.
On the other hand, our findings concerning the expression of the
S100A8 and S100A9 proteins are contrary to the previously published
studies. We estimate that a reason for the discrepancy to the other
studies might be the fact that (a) our analysis is based on different
tumor entities, (b) the level of mRNA does not necessarily correlate
with protein expression level because of translational control mech-
anisms, and (c) we used microdissection and reanalysis of the found
proteins by IHC to confirm our data. Only one recently published gene
expression study on head and neck tumor used IHC for the confirma-
tion of the results. Interestingly, these authors also found a decrease of
the expression of the S100A9 gene (48).
In conclusion, it can be stated that a better estimation of the
biological importance of certain cell populations and tumor clonal
Fig. 3. Technical triade for proteomic identification and characterization of cancer
biomarkers. Starting point is the tissue microdissection, where probes for ProteinChip
arrays are gained. After profiling the biomarkers identified by two-dimensional electro-
phoresis (2-DE), immunodepletion, and other techniques, they were characterized by
immunohistochemistry. Microdissection of immunohistologically positive areas and re-
analyzes on ProteinChip arrays close this circle.
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heterogeneity in regard to the progression from preneoplastic tissue
alterations to malignant tumors and the prediction of the metastasis
forming potential of a given cell population by biomarkers will be
necessary prerequisites for providing a more detailed insight and
understanding of tumor progression. The paradigmatic triade of mi-
crodissection, surface-enhanced laser desorption/ionization-based
ProteinChip technology, and IHC (Fig. 3) opens up this possibility
while reducing the complexity of the proteome by using a defined cell
population.
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Abstract. The aim of the study was to detect proteomic markers
usable to distinguish colorectal carcinoma from colon adenoma
for a better understanding of the molecular mechanisms in the
process of tumourigenesis. Therefore, we microdissected
colon carcinoma tissue, epithelial colon adenoma tissue as well
as normal adjacent colon epithelium and determined protein
profiles by SELDI-TOF MS. A multitude of significantly
different signals was detected. For their identification colon
biopsis were lysed and subjected to a two-dimensional gel
electrophoresis for separation. Subsequently, we identified
nearly 100 proteins by tryptic digestion, peptide fingerprint
mapping and database search. Calgizzarin (S100A11; S100C)
identified by peptide fingerprint mapping correlated very well
with a significantly differentially expressed signal found in
prior protein profiling. Using an immunodepletion assay we
confirmed the identity of this signal as calgizzarin. To localise
calgizzarin in tissues we performed immunohistochemistry.
For further confirmation of the identity of calgizzarin we re-
analysed IHC-positive as well as IHC-negative tissue sections
on ProteinChip arrays. This work demonstrates that biomarkers
in colorectal cancer can be detected, identified and assessed
by a proteomic approach comprising tissue-microdissection,
protein profiling and immunological techniques.
Introduction
Colorectal cancer is ranked the third most common form of
cancer worldwide in terms of incidence (estimated to result
in 945000 new cases, 9.4% of the world total population)
and mortality (492000 deaths, 7.9% of the total) in 2000 (1).
The majority of colorectal cancers are non-hereditary and
sporadic, which makes early detection even more important.
Tumourigenesis in sporadic colorectal cancer (CRC) has
been extensively studied and can be seen as a multistep
process, with each step representing specific gene mutations
or epigenetic changes (2). The progression from adenoma
to sporadic CRC results from the accumulation of genetic
and epigenetic alterations involving activation of oncogenes
and inactivation of tumour suppressor genes (3). Several
other molecular mechanisms were also shown to be involved
in tumour development, but tend to occur infrequently. Despite
the dominant role of the adenoma-carcinoma sequence these
changes are thought to be responsible for the different bio-
logical nature and clinical behaviour of CRC. In addition epi-
demiological studies revealed a strong impact of environmental
and dietary factors.
Regardless of the enormous efforts and introduction of
new parallel genomic and proteomic techniques in recent
years, relevant markers that can be used for early diagnosis
or improved therapy in cancer have only been established in
a few tumour diseases (4). One point might be that the in situ
situation in tumours is neglected, because results from starting
material like serum and non-microdissected tissue cannot be
traced back to the biological properties or the heterogeneity of
the tumour itself. Hence, microdissection, proteomic techniques
and immunohistochemistry have been combined in a technical
triade (5).
The proteomic technique, SELDI-MS (surface enhanced
laser desorption/ionization-mass spectrometry), uses chromato-
graphic surfaces able to retain proteins depending on their
physico-chemical properties followed by direct analysis via
time of flight mass spectrometry (TOF-MS) (6). This technique
does not require large amounts of samples making it ideal for
small biopsies or microdissected tissue which are required to
produce the homogeneous tissue samples indispensable in
cancer research (7-9). Microdissected tissue material, free of
contaminating and unwanted tissue components, is extremely
important for producing clean data for biomarker identification
in cancer diagnostics and in elucidating clonal heterogeneity
of tumours. In the present study, the epithelial tumour cells
respectively adenoma cells had to be separated from all
surrounding tissue constituents. This separation was done with
an extremely precise technique such as laser based micro-
dissection. This technique has previously been combined
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Different expression of calgizzarin (S100A11) in normal
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with ProteinChip technology to identify protein markers in
other cancers (10-12).
We analysed pure microdissected populations of cells from
colorectal carcinoma tissue, colon adenoma epithelium as well
as normal colon epithelium using SELDI-MS ProteinChip
technology.
The protein patterns derived by this analysis showed a
multitude of significant differences. To identify this dif-
ferentially expressed proteins crude extracts of biopsis were
separated by 2D gel electrophoresis followed by tryptic
digestion and peptide fingerprint mapping. Among nearly 100
identified proteins calgizzarin (S100A11; S100C) correlated
very well to a significantly different marker which was over-
expressed in CRC found in prior protein profiling. The identity
of this protein was also confirmed as calgizzarin by immuno-
logical techniques.
Materials and methods
Laser microdissection of tissue sections. All 13 CRC samples
and matched normal mucosa (n=19) as well as 30 adenoma
tissue samples were obtained after surgical resection at the
Department of General and Visceral Surgery of the Friedrich-
Schiller-University Jena; these were collected fresh, snap-frozen
in liquid nitrogen, and stored at -80˚C. Tumour specimens were
categorized according to their WHO classification. Most of
the tumours were classified as pT2 and pT3.
Laser microdissection was performed with a laser micro-
dissection and pressure catapulting microscope (LMPC; Palm,
Bernried, Germany) as described elsewhere (10). Briefly, we
microdissected on native air-dried cryostat tissue sections
~3000-5000 cells each in a maximum of 20-30 min. Proteins
were extracted by 10 µl lysis buffer (100 mM Na-phosphate
(pH 7.5), 5 mM EDTA, 2 mM MgCl2, 3 mM 2-ß-mercapto-
ethanol, 0.1% CHAPS, 500 µM leupeptin, and 0.1 mM PMSF)
for 30 min on ice. After centrifugation (15 min; 15000 rpm)
the supernatant was immediately analyzed or frozen in liquid
nitrogen for a maximum of one day.
Profiling of microdissected normal colon epithelium, adenoma
tissue and epithelial carcinoma tissue. The protein lysates from
microdissected tissues (carcinoma, adenoma and normal) were
analysed on strong anion exchange arrays (Q10; Ciphergen
Biosystems Inc., Fremont, CA) as described elsewhere (10).
In brief, array spots were preincubated by a washing/loading
buffer containing 100 mM Tris-buffer, pH 8.5 with 0.02%
Triton X-100 followed by application of 2 µl of sample
extract on ProteinChip arrays, which were incubated at room
temperature for 90 min in a humidity chamber. After washing
three times with the same buffers and two final washing steps
with water, 2x0.5 µl sinapinic acid (saturated solution in 0.5%
TFA/50% acetonitrile) was applied. Mass analysis was per-
formed in a ProteinChip Reader (Series 4000, Ciphergen
Biosystems Inc.) according to an automated data collection
protocol. Spectra were normalised with total ion current and
cluster analysis of the detected signals and the determination of
respective P-values for normal, adenoma and carcinoma tissue
was carried out with the CiphergenExpress Program (Version
3.0; Ciphergen Biosystems Inc.). For P-value calculation,
normalised spectra with signals in the range between 2.5 and
200 kDa exhibiting a signal-to-noise ratio (S/N) of at least 10
were selected and analysed with the Mann-Whitney U test
for non-parametric data sets.
Two-dimensional gel electrophoresis. Samples for two-
dimensional gel electrophoresis (2-DE) were prepared directly
from surgical material of colon tumour and corresponding
normal colon epithelium tissue assessed by a pathologist.
Proteins were isolated and 2-DE was performed as described
elsewhere (10). In brief, isoelectric focusing (IEF) was carried
out on a Multiphor II (Amersham) using 7 cm IPG strips.
Vertical SDS-PAGE was performed in a cooled Protean II xi
Cell (Bio-Rad) using 4-12% Bis-Tris Zoom™ gel (Invitrogen).
The gels were stained with Simply Blue Safe Stain (Enhanced
Coomassie, Invitrogen).
In-gel digestion. Protein patterns of the 2-DE gels from normal
colon epithelium and tumour tissue were comparatively
analysed and protein spots with a molecular mass of nearly
10-50 kDa were excised. In-gel digestion of proteins was per-
formed as described elsewhere (10). In brief, excised gel pieces
were destained and dried. After rehydration and digestion
with 10 µl of a trypsin solution (0.02 µg/µl; Roche) at 37˚C for
7 h supernatants were applied directly on a NP20 Protein
Chip array (Ciphergen Biosystems Inc.). An empty gel piece
underwent the same treatment as a control. After addition
of the matrix (CHCA; Ciphergen Biosystems Inc.), peptide
fragment masses were analysed using the ProteinChip Reader.
The spectra for the peptide mapping experiments were
externally calibrated using five standard proteins including
Arg8-vasopressin (1082.2 Da), somatostatin (1637.9 Da),
dynorphin (2147.5 Da), ACTH (2933.5 Da) and insulin ß-chain
(3495.94 Da). Proteins were identified using the fragment
masses generated through trypsin digestion by searching in a
publicly available database (http://129.85.19.192/profound_bin/
WebProFound.exe).
Immunodepletion assay. Anti-calgizzarin serum (2 µl) (gift
of Dr Jean-Christophe Deloulme) were incubated with 10 µl
protein A-agarose (Sigma) for 15 min on ice. A pellet was
generated by centrifugation and the supernatant was discarded.
The pellet was washed two times with a buffer containing
20 mM Hepes (pH 7.8), 25 mM KCl, 5 mM MgCl2, 0.1 mM
EDTA and 0.05% NP-40. Afterwards, 5 µl of a lysate from
laser-dissected CRC were incubated with this pellet for 45 min
on ice. As a negative control 5 µl of the lysate were incubated
with protein A-agarose without the specific antibody for 45 min
on ice. After incubation samples were cleared by centrifugation
and 3 µl of each supernatant were analysed by ProteinChip
arrays.
Immunohistochemistry. Cryostat sections (8-µm) of colon
cancer tissue and colon adenoma tissue were placed on slides,
air dried for approximately 60 min at 20˚C and fixed in para-
formaldehyde as described (10). After fixation, slides were
treated in the microwave at 80 watts (3x3 min) in 10 mM
citric acid pH 6.0 to inhibit endogenous peroxidatic activity.
Subsequently, they were rinsed twice with TBS pH 7.4, and
incubated overnight at 4˚C in humidity chamber with the
corresponding primary anti-calgizzarin serum. Slides were
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rinsed 3x10 min in TBS and the Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA) and the Jenchrom pxbl-
kit (MoBiTec, Göttingen, Germany) were used according to
the manufacturer's instructions to visualize the localization of
the antibody. Negative controls were incubated with the labeled
secondary antibody only. Sections cut in parallel to the IHC-
treated sections were stained by HE for better identification
of different tissue areas. IHC staining was evaluated by a
pathologist.
Results
Protein profiling of microdissected CRC, colon adenoma and
normal colonic epithelium. Areas corresponding to about
3000-5000 cells per tissue probe were excised, and 62 tissue
sections in total (13 carcinoma, 30 adenoma and 19 normal
colonic epithelium tissues) were successfully dissected by a
pathologist. All protein lysates from the microdissected tissues
were applied to Q10 arrays and analysed on a ProteinChip
Reader Series 4000 instrument. In the range between 2.5-
200 kDa, up to 158 peaks were detected with normalised
intensities. After evaluation with the CiphergenExpress
Program, a multitude of significantly different signals were
detectable for CRC, adenoma and normal tissue samples
(Table I).
Identification of a differentially expressed signal. For
identification of signals histologically checked pieces of
different colon tissues were lysed and subjected to 2-DE for
separation. Numerous protein spots in the range of about
10-50 kDa were excised from the gels and peptide finger-
prints of the tryptic digested spots were determined using
SELDI-TOF MS. In this way we were able to identify nearly
100 proteins by database search (profound; http://129.85.19.
192/profound_bin/WebProFound.exe). One of these proteins,
calgizzarin, correlated very well with a significantly different
signal found in prior protein profiling. This signal of ~12 kDa
showed an increased expression in samples derived from colo-
rectal carcinoma and discriminated significantly between CRC
and adenoma tissue and normal colon tissue (P=9.64x10-3) as
well as between CRC and adenoma or normal colon epi-
thelium, respectively (P=2.35x10-3 or 3.01x10-3, respectively).
The distribution of the intensities for the different tissues is
given in Fig. 1. Representative examples of SELDI-MS spectra
from CRC, colon adenoma and normal colon epithelium
are shown in Fig. 2 in the range from 10.5 to 14 kDa. The
identification of further significant signals is in progress.
The reassurance that calgizzarin matches to the
differentially expressed peak at 12 kDa found by ProteinChip
analysis was done with an immunodepletion assay using
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Table I. Significantly different signals which separate
CRC, adenoma and normal tissue samples detected on Q10
ProteinChip arrays. The signal representing the subsequently
identified calgizzarin is displayed bold.
–––––––––––––––––––––––––––––––––––––––––––––––––
MW (kD) P-value
–––––––––––––––––––––––––––––––––––––––––––––––––
4.968 1.04x10-2
5.087 3.83x10-5
8.212 1.24x10-2
8.406 2.91x10-3
9.757 3.24x10-2
10.179 2.42x10-5
10.357 9.38x10-5
10.396 9.83x10-6
10.532 7.77x10-6
12.001 9.64x10-3
12.189 6.18x10-3
16.810 6.01x10-3
16.937 8.93x10-3
18.480 5.5x10-3
23.826 2.61x10-4
24.785 2.08x10-3
27.973 3.18x10-4
46.581 4.09x10-4
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. The distribution of the intensities of 12 kDa peak in colon adenoma samples (adenoma), CRC samples (carcinoma) and normal colon epithelium
samples (TZ LCM). The spectra were obtained using Q10 arrays. X-axis indicate the sample groups, Y-axis the intensity (µA).
microdissected colorectal cancer tissue as starting material.
Analysis of the supernatant of the immunodepletion assay by
ProteinChip arrays showed that the peak corresponding to
calgizzarin was significantly reduced. In the negative control
without the specific antibody the peak at 12 kDa was clearly
detectable (Fig. 3).
Characterisation of calgizzarin by immunohistochemistry. To
characterise the identified marker and to localise calgizzarin in
tissue sections, we examined their expression in several colon
epithelium tissue samples by immunohistochemistry using a
specific anti-calgizzarin serum. Negative controls without the
primary antibody or without antibody at all demonstrated
negative results. Adenoma cells, normal colon epithelial cells
as well as CRC cells demonstrated cytoplasmic signals for
calgizzarin in all tissue samples examined. The CRC cells
showed an unequivocally increased signal compared to the
signal detected in normal epithelial cells or epithelial adenoma
cells, respectively (Fig. 4). Quantitative differences between
the expression of calgizzarin in normal epithelial colon cells,
adenoma cells and colorectal carcinoma cells are as clearly
noticeable as in ProteinChip array results.
To further confirm that the localised calgizzarin is identical
to the peak found by ProteinChip areas of similar size from
carcinoma and adenoma tissue that were prior positively
analysed in IHC were obtained by tissue laser microdissection.
In protein lysate from carcinoma tissue a signal identical in
mass to the peak obtained with the initial SELDI-MS analysis
was detected on a Q10 array. In the protein lysate derived
from colon adenoma this peak was significantly reduced
(Fig. 5).
Discussion
Genomic and proteomic techniques are used for profiling
studies of colon tumours (13-15). Besides these studies,
protein profiling experiments were carried out using the
proteomic technique surface-enhanced laser desorption/
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Figure 2. Representative examples of SELDI-TOF MS spectra of colon
adenoma, CRC and normal colon epithelium. Data are obtained using Q10
array. The peak of interest at 12 kDa is marked with a frame.
Figure 3. Immunodepletion assay of CRC. A peak (marked with a frame)
representing calgizzarin was detectable in the negative control and clearly
decreased in the corresponding depleted probe.
Figure 4. Immunohistochemistry of calgizzarin. (A) CRC (carcinoma) and normal colon epithelium (normal) and (B) colon adenoma (adenoma) with a
magnification of x100.
ionisation time-of-flight mass spectrometry (SELDI-TOF
MS) (ProteinChip technology) (16-18). In the present study,
we analysed 62 microdissected samples all derived from
CRC, colon adenoma and normal colon epithelium by
ProteinChip technology to find significantly differences
between CRC and colon adenoma for better understanding of
the molecular mechanisms behind the process of tumouri-
genesis. Among a multitude of various signals which
significantly differ between CRC and adenoma and normal
epithelium one signal corresponded very well to the molecular
mass of calgizzarin (also named S100A11 or S100C,
respectively). This signal was up-regulated in colorectal cancer
and distinguished significantly between colorectal carcinoma
and colon adenoma. We were able to confirm the identity of
this signal as calgizzarin by an immunodepletion assay. An
elevated calgizzarin expression in CRC compared to normal
colon epithelium is described on cDNA level as well as on
protein level (19,20). In the present study we confirmed this
up-regulation in CRC compared to normal colon epithelium
by ProteinChip technology as shown recently by 2D gel
electrophoresis (21). Beside this we determined also the
protein pattern of samples derived from epithelial colon
adenoma tissue and compared, to our knowledge for the first
time, the expression ratio between CRC and adenoma on
protein level. In a recent study, the transcriptional profiles
of intestinal tumours in mice were analysed by cDNA micro-
arrays and here as well as in human colorectal cancer cell
lines an up-regulation of the calgizzarin gene derived from
adenocarcinomas compared to adenoma was described (22).
Calgizzarin belongs to the group of S100 proteins involved in
the Ca2+ signaling network, and regulates intracellular activities
such as cell growth and motility, cell cycle progression, trans-
cription, and cell differentiation (23,24). It is a nuclear phospho-
protein linked to suppression of DNA synthesis in normal
confluent human fibroblasts, although in neoplastic cells such
as HeLa and Saos-2 cells loss of nuclear calgizzarin localisation
has been observed (25). In a study using also mass spectro-
metry a specific induction of calgizzarin protein expression
in response to the treatment with transforming growth factor-ß
(1) was measured in fibroblasts (26).
IHC demonstrates the heterogeneous distribution of
calgizzarin in all tissue samples examined underlining the
importance of tissue microdissection prior to all analyses.
Microdissection enabled exact separation of the epithelial and
mesenchymal tissue components and the separation of benign
and malignant cell complexes. Only in this way it is possible
to detect and to quantify the different levels of expression
of calgizzarin in biological different colon tissues. The clonal
heterogeneity of the tumour itself concerning the transcriptome
and the proteome is morphologically hard to recognise and
therefore cannot be completely solved by microdissection,
unless repeated cycles of microdissection, protein profiling and
immunohistochemical analysis with specific antibodies is
employed.
In this case the differential expression of calgizzarin could
be visualised so clearly by IHC as it could be done with
ProteinChip analysis. Re-analysis of IHC positive areas of
CRC, colon adenoma and normal colon epithelium by micro-
dissection and ProteinChip analysis display again a clear
difference in expression level.
In conclusion, through protein profiling, we were able to
detect, identify and characterise calgizzarin as a marker
differentially expressed in CRC and colon adenoma. The
combination of tissue microdissection with SELDI-MS and IHC
in a proteomic triade opens up the possibility for a more detailed
insight and understanding of tumour progression by reducing
the complexity of the proteome using a defined cell population.
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Background & Aims: Although colorectal cancer is one
of the best characterized tumors with regard to the
multistep genetic progression, it remains one of the
most frequent and deadly neoplasms in Western coun-
tries. This is mainly due to the fact that, up to now, no
clinically relevant serum markers could be established
in an early routine diagnostic procedure. Methods: We
comparatively analyzed microdissected normal and tu-
morous colonic epithelium by ProteinChip technology to
detect proteins specific for the tumor directly in the
tissue. Immunohistochemistry (IHC) was used for the in
situ localization of the discovered proteins, and an ELISA
was performed to quantify these proteins in serum.
Results: By this approach, we found and identified a-
defensins 1–3 (HNP1–3) to be more highly expressed in
the tumor than in normal epithelium. These findings
could be confirmed by IHC. Detection of these peptides
in the corresponding serum samples was subsequently
performed with ELISA, resulting in an average sensitivity
of 69% and specificity of 100% for the recognition of
colorectal cancer when using the HNP1–3 level in the
serum of the patients. Conclusions: The direct analysis
of microdissected tissue for the discovery of tumor-
specific markers followed by the specific detection of
these markers in serum by antibody-based methods
proved to be a successful strategy in this study. There-
fore, we can conclude that these promising markers
would not have been found in serum without the infor-
mation gained through the analysis of microdissected
tissue by ProteinChip technology.
Tumorigenesis in sporadic colorectal cancer (CRC) hasbeen extensively studied and can be seen as a mul-
tistep process, each step representing specific gene mu-
tations or epigenetic changes.1,2 DNA of CRC cells
usually shows mutations of the APC, K-ras, p53, and
DCC genes. The progression from adenoma to sporadic
CRC results from the accumulation of genetic and epi-
genetic alterations involving activation of oncogenes and
inactivation of tumor suppressor genes.3 Several other
molecular mechanisms were also shown to be involved in
tumor development but tend to occur infrequently. De-
spite the dominant role of the adenoma-carcinoma se-
quence, these changes are thought to be responsible for
the different biologic nature and clinical behavior of
CRC. In addition, epidemiologic studies revealed a
strong impact of environmental and dietary factors.
Regardless of this knowledge and enormous efforts for
CRC, up to now, no relevant serum markers have been
established that can be used for early diagnosis or im-
proved therapy in cancer. This remains the case, although
many new parallel genomic and proteomic techniques
have been introduced in the last 5 years. The strategy of
how to search for biomarkers, therefore, has to be recon-
sidered. Therefore, as a main part of our study, the
proteomic technique, surface-enhanced laser desorption/
ionization-mass spectrometry (MS)-based ProteinChip
(Ciphergen Biosystems Inc, Fremont, CA) technology
has been used.4–6 First described by Hutchens and Yip,7
the technology makes use of affinity surfaces to retain
proteins based on their physicochemical characteristics,
followed by direct analysis by time of flight MS. Proteins
being retained on chromatographic surfaces can be easily
purified from contaminants such as buffer salts or deter-
gents, thus eliminating the need for preseparation tech-
niques, as required with other MS techniques. Further-
more, the low sample requirements of this technique are
ideal for small biopsies or microdissected tissue.8–10 Mi-
crodissected tissue material, free of contaminating and
unwanted tissue components, is extremely important for
finding reliable biomarkers in cancer diagnosis11 and in
elucidating clonal heterogeneity of tumors. The compat-
ibility of laser-based microdissection with ProteinChip
Abbreviations used in this paper: CRC, colorectal cancer; IDM, inter-
action discovery mapping; IHC, immunohistochemistry; LMPC, laser
microdissection and pressure catapulting microscope.
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technology has been shown in a number of small stud-
ies,5,12–15 but, mainly, studies using serum from patients
and normal controls have been published.16–21 The ad-
vantage of serum is its availability and its easy way of
being processed, but the concentration of tumor-specific
proteins might be too low for detection, especially in
early stages. The advantage of tissue is that also minute
but tumor-specific changes in the protein pattern can be
detected. Therefore, it seems reasonable to combine the
advantages of serum and tissue analysis. This can be done
by first analyzing the microdissected tissue and identi-
fying differentially expressed proteins and then screening
for these markers in serum with antibody-based tests for
their presence and value for diagnosis.
Using the ProteinChip arrays,6,10 we analyzed protein
expression profiles of microdissected CRC tissue and
normal colonic epithelium. Three of the differentially
expressed peaks were identified as a-defensins 1–3
(HNP1–3) by immunocapturing and depletion assays.
The up-regulation of HNP1–3 in tumor tissue was con-
firmed by the corresponding immunohistochemical anal-
ysis. Positive tissue areas were microdissected in corre-
sponding serial unstained tissue sections and reanalyzed
using ProteinChip arrays to show that these proteins are
matched to the differentially expressed peaks found in
the prior analysis. The up-regulation of HNP1–3 could
also be proven in serum by an ELISA-based assay. Thus,
it could be shown for the first time that markers, orig-
inally discovered by the ProteinChip technology used
directly in microdissected tissues, can be redetected and
quantified by an ELISA in serum.
Materials and Methods
Laser Microdissection of Tissue Sections
All 39 colon tumor samples and adjacent normal mu-
cosa (n 5 40) were obtained after surgical resection at the
Department of General and Visceral Surgery of the Friedrich-
Schiller-University Jena; these were collected fresh, snap frozen
in liquid nitrogen, and stored at 280°C. Tumor specimens
were categorized according to their WHO classification. Most
of the tumors were classified as pT2 und pT3.
Laser microdissection was performed with a laser microdis-
section and pressure catapulting microscope (LMPC; Palm,
Bernried, Germany) as described elsewhere.10 In brief, we
microdissected approximately 3000 to 5000 cells from native
air-dried cryostat tissue sections—avoiding inflammatory in-
filtrated areas in tumor—each in a maximum of 20–30 min-
utes. Proteins were extracted by a lysis buffer (100 mmol/L
Na-phosphate (pH 7.5), 5 mmol/L EDTA, 2 mmol/L MgCl2,
3 mmol/L 2-b-mercaptoethanol, 0.1% CHAPS, 500 mmol/L
leupeptin, and 0.1 mmol/L PMSF) for 30 minutes on ice. After
centrifugation (15 minutes; 15,000 rpm), the supernatant was
immediately analyzed or frozen in liquid nitrogen for a max-
imum of 1 day.
Profiling of Microdissected Normal Colon
Epithelium and Epithelial Tumor Tissue
The protein lysates from microdissected tissues (tumor
and normal) were analyzed on both strong anion exchange
arrays (SAX2) and weak cation exchange arrays (WCX2; Ci-
phergen Biosystems Inc, Fremont, CA) as described else-
where.10 In brief, array spots were preincubated by a washing/
loading buffer containing 100 mmol/L Tris-buffer, pH 8.5,
with 0.02% Triton X-100 for SAX arrays and 100 mmol/L
Tris-buffer, pH 4.5, with 0.02% Triton X-100 for WCX
arrays followed by application of 2 mL sample extract on
ProteinChip arrays, which were incubated at room temperature
for 90 minutes in a humidity chamber. After washing 3 times
with the same buffers and 2 final washing steps with water, 2
3 0.5 mL sinapinic acid (saturated solution in 0.5% TFA/50%
acetonitrile) was applied. Mass analysis was performed in a
ProteinChip Reader (model PBS II; Ciphergen Biosystems Inc)
according to an automated data collection protocol.10 Cluster
analysis of the detected signals and the determination of
respective P values for normal and tumor tissue were carried
out with the Biomarker Wizard Program (version 3.0; Cipher-
gen Biosystems Inc). For P value calculation, spectra with at
least 10 signals in the range between 2 and 20 kilodaltons
exhibiting a signal-to-noise (S/N) ratio of at least 5 were
selected and analyzed with the Mann–Whitney U test for
nonparametric data sets.
Identification of Differentially Expressed
Protein Peaks
For immunodepletion, 2 mL (40 ng) antihuman mono-
clonal antibody for a-defensins 1–3 (HNP1–3; T-1034; BMA
Biomedicals; Augst, Switzerland) were incubated with 10 mL
Protein A-agarose (Sigma Chemical Co, St. Louis, MO) for 15
minutes on ice. A pellet was generated by centrifugation, and
the supernatant was discarded. The pellet was washed 2 times
with a buffer containing 20 mmol/L Hepes (pH 7.8), 25
mmol/L KCl, 5 mmol/L MgCl2, 0.1 mmol/L EDTA, and
0.05% NP-40. Afterward, 5 mL lysate from laser-dissected
tumor was incubated with this pellet for 45 minutes on ice. As
a negative control, 5 mL lysate was incubated with Protein
A-agarose without a specific antibody for 45 minutes on ice.
After incubation, samples were cleared by centrifugation, and
3 mL of each supernatant was analyzed on hydrophobic Pro-
teinChip arrays.
For immunocapturing of specific target proteins, Protein A
was directly coupled to Interaction Discovery Mapping (IDM)
affinity beads (Ciphergen Biosystems Inc); 10 mL beads were
washed extensively 5 times with 1.0 mL aqua bidest before 5
mL Protein A in acetate buffer, pH 5.0, was added and
incubated overnight at 4°C in an end-over-end mixer. After
incubation, the supernatant was removed, and the beads were
washed twice with acetate buffer, pH 5.0. Residual reactive
groups were subsequently blocked with 0.5 mol/L Tris-HCl,
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pH 9.0, 0.1% Triton X-100 for 2 hours at room temperature
with shaking. The beads were washed 3 times with 1 mL PBS.
Afterwards, 4 mg HNP1–3-specific monoclonal antibody (0.1
mg/mL; BMA) in 50 mmol/L sodium acetate, pH 5.0, was
applied to the beads and allowed to bind at room temperature
for 1 hour in an end-over-end mixer. Unbound antibody was
removed by washing in 0.5 mL PBS and 0.1% Triton X-100
and twice in 0.5 mL PBS. Twenty microliters cell extract
derived by laser microdissection was diluted in 100 mL PBS
and applied to the IDM beads for incubation overnight at 4°C
in an end-over-end mixer. The unbound proteins were washed
away by sequential washes in PBS, 0.5 mmol/L sodium chlo-
ride, 0.05% Triton X-100, 1 mol/L urea in PBS, PBS, and
aqua bidest. Bound proteins were eluted from the IDM beads
by 10 mL 50% acetonitrile/0.5% trifluoroacetic acid and
gently centrifuged for 5 minutes. Five microliters of the eluted
samples were applied to the activated, hydrophobic surface of
an H4 ProteinChip Array (Ciphergen Biosystems Inc) and
dried in air. The protein chip was analyzed in a PBS II reader.
Characterization of Proteins by
Immunohistochemistry
Eight-micrometer cryostat sections of colon cancer tis-
sue and normal colon epithelium were placed on slides, air
dried for ;60 minutes at 20°C, and fixed in paraformaldehyde
as described.10 After fixation, slides were treated in the micro-
wave at 80 watts (3 3 3 minutes) in 10 mmol/L citric acid, pH
6.0, to inhibit endogenous peroxidatic activity. Subsequently,
they were rinsed twice with TBS, pH 7.4, and incubated
overnight at 4°C in a humidity chamber with the correspond-
ing primary monoclonal antibody against a-defensins 1–3
(T-1034; BMA Biomedicals; Augst, Switzerland). Slides were
rinsed 3 3 10 minutes in TBS and incubated at room tem-
perature for 40 minutes with the secondary biotinylated mono-
clonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Slides were rinsed 3 3 10 minutes in TBS and the Vectastain
Elite ABC kit (Vector Laboratories, Burlingame, CA) and the
Jenchrom pxbl-kit (MoBiTec, Göttingen, Germany) were used
according to the manufacturer’s instructions to visualize anti-
body localization. Negative controls were incubated with the
labeled secondary antibody only. Sections cut in parallel to the
IHC-treated sections were stained by H&E for better identi-
fication of different tissue areas. IHC staining was evaluated by
a pathologist and an anatomist.
The 1-photon laser-scanning microscopy was performed
with a LSM 310 (Carl Zeiss, Oberkochen-Jena, Germany) in
the transmission mode using an Argon-ion laser at a wave-
length of 480 nm. In most cases, Zeiss objective NEOFLUAR
40X/1.30 oil was used at a scanning time of 60 seconds.22,23
Quantification of HNP1–3 in Serum of
Colon Cancer Patients and Normal Controls
In addition to the investigated tissue samples, we took
serum probes (n 5 26) from the same patients. These probes
were taken before surgery and immediately aliquoted and
frozen at 280°C. Serum samples from healthy donors (n 5 22)
were taken with the same protocol.
Serum HNP1–3 concentrations were determined using an
appropriate ELISA kit (HNP1–3; HyCult Biotechnology, The
Netherlands) in duplicate, according to the manufacturer’s
instructions. ELISA plates were measured on a microtiter plate
reader (MRX II; Dynex Technology, Chantilly, VA) at 450
nm. Concentration of the respective protein in serum was
calculated according to a standard curve. P values were calcu-
lated by 1-sided t test. Receiver operating characteristic (ROC)
curves were constructed for HNP1–3 serum concentration by
plotting sensitivity vs 1-specificity, and the areas under the
ROC curves (AUC) were calculated. To validate the results, a
second totally independent set of serum probes including 19
samples of healthy donors and 23 patient samples was ana-
lyzed.
Results
Profiling of Microdissected Normal Colonic
Epithelium and Tumor Tissue
For this study, areas corresponding to approxi-
mately 3000 to 5000 cells per tissue probe were excised,
and 79 tissue sections (39 tumor and 40 normal colonic
epithelium tissues) were successfully dissected by a pa-
thologist. All protein lysates from the microdissected
tissues were applied to SAX2 and WCX arrays and
analyzed on a PBS II instrument. In the low range (2–20
kilodaltons), up to 126 peaks were detected with nor-
malized intensities.
After evaluation with the Biomarker Wizard Program
(Ciphergen Biosystems Inc), peak masses that possessed
remarkably low P values were selected for further char-
acterization and identification. These signals of 3.37 (P
5 4.39 3 1025), 3.44 (P 5 1.88 3 1025), and 3.49
kilodaltons (P 5 9.91 3 1025) were up-regulated in
colon tumor tissue. The distribution of the intensities for
normal and tumor tissue is shown in Figure 1.
Identification of Differential Expressed
Protein Peaks
To confirm that HNP1–3 were matching to the
differentially expressed peaks at 3.37, 3.44, and 3.49
kilodaltons found by ProteinChip analysis, an immu-
nodepletion assay was performed with microdissected
tumor and normal colonic epithelium tissue. Analysis of
the supernatant of the immunodepletion assay by Pro-
teinChip arrays showed that the peaks corresponding to
HNP1–3 were significantly reduced. In the negative
control (immunodepletion process with no specific anti-
body), the corresponding peaks were clearly detectable
(Figure 2A). Furthermore, the pattern and sizes of
HNP1–3 were described or identified by Tandem MS
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elsewhere.24–26 The sequence of the processed peptides is
shown in Figure 3. The identification of additionally
found differentially expressed proteins is in progress.
For further confirmation of the identity of the differ-
entially expressed HNP1–3, an immunoassay was per-
formed using a monoclonal antibody against HNP1–3.
A specific anti-HNP1–3 antibody bound on IDM beads
captured a-defensins 1–3 from a cell extract derived
from laser microdissected colon carcinoma tissue. The
captured proteins were eluted from the beads and applied
to an H4 ProteinChip for analysis by SELDI-MS. The
spectra of the analysis showed peaks corresponding to
HNP1–3. In a control assay using IDM beads without a
specific antibody, no proteins specific for HNP1–3 were
captured (Figure 2B).
Localization of HNP1–3 by
Immunohistochemistry
Further to confirm identification and, above all, to
localize HNP1–3 in tissue sections, we examined their
expression in 5 different colon cancer tissues and adjacent
normal tissue sections using immunohistochemistry.
Normal colonic epithelium showed a weak positive re-
action (Figure 4A), tumor tissue an explicit strong reac-
tion (Figure 4A and 4B). Negative controls without the
primary or with no antibody at all demonstrated negative
results. A positive stain for HNP1–3 could also be found
in fibroblasts and macrophages of the mucous membrane.
To ensure that the localized HNP1–3 are identical to
the peaks found by ProteinChip analysis, IHC-positive
and -negative cell areas were obtained by tissue laser
microdissection. In protein lysates from the positive frac-
tion, signals identical in mass to the peaks obtained with
the initial ProteinChip analysis was detected. In the
protein lysate from the negative fraction, these peaks
were not visible (Figure 2C).
Analyses of HNP1–3 in Serum
Two serum sample sets from patients with colon
cancer and normal controls (n 5 48; n 5 42, respec-
Figure 1. Box plot of concentration of HNP1–3 in normal and tumor
tissue found by ProteinChip arrays (SAX2).
Figure 2. Identification of HNP1–3: (A) Normalized ProteinChip arrays profiles of the immunodepletion assays of microdissected colonic tissue.
For HNP1–3 identification, colon cancer tissue was used as starting material for immunodepletion assays by the corresponding monoclonal
antibody. The negative control was performed without a specific antibody. The peaks at 3.37, 3.44, and 3.49 kilodaltons representing HNP1–3
were detectable in a higher amount in the negative control. (B) Normalized ProteinChip arrays spectra of the immunocapturing assay of
microdissected colon carcinoma tissue. HNP1–3 were captured from microdissected colon carcinoma tissue by the corresponding monoclonal
antibody bound on IDM beads. The peaks at 3.37, 3.44, and 3.48 kilodaltons representing HNP1–3 were clearly detectable in samples eluted
from the IDM beads. In control assays without the specific antibody, no HNP1–3 were captured. (C) Areas with positive and negative reaction in
IHC were microdissected and analyzed on ProteinChip arrays. Signals with a molecular mass of 3.37, 3.44, and 3.49 kilodaltons representing
HNP1–3 were detectable in protein lysates from positive areas and were absent in the negative areas.
Figure 3. Structure of mature human HNP1–3. Amino acid sequence
is shown in single letter code, differences in bold letters.
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tively) were independently analyzed by ELISA for quan-
tification of HNP1–3. In the first set, the concentration
of HNP1–3 in serum from tumor patients was signifi-
cantly higher than in serum from normal controls (P 5
2.14 3 1025). The median for normal control was 8.1
ng/mL; for patients with colon carcinoma it was 29.4
ng/mL (Figure 5). ROC curves were constructed for
HNP1–3 serum concentration, resulting in a sensitivity
of 100% at a specificity of 69% and a cut-off of 14.8
ng/mL. The AUC was calculated as 0.77 (Figure 6). The
independent analysis of the validation set showed an
equal distribution like the first set and resulted in a P
value of .0056. The median for normal controls was 5.60
ng/mL and 14.99 ng/mL for patients (Figure 5). The
ROC resulted in a sensitivity of 100% at a specificity of
65.2% and a cut-off of 12.3 ng/mL. The AUC was
calculated as 0.840 (Figure 6).
Discussion
New molecular biomarkers or biomarker patterns
found by genomic or proteomic high-throughput tech-
niques will enable a more reliable early diagnosis of
malignant tumors and facilitate the prediction of their
progression. In this way, biomarkers may contribute to a
more differentiated, individually orientated tumor ther-
apy. Despite enormous efforts, until now, only in a few
tumor diseases, have relevant markers useful for screen-
ing been established.27,28
Besides 2-dimensional gel electrophoresis (2-DE), the
ProteinChip technology (for examples, see Petricoin et al16
and Rosty et al29) is a promising proteomic tool for the
detection of new proteomic cancer biomarkers. Until now,
this technique has been predominantly used for body fluid
analyses because they are fast and easy to analyze by direct
application onto ProteinChip arrays. Nevertheless, it is
known that inter- and intraindividual changes in serum
depending on sex, hormone level, nutrition state, or inflam-
mation are high and can change the protein profile drasti-
cally. Hence, it is possible that biomarkers present in low
level in serum could not be found or statistically differen-
tiated with 2-DE or ProteinChip technology. Despite these
concerns, a large number of studies using body fluids as
starting material have been published (serum,16,30 urine,24
nipple aspirate fluid,31 and pancreatic juice29). However, if
markers can be found, they would be ideal for screening
high-risk individuals or even individuals without elevated
risk, discussed by the latest study on ovarian cancer32 or
others.17,19,33,34
Figure 4. Immunohistochemistry (IHC) of HNP1–3 visualized by normal
and laser scanning microscopy (LSM; positive reaction is depicted in
blue). (A and B) IHC of HNP1–3 on colon carcinoma. (A) Increased signal
intensity in carcinoma (Ca) structures (overview with 325 magnification;
N, normal epithelium). (B) Strong positive reaction of invasive growing
carcinoma complexes (Ca; magnification of 3120).
Figure 5. Box plot of serum concentration of HNP1–3 for controls and patients with colon carcinoma for both independently analyzed sample
sets (A and B).
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In contrast to serum, the analysis of tissues is more
time consuming because here microdissection is neces-
sary to separate tumorous from healthy cells, although
the chance to find reliable tumor markers might be
higher than in serum. However, these markers could not
be used per se for an early diagnosis, but there is certainly
a higher chance of obtaining more information about the
biologic mechanisms leading to the genesis and progres-
sion of cancer. Studies using tissue as a starting material
have been underrepresented until now, and, in most
cases, a low number of samples was analyzed, which
might be due to the fact that even laser-based microdis-
section is tedious and has to be done by an experienced
pathologist. To date, prostate cancer,5,13,35 melanoma,9,36
lung tumors,14 renal cell carcinoma (RCC),12,36 and head
and neck squamous cell carcinoma (HNSCC)10,11 have
been assessed in this way.
In the present work, we combined the advantages of
biomarker search in microdissected tumor tissue and in
serum. First, we looked for significant markers by com-
paring tumor and normal tissue. Subsequently, we ana-
lyzed these identified proteins specifically in serum by a
corresponding ELISA. Three peaks were identified as
HNP1–3 (up-regulated in tumor) by size and character-
istic pattern published elsewhere25,26 and further con-
firmed by immunodepletion and capturing assays using
the same starting material. In situ localization of these
proteins in tissue was performed using IHC, and the
results were concurrent with those found by ProteinChip
technology. Positive tissue areas were microdissected and
reanalyzed using ProteinChip arrays to show that these
proteins are matching to HNP1–3. Furthermore, the
ELISA assay on serum revealed exactly the same results
for HNP1–3. Consequently, this study confirmed the
consistency of ProteinChip arrays, IHC, and ELISA re-
sults for HNP1–3 and therefore demonstrates for, to our
knowledge, the first time the efficiency of tissue-based
ProteinChip studies for the detection of serum markers.
In addition, HNP1–3 might be, at least in combination
with other screening methods, a potential serum marker
for colon cancer screening. In principle, ProteinChip
arrays could also be used for the specific and more
sensitive capturing of defensins by using antibody-cou-
pled arrays. Such assays have already been established for
the detection of defensins in urine.24 With this technol-
ogy, the limit of detection for synthetic defensin peptides
is reported to be in the lower femtomolar range.26
Defensins are small peptides that contain 6 cystein
residues, which form 3 disulfide bonds. On the basis of
the position of these residues, they can be divided into a-
and b-defensins. So far, only 2 enteric a-defensins (hu-
man defensins 5 and 6; HD-5 and -6) have been identi-
fied in humans,37 but many more probably exist.38 The
known human enteric HD-5 and HD-6 are predomi-
nantly expressed in Paneth cells and rarely present in
intermediate cells of the small intestine.39–41 Their ex-
pression seems to be constitutive and in contrast to
b-defensin 2 (HBD-2)42–44 bacterial stimuli are not re-
quired for their production. The 5=-flanking region of
the HD-5 gene contains consensus binding sites for a
nuclear transcription factor, nuclear factor interleukin-6
(NF-IL-6), which may provide a mechanism whereby
this up-regulation could occur in response to inflamma-
tory stimuli.45 Expression of HD-5 (and HD-6) has also
been demonstrated in the colonic epithelium in Crohn’s
disease and ulcerative colitis.46 In addition to the human
Figure 6. ROC curve for HNP1–3 serum concentration of colon cancer patients and normal controls. The AUC was calculated as 0.77: The
sensitivity of 100% is corresponding to a specificity of 69% (A). The independent analysis of the validation set (B) resulted in a P value of .0056.
The median for normal controls was 5.60 ng/mL and 14.99 ng/mL for patients. The ROC resulted in a sensitivity of 100% at a specificity of 65.2%
and a cut-off of 12.3 ng/mL. The AUC was calculated as 0.840.
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enteric defensins 5 and 6, neutrophil defensins (HNP-1,
-2, -3) may also be expressed in intestinal epithelial cells
in certain conditions. In a recent study, expression of
HNP1–3 was observed in epithelial cells of the ileum
and colon in cases of inflammatory diseases but not in
normal intestinal tissue.47,48 Whether this reflects induc-
tion of gene expression or uptake by epithelial cells of
peptides released by neutrophils in the vicinity remains
to be determined.41 In different cancer entities such as
RCC49 or oral squamous cell carcinoma (OSCC),50
HNP1–3 were also found up-regulated. Now, it can be
assessed that a-defensins expressed in the colon also
include HNP1–3. This has been demonstrated in our
study by ProteinChip technology and IHC. Nevertheless,
this expression might come from neutrophils, but neu-
trophils could be well visualized in H&E-stained sections
with the appropriate magnification. We avoided in our
study microdissecting areas with neutrophils, not be-
cause of the neutrophils, but because these regions are
normally inflamed. Therefore, it could be stated that the
microdissected tumor tissue does not contain more neu-
trophils than the normal tissue. So far, this is the first
study demonstrating the presence of human a-defensins
1–3 in the colonic mucosa. These findings strengthen the
hypothesis that the increased value in serum of patients
with colon cancer is derived from tumor cells.
In conclusion, we were able to show that, for biomar-
ker detection, it is an efficient approach to compare first
pure and defined normal and tumor cells to detect and
identify the up-regulation of tumor relevant proteins and
then to detect and quantify them specifically in serum.
Additionally, with this approach, we could show for the
first time the up-regulation of HNP1–3 in colon cancer
and its potential use as serum marker with high sensi-
tivity and specificity. If the present results can be con-
firmed further with higher sample numbers and addi-
tionally in adenoma tissue or early tumor stages,
HNP1–3 could be used in combination with other mark-
ers for an early and better diagnosis of colon cancer.
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Colon-Derived Liver Metastasis, Colorectal Carcinoma,
and Hepatocellular Carcinoma Can Be Discriminated by
the Ca2+-Binding Proteins S100A6 and S100A11
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Abstract
Background: It is unknown, on the proteomic level, whether the protein patterns of tumors change during metastasis or
whether markers are present that allow metastases to be allocated to a specific tumor entity. The latter is of clinical interest
if the primary tumor is not known.
Methodology/Principal Findings: In this study, tissue from colon-derived liver metastases (n = 17) were classified, laser-
microdissected, and analysed by ProteinChip arrays (SELDI). The resulting spectra were compared with data for primary
colorectal (CRC) and hepatocellular carcinomas (HCC) from our former studies. Of 49 signals differentially expressed in
primary HCC, primary CRC, and liver metastases, two were identified by immunodepletion as S100A6 and S100A11. Both
proteins were precisely localized immunohistochemically in cells. S100A6 and S100A11 can discriminate significantly
between the two primary tumor entities, CRC and HCC, whereas S100A6 allows the discrimination of metastases and HCC.
Conclusions: Both identified proteins can be used to discriminate different tumor entities. Specific markers or proteomic
patterns for the metastases of different primary cancers will allow us to determine the biological characteristics of
metastasis in general. It is unknown how the protein patterns of tumors change during metastasis or whether markers are
present that allow metastases to be allocated to a specific tumor entity. The latter is of clinical interest if the primary tumor
is not known.
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Introduction
Distant metastases are the principal causes of death in patients
with colorectal carcinoma (CRC). A common site of metastases
derived from CRC is the liver.[1] The underlying mechanisms of
liver metastasis of CRC are not fully understood, but metastases
are at least involved in tumor initiation and promotion,
uncontrolled proliferation, angiogenesis, invasion, intra- and
extravasation, and colony formation at the liver site.[2,3] The
analysis of the expression of a single protein is not practical
because these processes seem to be induced by the altered
expression of several different proteins. Proteomic approaches are
practical in the global analysis of altered protein patterns, in which
diverse mass spectrometry (MS)-based methods are used for these
kinds of high-throughput analyses.[4,5] In this context, surface-
enhanced laser desorption/ionization (SELDI) is a proteomic
high-throughput technique that uses chromatographic surfaces
that are able to retain proteins depending on their physico-
chemical properties, followed by direct analysis via time-of-flight
mass spectrometry (TOF-MS).[6] A multitude of studies using
ProteinChip technology have been carried out to establish the
protein profiles of biological fluids, especially serum samples.[7–9]
Because this technique demands only a small amount of sample, it
can be used for small biopsies or microdissected tissues, which
produce the homogeneous tissue samples typically used in cancer
research. The separation of functional tissue areas can be achieved
by laser-based microdissection (for review see [10]). When laser
microdissection was first introduced as a novel preparation
technique in 1998, the challenge was to prove that reliable results
could be achieved by selecting defined small amounts of isolated
cells from complex tissue sections.[11] Since then numerous
applications has been published in different fields and has proven
its necessity.[12] Microdissected tissue material free from contam-
inating and unwanted tissue components is extremely important
for the production of clean data for biomarker identification in
cancer diagnostics and in determining the clonal heterogeneity of
tumors. We have shown in a previous study that the detection of
differentially expressed proteins was only possible in pure
microdissected samples.[13] Laser-based microdissection has
previously been combined with ProteinChip technology to identify
protein markers in several cancer types.[14–16]
The aim of this study was to analyse the protein patterns of liver
metastases derived from CRC (MTS) and detect biologically and
diagnostically relevant signals. We wanted to analyze whether it is
possible to draw conclusions from the proteome of the MTS on the
origin/localization of the primary tumor.
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Materials and Methods
Laser microdissection of tissue sections
All 17 human samples from liver metastases derived from CRC
(MTS) were obtained after surgical resection at the Department of
General and Visceral Surgery of the Friedrich Schiller University,
Jena. They were collected fresh, snap frozen in liquid nitrogen,
and stored at 280uC. Primary tumor specimens were categorized
according to the WHO classification. Most of these tumors were
classified as pT2 and pT3.
Laser microdissection was performed with a laser microdissec-
tion and pressure catapulting microscope (LMPC; Palm, Bernried,
Germany) as previously described.[17] Briefly, we microdissected
native air-dried cryostat tissue sections of approximately 3000–
5000 cells, each in a maximum of 20–30 min. Proteins were
extracted in 10 mL lysis buffer (100 mM Na-phosphate [pH 7.5],
5 mM EDTA, 2 mM MgCl2, 3 mM 2-b-mercaptoethanol, 0.1%
CHAPS, 500 mM leupeptin, and 0.1 mM PMSF) for 30 min on
ice. After centrifugation (15 min; 15,000 rpm) the supernatant was
immediately analysed or frozen in liquid nitrogen for a maximum
of one day.
Profiling microdissected liver-localized metastases
The protein lysates from microdissected metastatic tissues were
analysed on strong anion exchange arrays (Q10) (Bio-Rad), as
previously described.[17] In brief, Q10 array spots were pre-
incubated in a washing/loading buffer containing 100 mM Tris
buffer (pH 8.5) and 0.02% Triton X-100. Then 2 mL sample
Figure 1. Distribution of the intensities of peaks expressed significantly differently in liver metastases derived from colorectal
carcinoma (MTS), colorectal carcinoma tumor (CRC), and hepatocellular carcinoma (HCC) tumor margins. Upper panel: Distribution of
the intensities of the 10.175 kDa signal. Bottom panel: Distribution of the intensities of the 11.997 kDa signal. The spectra were obtained using Q10
arrays. X-axis indicates the sample groups, Y-axis the intensity (mA).
doi:10.1371/journal.pone.0003767.g001
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aliquots were applied to the ProteinChip Arrays, which were
incubated at room temperature for 90 min in a humidified
chamber. After the samples had been washed three times with the
fresh buffer and twice with water, 260.5 mL of sinapinic acid
(saturated solution in 0.5% TFA/50% acetonitrile) were applied.
Mass analysis was performed with a ProteinChip Reader (Series
4000; Ciphergen Biosystems Inc., Fremont, CA), according to an
automated data collection protocol.
Immunodepletion assay
Two microlitres of anti-S100A6 antibody (ab 141; Swant,
Bellinzona, CH) or a specific antibody directed against S100A11
(rabbit polyclonal; Protein Tech Group, IL) were incubated with
10 mL of protein A–agarose (Sigma, St Louis, MO) for 15 min on
ice. A pellet was generated by centrifugation and the supernatant
was discarded. The pellet was washed twice with buffer containing
20 mM Hepes (pH 7.8), 25 mM KCl, 5 mM MgCl2, 0.1 mM
EDTA, and 0.05% NP-40. Then, lysate (5 mL) from the
microdissected tissue was incubated with this pellet for 45 min
on ice. As a negative control, 5 mL of the lysate was incubated for
45 min on ice with protein A–agarose without the specific
antibody. After incubation, the samples were cleared by
centrifugation and 3 mL of each supernatant (immunodepleted
sample) was analysed on the ProteinChip Arrays (Q10, BioRad).
Immunohistochemistry
Cryostat sections (8 mm) of MTS-containing tissue (n= 5) or
CRC tissue (n=5) were placed on slides, air-dried for about 60 min
at 20uC, and fixed in paraformaldehyde, as described previous-
ly.[18] After fixation, the slides were treated in a microwave at 80
watts (363 min) in 10 mM citric acid (pH 6.0) to inhibit
endogenous peroxidase activity. They were then rinsed twice with
Tris-buffered saline (TBS; pH 7.4), and incubated overnight at 4uC
in a humidified chamber with the corresponding primary anti-
S100A6 antibody or anti-S100A11 antibody. The slides were rinsed
three times, for 10 min each, in TBS. The Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA) and the Jenchrom pxbl-kit
(MoBiTec, Go¨ttingen, Germany) were used according to the
manufacturers’ instructions to visualize the antibodies. Negative
controls were incubated with only the labelled secondary antibody.
Sections cut in parallel to the immunohistochemically treated
sections were stained with haematoxylin–eosin for better identifi-
cation of the different tissue areas. Immunohistochemical staining
was evaluated by a pathologist.
Figure 2. Immunodepletion assays of S100A6 and S100A11. Normalized ProteinChipH array profiles of metastatic tissue show that the peaks
representing S100A6 (A, 10.162 kDa) or S100A11 (B, 12.009 kDa) were detectable in the negative controls but only with decreased intensity with the
corresponding depleted probes. Reference peaks that were not influenced by immunodepletion are labelled with asterisks.
doi:10.1371/journal.pone.0003767.g002
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Statistical Analyses
Mass spectra from ProteinChip arrays were normalized to a total
ion current and cluster analysis of the detected signals was
performed. The respective P values for MTS, CRC,[19] and
HCC [17] were determined with the CiphergenExpress program
(version 3.0; Ciphergen Biosystems Inc.). To calculate the P values,
normalized spectra with signals in the range of 2.5–200 kDa, with a
signal-to-noise ratio (S/N) of at least 10, were selected and analysed
with the Mann–Whitney U test for non-parametric data sets, and
the Kruskal–Wallis test. Receiver operating characteristic (ROC)
curves [20] were constructed for S100A6 and S100A11 expression
data derived CRC, MTS or HCC, respectively by plotting
sensitivity versus 1-specificity (CiphergenExpress 3.0).
Results
Proteomic analysis of microdissected tissues from liver
metastases derived from CRC, primary CRC, and HCC by
SELDI–MS
For this study, microdissected tissue probes containing about
3000–5000 cells each were successfully dissected from 17 liver
metastases derived from colorectal cancer (MTS) by an experienced
pathologist. All protein lysates were applied to strong anion
exchanger Q10 ProteinChip Arrays and analysed individually by
SELDI–MS on a ProteinChip Reader Series 4000 instrument. The
spectra generated from the MTS were compared with specific
spectra derived from primary CRC (n= 14) and HCC (n=46),
which were generated as described previously [17,19], to detect any
distinguishing protein signals. In the range of 2.5–200 kDa, up to
372 peaks were detected with normalized intensities. After
evaluation with the CiphergenExpress program, many significantly
different signals (n= 49) were detected for MTS, CRC, and HCC
(Table S1). Among these, the peak masses with markedly low P
values were selected for further identification and characterization.
The signals at 10.175 kDa (P=3.0061029) and 11.997 kDa
(P=1.8261026) were significantly upregulated in both MTS and
CRC compared with samples derived from HCC (Figure 1). The
signal with a molecular mass of 10.175 kDa was the most significant
single signal capable of discriminating between the two sample
groups in this analysis. The 11.997 kDa signal was ranked in 12th
position (Table S1). Representative examples of SELDI–MS spectra
of MTS, CRC, and HCC are shown in Figure S1.
Identification of differentially expressed protein peaks
The interesting proteins with molecular masses of 10.175 kDa
and 11.997 kDa, which corresponded very well to the Ca2+-
binding proteins S100A6 (NCBI NP_055439) and S100A11
(NCBI NP_005611), respectively, were also detected by Pro-
teinChip technology, as has been described by ours and other
groups [17,19,21]. To confirm that S100A6 and S100A11 match
the differentially expressed peaks observed at 10.175 kDa and
11.997 kDa, respectively, in this protein profiling analysis,
immunodepletion assays were carried out using microdissected
MTS tissue as the starting material. Analysis of the supernatants of
the immunodepletion assays by Q10 arrays showed that the peaks
corresponding to S100A6 and S100A11 were significantly
reduced. In the negative controls without specific antibodies, the
peaks were clearly detectable (Figure 2). The identification of other
differentially expressed proteins is in progress.
Characterization of the differentially expressed protein
signals
To assess the impact of S100A6 and S100A11 as discriminatory
signals for different tumorous tissue samples, we compared the
spectra derived from different sample groups in individual assays.
We found that S100A6 was significantly upregulated in CRC and
MTS compared with HCC (P=2.8161026) (Figure 3). Hence,
S100A again ranked first as the most significant signal (Table S2).
An analysis of CRC and HCC showed that S100A6
(P=2.6261027) and S100A11 (P=5.5461027) were both signif-
icantly upregulated in the samples derived from CRC (Figure 4).
In this analysis, S100A6 and S100A11 ranked in third place and
fourth place, respectively, in the most significant signals (Table S3).
Interestingly, neither S100A6 nor S100A11 were significantly
differentially expressed in MTS compared with CRC (Table S4).
Localization of S100A6 and S100A11 in tissue
To confirm their identification and in particular to localize
S100A6 and S100A11 in tissue sections, we assessed their
Figure 3. ROC curve of S100A6 in liver metastases derived from colorectal carcinoma (MTS) and in hepatocellular carcinoma (HCC).
S100A6 is significantly upregulated in MTS.
doi:10.1371/journal.pone.0003767.g003
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expression in MTS and in primary CRC by immunohistochem-
istry using specific antibodies. All these tissues showed a positive
reaction to the antibodies directed against S100A6 or S100A11
(Figure 5). In contrast to these findings, only very poor signals were
detectable in the tissue surrounding the MTS (Figure 5A and D).
Interestingly, the immunoreactivity of the tumor cell complexes
was stronger at the tumor margin than that in the central tumor
area in CRC, when we used the specific antibody directed against
S100A6 (Figure 5E). Consistent with the SELDI analysis of HCC,
neither signal was detectable by immunohistochemistry (data not
shown).
Discussion
Liver metastasis of CRC is a major reason for the poor
prognosis of patients. An improved understanding of the
molecular and cellular mechanisms underlying metastasis would
contribute greatly to its early detection and treatment. The
initiation of MTS affects the expression of multiple proteins.[22–
24] The identification of proteins that are characteristic of
metastasis might allow the discrimination of different tumor
entities. To address this challenge, specific proteomic approaches
have been used that focus on the complex analysis of protein levels
in metastases using cell lines.[2527] Such altered expression
patterns have been detected for cytokeratin 18, tissue transgluta-
minase, Rho GDP-dissociation inhibitor 1, fibroblast-type tropo-
myosin, interleukin-18, annexin I, disulfide isomerase, heat shock
protein 60, peroxiredoxin 1, chlorine intracellular channel protein
1, and creatine kinase B chain, as well as for some ribosomal
proteins. Since the early 1990s, a number of studies have
investigated, with genomic approaches, tissues derived directly
from both primary tumors and organs involved in metastasis.[28–
31] This is, to the best of our knowledge, the first study to use a
proteomic approach in a comparative investigation of tissues
derived from different metastasising primary tumors and in the
identification of proteins that can discriminate between these
Figure 4. ROC curves of S100A6 and S100A11 in colorectal carcinoma (CRC) and in hepatocellular carcinoma (HCC). Both proteins are
significantly upregulated in CRC.
doi:10.1371/journal.pone.0003767.g004
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tumor types and between tumors and metastases. In contrast to the
majority of SELDI–MS-based studies, we identified significantly
differentially expressed proteins. The Ca2+-binding proteins
identified here, S100A6 and S100A11, can distinguish very clearly
between MTS, primary CRC, and primary HCC, as well as
between CRC and HCC. A number of additional signals were
detected that discriminate between MTS and CRC, but S100A6
and S100A11 do not. The identification of specific signals that can
distinguish between metastases and the primary tumor is in
progress. Until now, only two small studies have comparatively
assessed the expression of S100A6 in human colorectal mucosa,
primary colorectal adenocarcinomas, and liver metastases using a
specific western blot analysis [32,33]. In contrast, we analysed an
extended number of samples using a hypothesis-free proteomic
approach and thereby detected and identified S100A6 as a factor
with the potential to discriminate between primary HCC and
MTS. S100A6 and S100A11 belong to the group of S100 proteins
involved in the Ca2+ signalling network, and regulate intracellular
activities such as cell growth and motility, cell-cycle progression,
transcription, and cell differentiation.[34,35] Both S100A6 and
Figure 5. Immunohistochemical analysis of S100A6 and S100A11 and corresponding H&E sections. (A) and (B) H&E section from liver
metastases derived from colorectal carcinoma (MTS) and colorectal carcinoma (CRC). (C) Corresponding section to (A) immunostained for S100A6
using a specific antibody. A positive immunohistochemical reaction was detectable in the MTS (labeled with arrows) and in adjacent necrotic tissue
(nec). The surrounding liver tissue was negative. (D) Corresponding section to (B). Scattered immunoreactive tumor cell complexes (labeled with
arrows) at the tumor periphery of a colorectal carcinoma (CRC) detected with anti-S100A6 antibody. (E) and (F) H&E section from liver metastases
derived from colorectal carcinoma (MTS) and colorectal carcinoma (CRC). (G) Corresponding section to (E). S100A11-positive tumor cell complex
(labeled with an arrow) in MTS. (H) Corresponding section to (F). Strong S100A11 immunoreactivity in CRC tumor cell complexes (labeled with
arrows). Immunoreactivity against S100A11 was stronger in the tumor margin compared to central tumor area.
doi:10.1371/journal.pone.0003767.g005
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S100A11 have been observed in several epithelial tumors and are
linked to metastasis.[19,32,36,37]
In this study, we have demonstrated the potential of SELDI–
MS in characterizing metastasis in terms of protein profiles and in
discriminating between different tumor entities. In future, it would
be very interesting to assess and compare the protein profiles of
metastases derived from different types of metastasising tumors.
We might expect to find a panel of protein signals or a ‘‘metastatic
protein profile’’ that is common to all metastatic tissues. This panel
will presumably contain proteins involved in the coordination of
metastatic processes. Although neither S100A6 nor S100A11 can
discriminate between MTS and the corresponding primary CRC,
they can discriminate between primary CRC and primary HCC.
Perhaps more importantly, S100A6 is a potential candidate to
discriminate between MTS and primary HCC. The discrimina-
tion of primary HCC and its metastases located in the liver is
presently complicated and afflicted with difficulties.[38] Therefore,
S100A6 might provide some resolution of this problem.
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Table S1. Significantly different signals that distinguish tissues from liver metastases derived 
from colorectal carcinoma (MTS), colorectal carcinoma (CRC), and hepatocellular carcinoma 
(HCC), detected on Q10 arrays. The signals representing the subsequently identified S100A6 
and S100A11 are shown in bold. 
Signal in MW (kD) P-value 
MTS 3.483 3.23x10-2 
CRC 4.968 8.66x10-4 
CRC 5.077 5.35x10-7 
HCC 5.362 1.82x10-7 
MTS 5.658 2.09x10-3 
CRC 5.943 4.12x10-2 
HCC 6.648 1.09x10-3 
HCC 6.736 8.35x10-4 
HCC 7.571 1.75x10-5 
HCC 7.667 1.07x10-4 
HCC 7.943 2.87x10-3 
CRC 8.225 6.54x10-6 
CRC 8.411 3.66x10-2 
HCC 9.163 1.02x10-4 
HCC 9.613 1.16x10-7 
HCC 9.976 4.07x10-6 
CRC 10.175 3.00x10-9 
CRC 10.358 2.80x10-7 
CRC 10.394 6.30x10-8 
MTS 11.315 1.35x10-2 
MTS 11.357 1.23x10-2 
CRC 11.683 4.49x10-2 
CRC 11.997 1.82x10-6 
HCC 13.546 1.39x10-3 
MTS 13.783 7.62x10-3 
MTS 14.018 1.48x10-2 
HCC 14.975 1.68x10-7 
HCC 15.138 5.14x10-6 
HCC 15.351 1.34x10-3 
HCC 15.882 8.32x10-5 
HCC 19.944 3.00x10-9 
HCC 20.845 1.40x10-8 
HCC 21.285 1.52x10-6 
HCC 22.271 3.20x10-5 
CRC 23.162 7.85x10-3 
CRC 23.807 3.50x10-6 
CRC 24.807 2.79x10-5 
MTS 28.117 1.59x10-3 
CRC 32.045 1.32x10-4 
HCC 41.762 4.20x10-8 
HCC 44.215 4.31x10-5 
HCC 46.497 1.65x10-2 
HCC 51.508 1.15x10-3 
MTS 53.673 2.16x10-2 
HCC 54.428 3.34x10-7 
HCC 55.435 3.00x10-9 
CRC 68.187 5.45x10-3 
MTS 78.225 2.46x10-5 
CRC 118.336 2.50x10-2 
Table S1. Significantly different signals that distinguish tissues from liver metastases derived 
from colorectal carcinoma (MTS), colorectal carcinoma (CRC), and hepatocellular carcinoma 
(HCC), detected on Q10 arrays. The signals representing the subsequently identified S100A6 
and S100A11 are shown in bold. 
Signal in MW (kD) P-value 
MTS 3.483 3.23x10-2 
CRC 4.968 8.66x10-4 
CRC 5.077 5.35x10-7 
HCC 5.362 1.82x10-7 
MTS 5.658 2.09x10-3 
CRC 5.943 4.12x10-2 
HCC 6.648 1.09x10-3 
HCC 6.736 8.35x10-4 
HCC 7.571 1.75x10-5 
HCC 7.667 1.07x10-4 
HCC 7.943 2.87x10-3 
CRC 8.225 6.54x10-6 
CRC 8.411 3.66x10-2 
HCC 9.163 1.02x10-4 
HCC 9.613 1.16x10-7 
HCC 9.976 4.07x10-6 
CRC 10.175 3.00x10-9 
CRC 10.358 2.80x10-7 
CRC 10.394 6.30x10-8 
MTS 11.315 1.35x10-2 
MTS 11.357 1.23x10-2 
CRC 11.683 4.49x10-2 
CRC 11.997 1.82x10-6 
HCC 13.546 1.39x10-3 
MTS 13.783 7.62x10-3 
MTS 14.018 1.48x10-2 
HCC 14.975 1.68x10-7 
HCC 15.138 5.14x10-6 
HCC 15.351 1.34x10-3 
HCC 15.882 8.32x10-5 
HCC 19.944 3.00x10-9 
HCC 20.845 1.40x10-8 
HCC 21.285 1.52x10-6 
HCC 22.271 3.20x10-5 
CRC 23.162 7.85x10-3 
CRC 23.807 3.50x10-6 
CRC 24.807 2.79x10-5 
MTS 28.117 1.59x10-3 
CRC 32.045 1.32x10-4 
HCC 41.762 4.20x10-8 
HCC 44.215 4.31x10-5 
HCC 46.497 1.65x10-2 
HCC 51.508 1.15x10-3 
MTS 53.673 2.16x10-2 
HCC 54.428 3.34x10-7 
HCC 55.435 3.00x10-9 
CRC 68.187 5.45x10-3 
MTS 78.225 2.46x10-5 
CRC 118.336 2.50x10-2 
Table S3. Significantly different signals that distinguish colorectal carcinoma (CRC) and 
hepatocellular carcinoma (HCC), detected on Q10 arrays. The signals representing S100A6 
and S100A11 are shown in bold. 
Signal in MW (kD) P-value 
CRC 4.968 2.98x10-4 
CRC 5.079 5.53x10-6 
HCC 5.271 3.25x10-2 
HCC 5.362 5.08x10-6 
HCC 5.658 1.11x10-3 
CRC 5.944 1.39x10-2 
HCC 6.648 3.28x10-3 
HCC 7.571 1.90x10-5 
HCC 7.661 2.41x10-5 
HCC 7.943 3.09x10-3 
CRC 8.226 1.96x10-6 
CRC 8.408 1.32x10-2 
HCC 9.163 1.27x10-4 
HCC 9.613 2.14x10-6 
HCC 9.974 7.08x10-5 
CRC 10.182 2.62x10-7 
CRC 10.359 5.54x10-7 
CRC 10.541 3.71x10-2 
HCC 11.315 2.15x10-2 
CRC 11.997 5.54x10-7 
HCC 13.546 4.36x10-3 
HCC 13.787 4.36x10-3 
HCC 14.018 8.81x10-3 
HCC 14.975 2.16x10-7 
HCC 15.138 1.26x10-5 
HCC 15.351 2.98x10-4 
HCC 15.882 1.47x10-4 
HCC 19.951 4.10x10-8 
HCC 20.845 1.13x10-5 
HCC 21.285 3.30x105- 
HCC 22.276 3.88x10-4 
CRC 23.166 2.54x10-3 
CRC 23.801 8.83x10-6 
CRC 24.807 9.09x10-5 
HCC 28.003 4.85x10-3 
CRC 32.045 4.45x10-4 
HCC 41.781 4.05x10-6 
HCC 51.559 2.37x10-4 
HCC 54.396 1.13x10-5 
HCC 55.435 1.98x10-6 
CRC 68.188 1.16x10-2 
HCC 82.182 3.30x10-5 
CRC 118.336 6.08x10-3 
CRC 172.524 5.85x10-4 
Table S4: Significantly different signals which separate tissues from liver metastases derived 
from colorectal carcinoma (MTS) and colorectal carcinoma (CRC) detected on Q10 arrays.  
Signal in MW (kD) P-value 
CRC 4.966 3.76x10-2 
MTS 5.655 1.26x10-2 
CRC 8.208 4.10x10-4 
CRC 10.356 2.40x10-3 
MTS 10.845 1.82x10-3 
MTS 11.308 3.39x10-2 
CRC 11.681 2.75x10-2 
CRC 11.835 4.60x10-2 
MTS 14.024 4.16x10-2 
CRC 23.162 6.94x10-3 
MTS 47.952 2.51x10-2 
MTS 51.431 3.62x10-3 
MTS 53.641 6.11x10-3 
MTS 94.521 8.90x10-3 
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ABSTRACT
Motivation: On the histological level the differentiation of normal
epithelial tissues is well known. The phenomenon of dedifferentiation,
which occurs as cells develop towards malignancy is also well
described. To identify an epithelial tumor-specific proteomic profile as
well as to measure the proximities between we used data from tumor
tissue and adjacent normal tissue microdissected from head and neck
and colon cancer samples which were analyzed using ProteinChip
technology and performed a bioinformatic meta-analysis on the result-
ing four complex datasets.
Results: All four groups could be identified based on their proteomic
signatures and the tumor tissues were found to be more similar to
one another than to the normal epithelial tissue from which they pro-
gressed. This study shows at the proteomic level that changes in the
histological features of tumors as compared to the tissues from which
they arise are reflected in the convergence of proteomic pattern during
the development to cancer.
Contact: fegg@mti.uni-jena.de
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
An epithelium is an assembly of polarized cells with defined apical
and basolateral domains that lines the inner and outer organ sur-
faces. There are many types of epithelia specialized to carry out
functions, including protection, secretion, nutrient resorption and
polarized transport between tissue compartments. The morphologi-
cal redirection of cellular differentiation during the progression to
cancer reflects the functional properties of malignant cells as
increased proliferation, invasion and metastasis. However, their
way to ‘simplicity’ was not revealed for the expression of genes
and proteins.
The ProteinChip technology (surface-enhanced laser desorption/
ionization mass spectrometry; SELDI) which utilizes chromato-
graphic surfaces able to retain proteins depending on their physico-
chemical properties followed by direct analysis via time of flight
mass spectrometry (von Eggeling et al., 2001; Hutchens and Yip,
1993) has been predominantly used to analyze bodily fluids
including serum (Zhang et al., 2004), urine (Vlahou et al.,
2001), nipple aspirates (Paweletz et al., 2001) and pancreatic
juice (Rosty et al., 2002). We employed microdissected tumor tissue
free of adjacent, non-malignant tissue for ProteinChip analysis to
improve the chances of identifying reliable biomarkers for cancer
diagnostics (Melle et al., 2005; Melle et al., 2004a). The principal
task of studies utilizing ProteinChip technology to date has been
tumor marker identification, and not the global analysis of the
differences in the tumor and normal tissue proteomes.
From histological prospective, epithelial cells appear to undergo a
dedifferentiation process during their progression towards malig-
nant neoplasias. These changes should also be apparent at the
biochemical level of the tissue proteome. Bioinformatic analysis
methods that are capable of analyzing and comparing the entire
proteomes of tumor and normal tissue on a global level should
make it possible to identify a potential tumor-specific proteomic
signature as well as to show the convergence to a more common
protein signature (Fig. 1).
We combined the proteomic profiles generated in previous
studies of microdissected tissue areas from head and neck cancers
and the adjacent normal pharyngeal epithelium with the proteomic
profiles from non-hereditary colorectal cancer and the adjacent
normal colonic epithelium in a meta-analysis. We show that
these groups can be separated by specific peaks or signatures,
and that the two different cancer types are more similar to each
other than to the epithelia from which they developed.
2 METHODS
2.1 Tumor specimens and analysis of microdissected
tissue by ProteinChip arrays
Tumor samples were obtained after surgical resection in the Department of
General and Visceral Surgery and the ENT Department of the Friedrich
Schiller University in Jena. Staging and grading information can be
found in former studies (Melle et al., 2005, 2004a, 2003). Laser microdis-
section of normal tumor epithelium was performed with a laser microdissec-
tion and pressure catapulting microscope (LMPC; Palm, Bernried, Germany)
(Melle et al., 2005, 2003). Protein lysates were prepared from microdis-
sected tissues, and lysates were analyzed on strong anion exchange arrays
(SAX2; Ciphergen Biosystems Inc, Fremont, CA) as described (Melle et al.,
2003). Mass analysis was performed in a ProteinChip Reader (model PBS
IIc, Ciphergen Biosystems Inc, Fremont, CA). Spectra with at least 10 signals
in the range between 2 and 20 kDa exhibiting a signal-to-noise ratio (S/N) of
at least 5 were selected and exported for further analysis.
To whom correspondence should be addressed.
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2.2 Data
The data generated from ProteinChip arrays for 172 (¼ m) protein peaks
and 106 samples were averaged over the following groups of samples:
NCOL (normal colonic epithelial tissue, n ¼ 18), TuCOL (colorectal carci-
noma tissue, n ¼ 29), NHN (normal pharyngeal epithelial tissue, n ¼ 28),
TuHN (head and neck tumor tissue, n ¼ 31), NALL (normal colonic and
pharyngeal epithelial tissues, n ¼ 46), TuALL (colorectal carcinoma and
head and neck tumor tissue, n ¼ 60), COLALL (normal colonic epithelium
and colorectal carcinoma, n ¼ 47) and HNALL (normal pharyngeal epithe-
lium and head and neck tumors, n ¼ 59).
2.3 Statistical and bioinformatic analysis
The following groups were compared using two-sided t-tests: NALL versus
TuALL, NCOL versus TuCOL, NHN versus TuHN, COLALL versus
HNALL, NCOL versus NHN and TuCOL versus TuHN. The probability
that two samples were from a normal distribution with unknown but equal
variances and had the same mean was analyzed in these t-tests and P-values
were calculated and adjusted according to the Bonferroni method (signifi-
cance level a, p/m < a) (Bonferroni, 1936).
Decision trees were generated to classify the same six pairs of sample
subsets that were analyzed using t-tests (Breiman et al., 1993). The tree-
based models were fitted using the MATLAB function, treefit (MathWorks
Inc., Natick, MA). Gini’s diversity index was applied as the split criterion.
Random forest (RF) is a classification tool based on decision trees. The
implementation of RF in R (www.r-project.org) was used in this study. For
classification, the program was run in the supervised mode to build 5000
trees using an mtry-parameter of 30. Characteristic features (peaks) were
identified and their importance was calculated.
Average group proximities (Breiman, 2004, http://oz.berkeley.edu/users/
breiman/Using_random_forests_V3.1.pdf) describing the intrinsic similarity
between two sample groups were calculated from the individual proximities
from an RF run in the unsupervised mode. Support vector machines (SVMs)
(Ma et al., 2005, http://www.eleceng.ohio-state.edu/~maj/osu_svm; Vapnik,
1998) were applied to identify profiles that could decide among the six pairs
of sample groups listed above in the data description. The classifier was
validated using leave-one-out cross-validation. The prediction accuracy was
determined as a quotient, Q, dividing the number of true predicted observa-
tions by the total number of tests (which equals the number, n, of samples
considered).Q characterizes the predictive strength of a parameter pair. Pairs
or triples of parameters with the maximum prediction accuracy were
selected.
3 RESULTS
3.1 Classification and search for characteristic
features
Classification was performed using different methods for six pairs
of sample groups which are listed in Supplementary Table 1. As
results, the following information was derived: (1) features distin-
guishing the two groups (classificators), their number as well as
their significance and (2) quality of class prediction/error rate.
3.1.1 t-test The number of proteins whose mean expression data
averaged over two groups of tissues differ significantly (Supple-
mentary Table 1). Many proteins, i.e. 61 with a significance level of
5% and 33 with a significance of 0.01% of the 172 investigated
proteins are differentially expressed in tissues head and neck versus
colon. However, the number of proteins which are differentially
expressed in normal versus tumor cells are only few. Proteins iden-
tified by t-test on the significance level 5% are shown in Supple-
mentary Table 2. Supplementary Figure 2 (Supplementary Data)
illustrates that the mean values of expression signals for the protein
at 9645 Da is different, averaged over normal and tumor samples.
3.1.2 Decision trees Also here all the six comparision were car-
ried out. For the comparision NCOL–NHN, the most clear decision
tree was found: there was just one split point corresponding to the
peak at 10 848 Da, which was identified in a former study as cal-
granulin A (Melle et al., 2004a). Here intensities smaller than 1
exclusively belong to the group NCOL and such bigger one to NHN.
For the other five comparisons more complex trees were found,
indicating that these pairs are less different.
3.1.3 Random forest classification The RF for the whole dataset
(four classes at once) gave a classification with an error rate close to
20%. This result was attained after parameter optimization. The
confusion matrix (Supplementary Table 3) shows for each tissue
class the number of samples and the class labels RF assigned to
them. The tissue type [colon or head and neck (pharynx)] was
almost correctly assigned for both N-groups, except from two
cases where TuCOL samples are classified as TuHN. On the
contrary, frequent confusion occurred between normal and tumor
samples of the same tissue type. From the above classification, the
importance of the features making up the forest was derived. These
calculations yielded about 50 features which were more important
than the background. The 20 most important peaks are listed in
Supplementary Table 4 in order of decreasing importance. Among
all these classifiers, it is worth noting two outstanding features, the
peaks corresponding to and at 13 245.3 Da and 10 848.5 Da are
clearly more important than the rest. The importance value of the
latter is not so apart from the others, however, this feature has
special properties: m/z 10 848.5 was found to play an important
role in the identification of each of the four classes. After that,
RF for two classes was run. RF performed a perfect classification
of normal tissue samples (NCOL versus NHN). In contrast, in
all other cases (TuCOL versus TuHN, NHN versus TuHN,
NCOL versus TuCOL) misclassification of samples occurred
(Supplementary Table 5).
Fig. 1. Convergence of proteomic pattern in cancer (freehand delineation, not
to scale).
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3.1.4 Support vector machines SVM were used to calculate
the prediction accuracy as a quotient Q dividing the number of
true predicted observations by the total number of tests. A total
of 50 pairs of proteins were found whose expression signals predict
the samples NCOL versus NHN with the prediction accuracy of
100% (Supplementary Table 6). The expression signals of one of
these pairs are shown in Supplementary Figure 3. In opposition to
the error free prediction of colon versus head and neck for normal
cells (NCOL versus NHN) the prediction accuracy is <94% for
tumor cells (TuCOL versus TuHN) (Supplementary Table 6). A
total of eight protein pairs were found that allow a prediction accu-
racy >90% but <94%. The prediction of tumor versus normal tissue
is found to be possible only with a reduced accuracy <90%. The
pairs of proteins whose expression signals allow an accuracy >85%
for the prediction TuCOL versus NCOL are shown in Supplemen-
tary Table 7. The prediction accuracy for tumor versus normal head
and neck tissue is <85%. A total of 19 pairs of proteins were found
whose expression signals allow a prediction accuracy between
80 and 85%, no pair exists with a prediction accuracy >85%
(Supplementary Table 6).
3.2 Similarity measures
3.2.1 RF-proximities The average proximities were derived for
the same six pairs of sample groups that were compared in the
classifications (Supplementary Figure 4). Sorted by magnitude,
the proximity values increase almost evenly from 0.06 to 0.16.
As a conclusion, it can be stated that there is higher proximity
between normal and tumor samples (from one tissue type as well
as from both tissue types together) than between samples of differ-
ent tissue types. It is noted that the lowest proximity is the one
between NCOL and NHN, these two classes are the most dissimilar
classes.
3.2.2 Mean square distances for classifiers found with random
forest For the most important peaks from the RF classification
NCOL–NHN, the mean square distances for the six pairs of sample
groups were calculated. For the peak at 10 848.5 Da, the result is
shown in Figure 2. The mean square distance between colon, head
and neck tissue is significantly larger in the normal state than in the
tumor state. This should be taken into account because it is not an
isolated fact considering 10 of the most important peaks, in 6 cases,
the COL–HN distances are larger in the normal state than in the
tumor state. The difference between the two values is mainly not so
striking as in the above example. However, these data allow to
ascertain a tendency. From the overall RF classification, the 20
most important features (listed in Supplementary Table 8) were
investigated. For nine among them, mean square distances between
COL and HN behave according to the tendency stated in Supple-
mentary Figure 4 (data not shown).
4 DISCUSSION
The combination of different chip-based genomic and proteomic
techniques with bioinformatic analysis methods is indispensable for
the search of tumor-specific signatures. In addition, the relatedness
of different tissues to the tumors arising from these tissues is impor-
tant to completely understand the biology of cancer. Expression
studies have been carried out for many different tumor types.
Most of these studies compared homogenates of whole tumor
biopsies that contain enough cells of the normal tissue in order
to deliver a mixed tumor and normal signature. This provides
problems with the analysis, because the tumor signature is not
clearly definable.
Two basic questions arose during the course of our studies of
different microdissected epithelial tumor entities using ProteinChip
technology (Melle et al., 2005, 2004a,b, 2003; von Eggeling et al.,
2000). The central question whether it is possible to identify a single
or set of individual peaks differentiating between normal and tumor
tissues has been affirmatively answered in several studies by our
own group as well as others (Melle et al., 2005; Zhang et al., 2004;
Wilson et al., 2004; Melle et al., 2004a,b). We became curios as to
whether a common signature for malignancies arising from various
epithelial tissues could be identified. Pathologists have long
described that during tumorigenesis a morphological dedifferentia-
tion in comparison with the tissue of tumor origin takes place.
However, this process of dedifferentiation has only partly been
shown on a molecular level. Proteomic profiling using purely
defined tissue material presents an ideal method to show the mole-
cular equivalents of this process as well as to investigate what
changes dedifferentiation entails. To approach these questions,
we analyzed the data produced from proteomic profiling of micro-
dissected normal and tumor tissues from head and neck and colon
cancers using two different bioinformatic approaches.
The different bioinformatic algorithms applied for the meta-
analysis of the proteomic profiles of the four tissue groups focused
on two different questions. First, to identify characteristic features
differentiating between the four tissue groups, and second, to ana-
lyze how similar the groups were to one another. Classification of
the group using characteristic features was possible using all the
bioinformatic methods applied to a certain extent. The comparison
NCOL–NHN was the only case where sample classes could be
predicted perfectly, whereas in all other comparisons classification
errors occurred. We conclude, that these two groups appear to be the
most different from one another. Similar features can be found in all
the resulting peak lists generated using different methods, indicating
that the patterns generated using different methods were quite simi-
lar (see Supplementary Tables 2, 4, 7 and 8). That these features
were identified by more than one method underlines the significance
of these classifiers. The similarity measures calculated in this study
agree with the interpretation of the group classification results. Both
proximities as well as mean square distances between groups
revealed that the tumorous tissues (COL and HN) were more similar
than the normal tissues from which they were derived. This is
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Fig. 2. Mean square distances of the four tissue classes concerning the peak at
10 848.5 Da.
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especially true for the peak at 10 848 Da, which could be identified
as a classifier in a former study (Melle et al., 2004a).
The results from both bioinformatic approaches concluded that
the differences between normal epithelial tissues are larger than
between the tumor tissues arising from these epithelial tissues.
These results support the hypothesis that epithelial tissues become
more similar during their progression towards a tumorous state at
the proteomic level (Fig. 1). This conclusion is consistent with the
biological features of these tissues. The epithelia from colon and
pharynx develop namely from the entoderm, but are functionally
reflected in their proteomic distance. The hypo- and mesopharynx is
lined by a multi-layered, squamous epithelium that assures a pro-
tective function. The colon, however, is lined by a prismatic, single-
layered epithelium with predominantly secretory (mucine) und
resorptive (water) capabilities in addition to a function for the
excretion of heavy metals. In contrast, TuCOL and TuNH display
a more closely related common tumor signature that is recognized in
bioinformatic analysis through the closer similarity or proximity of
these groups. For the tumor, functions such as proliferation, inva-
sion and metastasis become more important for tumor survival than
the maintenence of the normal epithelial cell functions. Therefore,
structural and functional dedifferentiation from the functionality of
the tissue of origin is the result also reflected in the histological
appearance of the tumor tissue. Interestingly the dedifferentiation is
also known in the histopathological grading which forms the basis
for the classification of tumors. Additionally, it could be shown that
common signatures are present for the two normal epithelial tissues
and for the two tumor tissues. Specific classifiers could be identified
using both bioinformics methods employed here to distinguish
among all four tissue groups. For the groups with the lowest proxi-
mity (NHN versus NCOL) only one peak (10.8 kDa) is necessary,
but for groups with a high proximity the classifier becomes more
complex. Especially for the classification of clinically relevant
groups (e.g. NHN versus TuHN), it becomes clear that a reliable
diagnosis can only be achieved using a multi-marker classifier or a
specific signature of expressed genes or proteins.
Our analyses support the notion that the identification of a
general tumor signature including similarities indicating features,
such as malignancy, will be feasible in future. This proteomic sig-
nature may further contribute, especially in combination with addi-
tional methods, mainly an optimized tissue microdissection and
analysis [e.g. Ernst et al. (2006)], to reveal the heterogeneity of
the tumor and to identify metastasizing clones inside the malignant
tissue.
In conclusion, we provide proof-of-principle at the proteomic
level that changes in the histological features of tumors as compared
with the tissues from which they arise are reflected in the conver-
gence of proteomic pattern during the development to cancer.
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Supplementary Data 
 
Tables  
 
Table 1: Number of differentially expressed proteins (t-test, significance level α adjusted 
according Bonfferoni [1]; n  number of samples considered) 
Significance level αComparison n
5 % 1 % 0.1 % 0.01%
NALL vs TuALL  
NCOL vs TuCOL 
NHN vs TuHN 
 
HNALL vs COLALL 
NHN vs NCOL 
TuHN vs TuCOL 
106 
47 
49 
 
106 
46 
60 
 5
1
15 
 
61 
 50
21 
 2
1
11 
 
47 
 39 
 13 
 0
0
1
40 
 25 
 7
0
0
0
33 
 15 
 3
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Table 2: Protein peaks differentially expressed for normal versus tumor tissue (t-test, 
significance 5% *, 1% **, 0.1 ***) 
Peak, Protein [Da] NALL vs 
TuALL 
NCOL vs 
TuCOL 
NHN vs TuHN  
 
5
63 
 90
110 
 113 
 115 
 116 
 117 
 118 
 119 
 123 
 124 
 125 
 126 
 153 
 3115.18 
 5519.20 
 7353.84 
 9087.29 
 9334.72 
 9645.24 
 9773.54 
 9888.74 
 9978.04 
 10106.6 
 10434.6 
 10544.2 
 10640.4 
 10848.5 
 14705.7 
** 
 
*
** 
*
*
** 
** 
*
** 
** 
** 
*** 
** 
** 
*
** 
*
** 
** 
*
** 
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Table 3: Result of the supervised RF classification of the whole dataset in a confusion matrix. 
 classified as 
NCOL 
classified as 
NHN 
classified as 
TuCOL 
classified as 
TuHN 
NCOL 13 0 5 0 
NHN 0 24 0 4 
TuCOL 3 0 24 2 
TuHN 0 6 2 23 
Müller/Ernst et al. (Supp) 
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Table 4: The importance of features (protein peaks) found by RF. The first three were 
identified in former studies (8;9). Tandem MS data for calgranulin A (10.8 kDa) and 
calgranulin B (13.2 kDa) are shown in supplemental data (Fig S1 + S2). 
Importance  Peak at m/z [Da] 
4.63 13245.30 
3.85 10848.50 
3.83 3471.67 
3.68 7353.84 
3.58 15823.00 
3.56 11056.90 
3.34 12490.90 
3.30 7910.54 
3.27 10544.20 
3.23 3798.21 
3.21 9645.24 
3.17 9087.29 
3.13 3400.80 
2.86 6145.28 
2.83 12347.00 
2.82 16238.70 
2.81 5519.20 
2.76 18355.20 
2.59 3515.31 
2.56 3115.18 
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Table 5: Error rates of supervised RF classification dealing with pairs of sample groups 
Comparison Error rate [%]
NCOL vs TuCOL 
NHN vs TuHN 
 
NHN vs NCOL 
TuHN vs TuCOL 
17.0
18.6
0.0
3.3
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Table 6: Maximum prediction accuracy obtained by SVM together with cross-validation  
Comparison Qmax [%]
NALL vs TuALL  
NCOL vs TuCOL 
NHN vs TuHN 
 
HNALL vs COLALL 
NHN vs NCOL 
TuHN vs TuCOL 
78.3
87.2
84.8
94.2
100.0
93.3
Müller/Ernst et al. (Supp) 
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Table 7: Seven pairs of protein peaks whose expression signals allow a prediction of TuCOL 
versus NCOL with an accuracy greater than 85%  
Peak, Protein 1 [Da] Peak, Protein 2 [Da] Q [%] 
17
12
21
20
17
12
12
3697.31 
3471.67 
3798.21 
3763.08 
3697.31 
3471.67 
3471.67 
21
37
129
21
123
127
21
3798.21
4343.47
11056.9
3798.21
10434.6
10923.8
3798.21
87.2 
87.2 
85.1 
85.1 
85.1 
85.1 
85.1 
Müller/Ernst et al. (Supp) 
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Table 8: Mean square distances for the ten most important peaks from the RF classification 
NCOL vs NHN. For the identification of the first two peaks by Tandem MS see supplemental 
data figure S1 + S2. 
Peak at m/z [Da] 
Mean square 
distance NCOL-
NHN 
Mean square 
distance TuCOL-
TuHN 
10848.50 38.82 7.40
13245.30 3.69 0.74
12490.90 0.25 0.14
10923.60 13.31 3.08
9773.54 0.77 0.70
11056.90 5.77 2.21
5427.23 13.44 5.53
12347.00 0.14 0.17
12278.50 0.13 0.11
10981.50 3.50 1.67
Müller/Ernst et al. (Supp) 
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Figure legends 
 
Figure 2: Distribution of samples from normal and tumor tissue from pharynx (left) and colon 
(right) with respect to the expression signal of the protein at 9645 Da.  
 
Figure 3: Expression signals of the peaks at 13245.3 versus 16238.7 for the samples NCOL 
() and NHN (o) 
Figure 4: Average proximities between the sample groups (pairs of groups according to the 
comparisions in chapter t-test). 
Müller/Ernst et al. (Supp) 
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Figures:  
Müller et al., Fig. 2
Müller et al., Fig. 3
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Müller et al., Fig. 4
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Detection and Identification of Protein Interactions of S100 Proteins
by ProteinChip Technology
Roland Lehmann,† Christian Melle,*,† Niko Escher, and Ferdinand von Eggeling
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The aim of this work was to establish an approach for identification of protein interactions. This assay
used an anti-S100A8 antibody coupled on beads and incubated with cell extract. The bead eluates
were analyzed using ProteinChip technology and subsequently subjected to an appropriate digestion.
Molecular masses of digestion fragments were determined by SELDI-MS, and database analysis
revealed S100A10 as interacting protein. This result was confirmed by co-immunoprecipitation and
immunocapturing. Using S100A10 as new bait, a specific interaction with S100A7 was detectable.
Keywords: S100 proteins • protein-protein interaction assay • surface-enhanced laser desorption/ionization-mass
spectrometry (SELDI-MS) • immunoprecipitation
Introduction
Functional characterization of the proteome interaction
studies are of particular interest, because it is known that most
of the proteins are usually interconnected. Interacting proteins
are often involved in the same biochemical pathway. The
identification of an interacting partner of a protein of unknown
function can help to clarify its function. Defining the interaction
partners of known proteins is invaluable to detailing its
mechanism of action and regulation. The idea of temporal and
spatial localization of different proteins at specific sites in the
cell suggests that interactions of different components involved
in the same cellular processes are required. The clarification
of the association of a molecular machine or regulatory factor
may help to understand cellular regulatory mechanisms.1
Recently, many different techniques have been used to define
protein-protein interactions.2 In vitro techniques are recog-
nized as often generating false positives.3 To avoid this problem,
a multitude of in vivo methods have been developed including
yeast two hybrid assays.4 However, yeast two hybrid screens
can also generate a fairly high number of both false positives
and negatives.5 Recently, a new technique named SELDI-MS
(surface-enhanced laser desorption/ionization mass spectrom-
etry) was developed which comprises ProteinChip arrays and
mass spectrometry.6,7 The ProteinChip array carries spots with
different chromatographic surfaces to retain proteins regarding
their physicochemical properties. The spots can easily be
purified from contaminants such as buffer salts or detergents
by washing, thus eliminating the need for prepurification
techniques as required with other MS techniques. For this
reason, crude biological extracts, such as cell lysis extract,
serum ,or other biological fluids can be spotted directly on the
ProteinChip arrays for mass spectrometric analysis. One ap-
plication of SELDI-MS is the analysis of protein patterns of
different biological samples mainly derived from cancer and
noncancer patients.8-12 In a former protein profiling study of
head and neck squamous cell carcinoma (HNSCC) carried out
by SELDI-MS, a decreased expression of S100A8/A9 in micro-
dissected tumor tissue was detected.13 These proteins are
members of the S100 Ca2+ binding family and have received
increased attention because of their involvement in several
human diseases such as rheumatoid arthritis, acute inflam-
matory lesions, cardiomyopathy, Alzheimer’s disease, and can-
cer.14,15 The aim of the present study was the proof of principle
of a procedure composed of immunoprecipitation techniques
and SELDI technology to detect and identify protein-protein
interactions from crude cell extracts. On this account, we
started to analyze the interaction partners of S100A8/A9.
Hereby, we were able to detect specific interactions between
different S100 proteins using specific immunoaffinity beads.
These interactions were visible by SELDI-MS and the interac-
tion partners were identified as S100A10 (calpactin light chain;
p11) and S100A7 (psoriasin), respectively, and further con-
firmed using co-immunoprecipitation and immunocapturing.
Materials and Methods
Cell Culture. HaCaT cells, a spontaneously immortalized
human keratinocyte cell line, were cultured in DMEM supple-
mented with 10% fetal bovine serum.16 Cells were grown to 80%
confluence and were passaged at a split ratio of 1:4. At 95%
confluence, cells were harvested and lysed in a buffer contain-
ing 100 mM sodium phosphate pH 7.5, 5 mM EDTA, 2 mM
MgCl2, 3 mM 2-â-mercaptoethanol, 0.1% CHAPS, 500 µM
leupeptin, and 0.1 mM PMSF. After centrifugation (15 min;
15 000 rpm) the supernatant was used immediately.
Protein-Protein Interaction Assay. A twenty-microliter
portion of Interaction Discovery Mapping (IDM) beads (Ci-
phergen Biosystems Ltd., Fremont, Ca) was incubated with 4
µL protein A (Sigma) overnight at 4 °C. A pellet was generated
by centrifugation, and the supernatant was discarded. The
pellet was washed twice with a buffer containing 50 mM
sodium acetate pH 5.0. Afterward, the beads were incubated
in a buffer containing 0.5 M Tris/HCl pH 9.0, 0.1% Triton X-100
* To whom correspondence should be addressed. Tel: +49(0)3641-935529.
Fax: +49(0)3641-935518. E-mail: christian.melle@mti.uni-jena.de.
† These authors contributed equally to this work.
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for 2 h at room temperature for blocking residual reactive
groups. The beads were washed three times with 1× PBS.
Thereafter, 40 µL of specific antibody (0.2 µg/µL) against human
S100A8 (S13.67; BMA Biomedicals; Augst, Switzerland), human
S100A9 (S36.48; BMA Biomedicals; Augst, Switzerland), and
human S100A10 (H-21; Swant; Bellinzona, Switzerland), re-
spectively, or normal rabbit IgG (Pepro Tech Inc.; Rocky Hill,
NJ) as negative control, in 50 mM sodium acetate pH 5.0 were
applied to the beads and allowed to bind at room temperature
for 1 h in an end-over-end mixer. Unbound antibody was
removed by washing in 50 mM sodium acetate. Unspecific
binding sites were blocked using a buffer containing 2 mg/mL
bovine serum albumin in 0.5 M Tris/HCl pH 9.0, 0.1% Triton
X-100 for 2 h at room temperature in an end-over-end mixer.
Afterward, the beads were washed in 1× PBS, 0.1% Triton X-100
and in 1× PBS and incubated with 100 µL of crude HaCaT cell
extract overnight at 4 °C in an over-end-over mixer. The
unbound proteins were washed away by sequential washes in
PBS, 0.5 mM sodium chloride, 0.05% Triton X-100, 1 M urea
in PBS, PBS, and aqua bidest. Bound proteins were eluated
from the IDM beads by 10 µL 50% acetonitrile/0.5% trifluoro-
acetic acid and gently vortexed for 5 min. Five µL of the eluated
samples were applied to the activated, hydrophobic surface of
an H50 ProteinChip Array (Ciphergen Biosystem Inc.; Fremont)
and dried on air. After washing with 3 µL aqua bidest 0.5 µL
sinapinic acid (saturated solution in 0.5% TFA/50% Acetonitrile)
was applied twice and the array was analyzed in a PBS II reader
(Ciphergen; Fremont) according to an automated data collec-
tion protocol.
Tryptic Digestion of IDM Eluates. For the analysis of
fragment masses proteins eluated from IDM beads were tryptic
digested. Hereby, the volume of the samples was reduced to
nearly 5 µL, mixed with 5 µL of a buffer containing 6 M urea,
3 mM 2-â-mercaptoethanol and denaturated for 20 min at 95
°C. Afterward, sample volume was increased until samples
contained a maximum of 1 M urea, 15 µL of a tryptic solution
(4 ng/µL; in 25 mM ammonium bicarbonate) was added and
incubated for 24 h at 35 °C. Samples were sonicated for 5 min,
5 µL of them were applied directly to the activated reverse
phase surface of an NP20 array (Ciphergen; Fremont) and dried
on air. After addition of the matrix (CHCA), peptide fragment
masses were analyzed using the PBS II instrument. A standard
protein mix (all-in-1 peptide standard mix; Ciphergen, Fre-
mont), including Arg8-vasopressin (1082.2 Da), somatostatin
(1637.9 Da), dynorphin (2147.5 Da), ACTH (2933.5 Da), and
insulin beta-chain (3495.94 Da) was used for calibration.
Proteins were identified using the fragment masses generated
through trypsin digestion by searching in a publicly available
database (http://129.85.19.192/profound_bin/WebProFound.exe).
Immunocapturing Assays. For immunocapturing of specific
target proteins 2 µL protein A in 2 µL of 50 mM NaHCO3 pH
9.2 was directly coupled to RS100 ProteinChip arrays (Cipher-
gen; Fremont) overnight at 4 °C in a humidity chamber. After
incubation the supernatant was removed and 2 µL BSA (2µg/
µL) (Sigma) in 2 µL 1× PBS pH 7.2 was spotted for 2 h at room
temperature to block any remaining active sites. Afterward, BSA
was removed, spots were washed with 1× PBS pH 7.2 and 2
µL of specific antibody (0.2 µg/µL) against human S100A10 (H-
21; Swant; Bellinzona, Switzerland) or human S100A7 (ab13680;
Abcam; Cambridge, UK), respectively, or, as negative control,
normal rabbit IgG (Pepro Tech Inc.; Rocky Hill, NJ) in 2 µL of
50 mM NaHCO3 pH 9.2 were applied to the arrays for 2 h at
room temperature in a humidity chamber. Unbound antibody
was removed and spots were washed with 5 µL 1× PBS for 2
min. Afterward, the ProteinChip array was fixed in a Biopro-
cessor (Ciphergen, Fremont) and 50 µL of crude cell extract
diluted in 50 µL of a 0.1% Triton X-100 in 1× PBS pH 7.2 were
applied to each spot and incubated for 2 h at room temperature
on a shacking platform. The unbound proteins were washed
away by sequential washes in 1× PBS, 0.5 mM sodium chloride,
0.05% Triton X-100, 1 M urea in 1× PBS, 1× PBS, and aqua
bidest. The array surface was allowed to dry for 5 min, 0.5
saturated sinapinic acid was added twice and the ProteinChip
was analyzed in a PBS II reader according to an automated
data collection protocol.
Co-immunoprecipitation. Antibodies against human S100A7
(ab13680; Abcam; Cambridge, UK), human S100A8 (S13.67;
BMA Biomedicals; Augst, Switzerland), human S100A9 (S36.48;
BMA Biomedicals; Augst, Switzerland), and human S100A10 (H-
21; Swant; Bellinzona, Switzerland), or, as negative control,
normal rabbit IgG (Pepro Tech Inc.; Rocky Hill, NJ) were bound
on protein A-agarose beads. Crude extract (250 µL) from human
HaCaT cells was incubated with the antibody loaded beads for
1 h at 4 °C. Then the resins were washed three times with Co-
IP buffer containing 20 mM HEPES/KOH pH 8.0, 50 mM KCl,
0.1 mM EDTA and 0.05% CHAPS. Bound proteins were sub-
jected to 10% SDS-PAGE and detected by immunoblotting with
anti-S100A7, anti-S100A8, anti-S100A9 (S36.48; BMA Biomedi-
cals; Augst, Switzerland), or anti-S10010 antibody, respectively.
Results
Detection of S100A8 Protein Interaction Partners. We first
assessed possible interaction partners of S100A8/A9 by SELDI-
MS. Hereby, among other peaks we found a specific signal at
nearly 11.07 kDa using anti-S100A8 antibody-coupled IDM
beads compared to approaches using nonspecific antibody
(Figure 1). Beside this mentioned signal, we detected a signal
at nearly 13.22 kDa, too. This molecular mass correlates well
to the molecular mass of S100A9 that is known as a binding
partner of S100A8.
Protein Identification by Tryptic Digestion and Database
Search. Proteins eluated from both anti-S100A8 antibody
Figure 1. Protein-protein interaction assay using specific anti-
S100A8 antibody. An anti-S100A8 antibody was bound on IDM
beads, incubated with crude HaCaT cell extract and binding
partners were analyzed by SELDI-MS. Among signals of 10.87
kDa and 13.22 kDa that represent S100A8 and S100A9, respec-
tively, a signal of nearly 11.06 kDa was detected. In a negative
control using a nonspecific antibody no specific signal was
detectable. (Signal labeled by asterisk is still to identify).
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coupled or nonspecific antibody coupled IDM beads were
tryptic digested for analysis of fragment masses. The digested
solutions were spotted on an NP20 array and the size of the
obtained fragments was determined by the PBS II instrument.
In parallel, a theoretical tryptic digestion of known proteins of
the eluates (e.g., the bait, known interaction partners of the
bait, antibody subunits etc.) was carried out using a public
database (Expasy findpept tool; http://us.expasy.org/tolls/
findpept.html). Afterward, peptide fragments derived from
known proteins were eliminated. Database searches (Profound;
http://129.85.19.192/profound_bin/WebProFound.exe) using
retained peptide fragments revealed S100A10 as a possible
candidate. The calculated mass of human S100A10 is 11.072
kDa (www.expasy.ch), and thus slightly higher than the average
mass of about 11.065 kDa found in these experiments (Figure
1).
Immunocapturing of S100A10. For confirmation of the
identity of the interaction partner of S100A8, an immunoassay
was performed using a monoclonal antibody against S100A10.
Hereby, a specific antibody bound on RS100 ProteinChip arrays
captured S100A10 from HaCaT cell extract. The spectra of the
analysis showed a peak corresponding to S100A10. In a control
assay using a nonspecific antibody no proteins specific for
S100A10 were captured (Figure 2).
Co-immunoprecipitation of S100A8/A9 by an anti-S100A10
Antibody. In a co-immunoprecipitation assay, we were able
to precipitate both S100A8 and S100A9 using protein A-agarose
beads with a specific antibody against S100A10 from a crude
extract of HaCat cells (Figure 3, lane 1 and 3, respectively). In
an approach using a nonspecific antibody bound on protein
A-agarose neither S100A8 nor S100A9 was detectable (Figure
3, lane 2 and 4, respectively). As a control the specific antibody
against S100A10 precipitated its antigene (Figure 3, lane 5).
Detection and Identification of a S100A10 Protein Interac-
tion Partner. In the next step, we assessed S100A10 for possible
protein interaction partners. Hereby, we found an interaction
partner possessing a molecular mass of nearly 11.29 kDa using
anti-S100A10 antibody coupled IDM beads compared to non-
specific antibody coupled IDM beads by SELDI-MS (Figure
4A). Database search (profound) of the tryptic digestion frag-
ments of the eluted proteins revealed S100A7 as a good
candidate. For confirmation of this result, an immunocapturing
assay using an anti-S100A7 antibody was carried out. Hereby,
a signal of nearly 11.37 kDa was detectable. This molecular
mass is slightly higher (0.39%) than the calculated mass
(expasy). In the control assay, using a nonspecific antibody no
signal compared to the molecular mass of S100A7 was detect-
able (Figure 4B). In a co-immunoprecipitation approach, both
an anti-S100A10 and an anti-S100A7 antibody were able to
precipitate S100A7 (Figure 4C, lane 1 and 3, respectively). When
we used antibodies that recognize S100A8 or S100A9, no clear
S100A7 signal was detectable (Figure 4C, lane 2 or data not
shown).
Discussion
In the present study, we performed an approach to inves-
tigate protein-protein interactions by ProteinChip technology.
By the appearance of both false positive and negative results
in other in vivo interaction assays we analyzed the endogenous
interacting partners in crude cell extract by mass spectrom-
etry.17 The assay comprises the detection of interaction partners
by SELDI-MS and the identification using immunocapturing
experiments and coprecipitation, respectively. In our knowl-
edge, it is one of the first studies using SELDI-MS to assess
protein interactions.18,19 As a model system we used members
of the S100 Ca2+-binding family. A multitude of protein
interactions is known to be performed by S100 proteins.20 S100
proteins are involved in several human diseases such as
Figure 2. Normalized ProteinChip Arrays spectra of the immu-
nocapturing assay of crude cell extract. S100A10 was captured
from HaCat cell extracts by the corresponding monoclonal
antibody bound on RS100 ProteinChip arrays. The peak at 11.07
kDa representing S100A10 was clearly detectable. In control
assays without the specific antibody no S100A10 signal was
captured.
Figure 3. Co-immunoprecipitation of S100A8/A9 and S100A10. Specific anti-S100A10 antibody or, as negative control, nonspecific
antibody was coupled to protein A-agarose beads and incubated with HaCaT cell extracts. Beads were washed with Co-IP buffer and
bound proteins were subsequently subjected to SDS-PAGE and analyzed by immunoblotting using specific antibodies against S100A8
(lane 1), S100A9 (lane 3), and S100A10 (lane 5), respectively. Co-immunoprecipitation assays using a nonspecific antibody showed no
signal (lanes 2, 4, 6).
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rheumatoid arthritis, acute inflammatory lesions, cardiomy-
opathy, Alzheimer’s disease, and cancer.14,15 Recently, we
showed in a study that S100A8/A9 are less expressed in head
and neck squamous cell carcinoma compared to normal
tissue.13 S100A8 and S100A9 achieve an interaction together and
under physiological conditions, a heterodimer is often exis-
tent.21 Among different protein binding partners S100A8 forms
specific interactions to for example cytochrome b558, p67
(phox), and Rac-2 and initiates so the NADPH oxidase activa-
tion.22,23 As we demonstrated, the interaction between S100A8/
A9 and S100A10 is detectable under in vivo conditions by mass
spectrometry and immunological techniques. It is not clear
whether the single components of the S100A8/A9 complex
alone are able to bind S100A10 or if this interaction requires a
full complex of both. In our knowledge, this study shows for
the first time an interaction between S100A8/A9 and S100A10.
Further studies will be needed to reveal a potential biological
context of this protein interaction. S100A10 forms an interac-
tion with annexin II that results in the formation of a het-
erotetramer.24 This interaction can be inhibited by a protein
kinase C dependent phosphorylation of a specific serine residue
in the annexin II.25 The S100A10/annexin II complex has been
implicated in the structural organization and dynamics of
endosomal membranes and cell membrane cytoarchitecture,
and is as well involved in the formation of adherent junctions.26-28
Surprisingly, we only detected the mentioned interaction
between S100A10 and annexin II when we used an anti-
S100A10 antibody. In the protein-protein interaction assays
carried out with the anti-S100A8 antibody, we detected S100A10
but never annexin II (supplementary Figure 1). Until now, we
have no explanation for this fact. It might be possible that
S100A8 as well as annexin II share a similar binding site to
S100A10, because there are no data available about the biologi-
cal function of S100A10 beyond the complex with annexin II.
The interaction between S100A10 and S100A7 detected by
several proteomic approaches is described in the present study
for the first time. Due to our data, we do assume that S100A8/
A9 is not involved in this mentioned interaction as a bridging
protein, because no S100A7 signal was detectable using specific
anti-S100A8 or anti-S100A9 antibodies in co-immunoprecipi-
tation. The S100A7 Ca2+-binding protein is highly upregulated
in psoriatic epidermis as well as in primary human kerati-
nocytes undergoing abnormal differentiation.29 It is primarily
expressed in breast cancer cells and at very low level in normal
breast epithelial cells.30 Also an overexpression in gastric cancer
is described.31 S100A7 interacts with Jab 1 in ductal carcinoma
in situ (DCIS) of the breast and because of that it may influence
the progression of breast carcinoma.32 Besides this interaction,
an interaction with RanBPM may contribute to breast tumor
progression, as well as interactions in keratinocytes with both
E-FABP and epidermal fatty acid binding protein are de-
scribed.33-35 It seems that several members of the S100 Ca2+-
binding protein family form interactions with each other that
could be involved in different physiological processes. To assess
the biological role of these protein interactions, additional
studies are needed. The identification of further interaction
partners that is still in process may clarify possible biological
functions. In this study, we show a possible proteomic ap-
proach composing ProteinChip technology and immunological
techniques to detect and identify protein-protein interactions.
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Supplementary material 
Supplementary figure 1: Protein-protein interaction assay using specific anti-S100A8 
antibody or anti-S100A10 antibody. Anti-S100A8 antibody or anti-S100A10 antibody were 
bound on IDM beads, incubated with crude HaCaT cell extract and binding partners were 
analysed by SELDI-MS. In the assay using the anti-S100A10 antibody a signal nearly 38,41 
kDa was detectable. This signal was neither detectable using anti-S100A8 antibody nor non-
specific antibody. 
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S100A11 is involved in a variety of intracellular activities such as growth regulation and differentiation. To gain more
insight into the physiological role of endogenously expressed S100A11, we used a proteomic approach to detect and
identify interacting proteins in vivo. Hereby, we were able to detect a specific interaction between S100A11 and Rad54B,
which could be confirmed under in vivo conditions. Rad54B, a DNA-dependent ATPase, is described to be involved in
recombinational repair of DNA damage, including DNA double-strand breaks (DSBs). Treatment with bleomycin, which
induces DSBs, revealed an increase in the degree of colocalization between S100A11 and Rad54B. Furthermore, S100A11/
Rad54B foci are spatially associated with sites of DNA DSB repair. Furthermore, while the expression of p21WAF1/CIP1 was
increased in parallel with DNA damage, its protein level was drastically down-regulated in damaged cells after S100A11
knockdown. Down-regulation of S100A11 by RNA interference also abolished Rad54B targeting to DSBs. Additionally,
S100A11 down-regulated HaCaT cells showed a restricted proliferation capacity and an increase of the apoptotic cell
fraction. These observations suggest that S100A11 targets Rad54B to sites of DNA DSB repair sites and identify a novel
function for S100A11 in p21-based regulation of cell cycle.
INTRODUCTION
Proteins may exist in several complexes in a spatial and
temporal manner to accomplish distinct functions. Analyses
of the interacting partners will provide a strong insight into
the physiological role of a particular factor. Therefore, it is
essential to identify ideally all interacting partners of pro-
teins in vivo to precisely be able to define their biological
function. The investigation of protein complexes of solely
endogenously expressed proteins avoid the tendency to de-
tect false positive protein–protein interactions of examina-
tions performed in vitro. A multitude of proteins are in-
volved in both the detection and the repair of DNA
damages. It is conceivable that some protein complexes in-
volved in these processes are not yet discovered. A severe
form of DNA damage that threaten the integrity of the
genome are DNA double-strand breaks (DSBs). DSBs can
lead to cell cycle arrest or illegitimate DNA rearrangements
that can contribute to cell dysfunction, cell death, or carci-
nogenesis (Hoeijmakers, 2001). Homologous recombination
is a major DNA repair pathway by which DSBs are repaired
(Lettier et al., 2006).
For the identification of specific interacting proteins of
S100A11 (S100C, calgizzarin) we used in the present study a
proteomic approach comprising mass spectrometry and im-
munological techniques. S100A11 belongs to the group of
S100 proteins that are considered as multitasking proteins
involved in several biological processes such as the Ca21
signaling network, cell growth and motility, cell cycle pro-
gression, transcription, and cell differentiation (Schafer and
Heizmann, 1996; Donato, 2001; Eckert et al., 2004). It has
been proposed that the S100 proteins are involved in the
differentiation of specific tissues including epidermis and
that some members of this family are differentially ex-
pressed in normal human skin and melanocytic lesions
(Boni et al., 1997). In several studies, S100A11 was detected
to be up- and down-regulated in different tumors including
melanoma (van Ginkel et al., 1998; Chaurand et al., 2001;
Melle et al., 2006). S100A11 plays a dual role in growth
regulation in human keratinocytes as it is able to mediate a
Ca21-induced growth inhibition as well as it stimulates the
growth by enhancement of the level of EGF family proteins
(Sakaguchi et al., 2003, 2008). During growth inhibition,
S100A11 is specifically phosphorylated by PKCa that is a
prerequisite for binding to nucleolin and transfer into the
nucleus. In the nucleus, a functional cascade activates the
cell cycle modulatory properties of p21WAF1/CIP1 (Sakaguchi
et al., 2004). The activity of p21 is typically induced by p53
and results in an arrest of the cell cycle in G1 through the
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inhibition of CDKs (El-Deiry et al., 1993; Dulic et al., 1994).
This allows repair of possible DNA damages before the next
replication cycle. In cells containing only a mutated form of
p53, alternative induction pathways of the p21 activity oc-
curs, and its expression can be positively regulated through
several p53-independent mechanisms (Gartel and Tyner,
1999; Tsuda et al., 2005; Fang et al., 2007). One of these
induction mechanisms of p21 seems to be mediated by
S100A11 (Sakaguchi et al., 2003). The aim of this study was
to identify endogenously expressed interacting partners of
S100A11 and to investigate their functional interplay in hu-
man cells.
MATERIALS AND METHODS
Cell Culture
The human keratinocyte cell line HaCaT (Boukamp et al., 1988) was cultured
in DMEM supplemented with 10% fetal bovine serum.
For protein–protein interaction experiments cells were grown to 80% con-
fluence and were passaged at a split ratio of 1:4. Cells were harvested at
70–90% confluence and lysed in a buffer containing 100 mM sodium phos-
phate, pH 7.5, 5 mM EDTA, 2 mM MgCl2, 0.1% CHAPS, 500 mM leupeptin,
and 0.1 mM PMSF. After centrifugation (15 min; 15,000 rpm) the supernatant
was immediately used.
Antibodies
Anti-S100A11 rabbit polyclonal antibody (BC001410; Protein Tech Group,
Chicago, IL), anti-Rad54B rabbit polyclonal antibody (Wesoly et al., 2006),
anti-Rad54 mouse mAb (ab11055; Abcam, Cambridge, MA), anti-actin rabbit
polyclonal antibody (A266; Sigma, St. Louis, MO), and normal rabbit IgG
(PeproTech, Rocky Hill, NJ) were used in protein–protein interaction detec-
tion assays as well as in coimmunoprecipitation experiments. Anti-S100A11
chicken polyclonal antibody (ab15612; Abcam), anti-Rad54B rabbit polyclonal
antibody (Wesoly et al., 2006), anti-SC-35 mouse mAb (S4045; Sigma), anti-
Rad54 mouse mAb (ab11055; Abcam), anti-Ku80 mouse mAb (AB-4/N3H10;
Labvision, Fremont, CA), anti-PCNA (proliferating cell nuclear antigen)
mouse mAb (PC 10; Santa Cruz Biotechnology, Santa Cruz, CA), and anti-
gH2AX (Ser139; clone JBW301; Upstate Biotechnology, Lake Placid, NY) were
used in two- or three-color immunofluorescence staining as primary antibod-
ies, which were detected with species-specific secondary antibodies linked to
fluorescein, Cy3 or Cy5 (Dianova, Rodeo, CA).
Protein–Protein Complex Detection Assay
The protein–protein complex detection assay was described elsewhere
(Escher et al., 2007). Briefly, 20 ml of Interaction Discovery Mapping (IDM)
beads (Bio-Rad, Richmond, CA) were incubated with 4 ml protein A (Sigma)
overnight at 4°C. A pellet was generated by centrifugation, and the superna-
tant was discarded. The pellet was washed twice with a buffer containing 50
mM sodium acetate, pH 5.0. Afterward, the beads were incubated in a buffer
containing 0.5 M Tris/HCl, pH 9.0, 0.1% Triton X-100 for 2 h at room
temperature for blocking residual reactive groups. The beads were washed
three times with 13 PBS. Thereafter, a specific antibody against human
S100A11 or normal rabbit IgG as negative control, in 50 mM sodium acetate,
pH 5.0, was applied to the beads and allowed to bind at room temperature for
1 h at 4°C in an end-over-end mixer. Unbound antibody was removed by
washing in 50 mM sodium acetate. Afterward, the beads were washed in 13
PBS, 0.1% Triton X-100 and in 13 PBS and incubated with 250 ml of crude
HaCaT cell extract for 2 h at 4°C in an end-over-end mixer. The unbound
proteins were washed away by sequential washes in PBS, 0.5 M sodium
chloride, 0.05% Triton X-100 in PBS, PBS, and aqua bidest. Bound proteins
were eluated from the IDM beads by 25 ml 50% acetonitrile/0.5% trifluoro-
acetic acid and gently vortexed for 30 min. Five microliters of the eluated
samples were applied to the activated, hydrophobic surface of an H50 Pro-
teinChip Array (Bio-Rad) and dried on air. After washing with 3 ml aqua
bidest, 0.5 ml sinapinic acid (saturated solution in 0.5% TFA/50% acetonitrile)
was applied twice and the array was analyzed in a ProteinChip Reader (series
4000; Bio-Rad) according to an automated data collection protocol by SELDI-
MS. This includes an average of 265 laser shots to each spot with a laser
intensity of 2300 and 3500 nJ, respectively, dependent on the measured region
(low 5 2.5–20 kDa and high 5 20–200 kDa, respectively) and an automatically
adapted detector sensitivity.
Peptide Fingerprint Mapping
Peptide fingerprint mapping was carried out as described elsewhere (Escher
et al., 2007). In brief, the volume of eluated samples was reduced to a
maximum of 10 ml using a speed-vac (ThermoSavant, Fisher Scientific, Pitts-
burgh, PA) and subjected to SDS-PAGE for separation of containing proteins
followed by staining with Simply Blue Safe Stain (Enhanced Coomassie,
Invitrogen, Carlsbad, CA). Specific gel bands were excised, destained, and
dried, followed by rehydration and digestion with 10 ml of a trypsin solution
(0.02 mg/ml; Promega, Madison, WI) at 37°C overnight. The supernatants of
the in-gel digestions were applied directly to NP20 arrays (Bio-Rad). After
addition of the matrix (CHCA), peptide fragment masses were analyzed
using the ProteinChip Reader, series 4000 instrument. A standard protein mix
(all-in-1 peptide standard mix; Bio-Rad), including Arg8-vasopressin (1082.2
Da), somatostatin (1637.9 Da), dynorphin (2147.5 Da), ACTH (2933.5 Da), and
insulin beta-chain (3495.94 Da) was used for calibration. Proteins were iden-
tified using the fragment masses searching in a publicly available database
(http://prowl.rockefeller.edu/prowl-cgi/profound.exe).
Coimmunoprecipitation
The coimmunoprecipitation (coIP) assays were carried out as described
(Escher et al., 2007). Briefly, specific anti-S100A11 or anti-Rad54B antibody,
respectively, or, as negative control, normal rabbit IgG were bound on protein
A-agarose beads. Crude extract (100 ml) from HaCaT cells was incubated with
the antibody loaded beads for 1 h at 4°C. Then the resins were washed three
times with coIP buffer containing 20 mM HEPES/KOH, pH 8.0, 50 mM KCl,
0.1 mM EDTA, and 0.05% CHAPS. Bound proteins were subjected to 10%
SDS-PAGE and detected by immunoblotting.
Immunocytochemistry and Confocal Microscopy
Cells grown on coverslips were fixed by treatment with methanol at 220°C
for 5 min followed by acetone (prechilled to 220°C) for 2 min or by incubation
in 2% paraformaldehyde for 20 min at room temperature followed by acetone
treatment (prechilled to 220°C) for 2 min. Immunofluorescence was per-
formed as previously described (von Mikecz et al., 2000). Samples were
scanned with a Zeiss LSM 510 laser scanning confocal device attached to an
Axioplan 2 microscope using a 633 Plan-Apochromat oil objective (Carl
Zeiss, Jena, Germany). Fluorescein, Cy3, or Cy5 dyes were excited by laser
light at a 488-, 552-, or 633-nm wavelength, respectively. To avoid bleed-
through effects in double- or triple-staining experiments, each dye was
scanned independently using the multitracking function of the LSM 510 U.
Single optical sections were selected either by eye-scanning the sample in
z-axis for optimal fluorescence signals or were taken from stack projections.
Images were electronically merged using the LSM 510 (Carl Zeiss) software
and stored as TIFF files. Figures were assembled from the TIFF files using
Adobe Photoshop software (San Jose, CA).
Colocalization Analysis
Colocalization in image pairs was assessed from scatter plots of midnuclear
confocal images as described previously (von Mikecz et al., 2000) and quan-
tified using the LSM 510 META software (Carl Zeiss). The colocalization
coefficient for two signals was determined according to Manders et al. (1993),
which provides a value range between 0 and 1 (0, no colocalization; 1, all
pixels colocalize). Only signals above a threshold gray value of 100 (of four-bit
images, gray value intensity 0–255) were considered for the colocalization
analysis.
Induction of DNA Damages by Bleomycin
HaCaT cells were seeded at six-well plates on coverslips for 16 h. DMEM
supplemented with 10% fetal calf serum (FCS) was exchanged to fresh DMEM
supplemented with 10% FCS, and cells were treated with 12.5 IU/ml bleo-
mycin (BLM). Medium was exchanged after 30 min, and cells were harvested
after different time points.
Colony-forming Assay
To assess the survival rate of cells after BLM treatment, 104 cells were seeded
into 10-cm Petri dishes. After 24 h, the cells were treated with different
concentrations of the drug and cultured for another 10 d. In control treat-
ments, single cells had formed colonies of ;30 cells after that time. Colonies
were then washed once with PBS, fixed with methanol for 15 min, stained
with Giemsa dye, and finally air-dried. The number of colonies formed was
then determined.
Small Interfering RNA–mediated Knockdown of S100A11
Small interfering RNA (siRNA) duplex oligonucleotides used in this study are
based on the human cDNAs encoding S100A11. S100A11 siRNA as well as a
nonsilencing control siRNA were obtained from QIAGEN GmbH (Hilden,
Germany). The siRNA sequences applied to target S100A11 were 59-GAAC-
UAGCUGCCUUCACAAdTdT-39 (sense) and 59-UUGUGAAGGCAGCUAG-
UUCdTdG-39 (antisense). The siRNA sequences used as negative controls
were 59-UUCUCCGAACGUGUCACGUdTdT-39 (sense) and 59-ACGU-
GACACGUUCGGAGAAdTdT-39 (antisense). HaCaT (2 3 105) were plated
on six-well plates 18 h before transfection and were 50% confluent when
siRNA was added. The amount of siRNA duplexes applied was 1.5 mg/well
for S100A11. Transfection was performed using the amphiphilic delivery
system SAINT-RED (Synvolux Therapeutics B.V., Groningen, The Nether-
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lands) according to the manufacturer’s instructions. Briefly, siRNA was com-
plexed with 15 nmol of transfection reagent and added to the cells for 4 h.
Subsequently, 2 ml of culture medium was added and incubation proceeded
for 72 h.
In colony-forming assays as well as in flow-cytometric experiments, HaCaT
cells were retransfected with the specific S100A11 siRNA or a nonsilencing
control siRNA after 72 h for a stable down-regulation of S100A11.
RESULTS
Identification of Rad54B as an Interacting Protein of
S100A11
S100A11 appears to be involved in a number of cellular
processes. Therefore, it is assumed that S100A11 interacts
with a number of specific proteins to achieve several func-
tions. It is conceivable that some of these interacting partners
are not yet discovered. For this reason, we first performed a
protein–protein complex detection assay to identify interact-
ing proteins of endogenously expressed S100A11 in crude
extracts of HaCaT cells, an immortalized human keratino-
cyte line (Boukamp et al., 1988). This assay was used previ-
ously for the identification of protein complexes involved in
cell cycle regulation as well as of the transcription machin-
ery (Escher et al., 2007; Kob et al., 2007). S100A11-containing
protein complexes were captured by a specific antibody
against S100A11 coupled to IDM beads followed by elution
of the captured proteins and analysis of the complex com-
position using SELDI-MS (Figure 1A). Hereby, a specific
signal possessing an m/z of 11642 was detected that corre-
sponds very well to the relative molecular mass of S100A11.
Beside this signal and other specific peaks, we captured an
additional specific signal of approx. 103 kDa. Signals de-
rived from S100A11 and at 103 kDa were absent in the
negative control using an unspecific antibody. For identifi-
cation of the 103-kDa signal we subjected the eluted proteins
to SDS-PAGE and detected a specific band in the range of
approx. 105 kDa. Thus, we confirmed the presence of a
specific S100A11-interacting protein. The negative control
using rabbit IgG as unspecific antibody did not show a band
at that position (Figure 1B). This specific band was excised
from the gel and subsequently subjected to an in-gel diges-
tion by trypsin and protein identification. As a control, an
empty gel piece underwent the same treatment. The digest
yielded solution was spotted on a NP20 array and the pep-
tide mass fingerprints (PMF) were determined by SELDI-MS.
Database searches (Profound; http://prowl.rockefeller.edu/
prowl-cgi/profound.exe) revealed Rad54B as the best candi-
Figure 1. Detection and identification of the DNA-dependent ATPase Rad54B as a specific interacting protein of S100A11 by a protein–
protein complex detection assay. (A) An anti-S100A11 antibody was coupled on IDM beads and incubated with HaCaT cell extract. Bound
proteins were analyzed by SELDI-MS. Top, spectra of the measured area of m/z 0–120,000; bottom, the enlarged area of m/z 11,000–13,000
or m/z 90,000–120,000, respectively. A number of specific peaks were detectable in the assay using the S100A11 antibody compared with the
experiments using an unspecific antibody. Among a signal of approx. 11.7 kDa, which corresponds well to the relative molecular mass of
S100A11 (labeled by a peak tic and an asterisk in the top panel), a signal at approx. 103.5 kDa was detectable (labeled by peak tic only in the
top panel) using the specific anti-S100A11 antibody. Both signals were absent in the assay using an unspecific antibody. (B) Eluted proteins
from IDM beads were subsequently subjected on an SDS-PAGE for separation and a specific band at ;105 kDa (labeled by an arrow) was
excised and used for a tryptic in-gel digestion. Peptide mass fingerprints obtain from digestion were analyzed by SELDI-MS and used for
a database quest that revealed Rad54B. (C) For an unequivocally confirmation of this result, a coimmunoprecipitation was used. Thereby, a
specific anti-S100A11 antibody was capable to precipitate Rad54B from HaCaT cell extract as shown in an immunoblot (lane 2). coIP using
an unspecific antibody detected no signal (lane 1). In a reciprocal experiment an anti-Rad54B antibody precipitated S100A11 (lane 2, bottom
panel) compared with the negative control (lane 1, bottom panel).
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date with an estimated Z-score of 1.33. Rad54B is a homolog
of the DNA repair and recombination protein RAD54 as well
as a DNA-dependent ATPase and seems to play an unique
role in homologous recombination (Miyagawa et al., 2002;
Tanaka et al., 2002). Additionally and as an internal control
for the detection of protein–protein interactions in vivo us-
ing our approach, we confirmed the well-known protein
interaction between S100A11 and actin (Supplemental Fig-
ure S1; Xhao et al., 2000). The protein complex between
S100A11 and actin occurs temporally and spatially in a
manner different from the complex containing S100A11 and
Rad54B, because S100A11 interacts with actin exclusively in
the cytoplasm.
To confirm the presence of protein complexes containing
S100A11 and Rad54B, coIP experiments were carried out
with crude extracts of HaCaT cells. In line with the previ-
ously determined results, a specific antibody that recognizes
S100A11 was able to coprecipitate Rad54B (Figure 1C, top
panel). In the negative control using an unspecific antibody,
a clear signal corresponding to Rad54B was not detectable.
Additionally, we were able to coprecipitate S100A11 by a
specific anti-Rad54B antibody in a reciprocal coIP (Figure
1C, bottom panel). Hereby, we detected an, albeit slight, but
clearly detectable signal compared with the negative control
using the unspecific antibody. A reason for this only slightly
coprecipitated signal corresponding to S100A11 might be
that solely endogenous proteins were investigated. These
results suggest that endogenous S100A11 and endogenous
Rad54B exist, at least transiently, in one and the same stable
protein complex.
S100A11 and Rad54B Colocalize in the Nucleus of
Human Cells
Afterward, we examined the subcellular localization of
S100A11 and Rad54B by immunofluorescence experiments
on HaCaT cells followed by confocal laser scanning micros-
copy. S100A11 is described to localize predominantly in the
nucleus of gliomablastoma cells and in both, the cytoplasm
and the nucleus of normal human epidermis cells (Inada et
al., 1999; Broome et al., 2003). Rad54B was described to
contribute to homologous recombination-mediated DNA
damage repair (Wesoly et al., 2006). On the basis of this
function, Rad54B is expected to predominantly localize to
the nucleus. Both S100A11 as well as Rad54B were found
concentrated at discrete sites throughout the nucleoplasm of
human HaCaT cells (Figure 2). The colocalization analysis
revealed significant, albeit not complete, overlap between
S100A11 and Rad54B in this foci-like pattern. These obser-
vations are consistent with the finding that S100A11 and
Rad54B reside within the same complexes endogenously
(Figure 1) and suggest that these complexes are enriched in
a dot-like pattern within the nucleoplasm. No or very little
colocalization could be detected between S100A11 or
Rad54B, respectively, and the non-snRNP (small nuclear
ribonucleoproteins) splicing factor SC-35, which concen-
trates in a speckle like pattern (Supplemental Figure S2;
Bisotto et al., 1995). This result indicates that the regions of
overlap between S100A11 and Rad54B are not coincidental
(see also Figure 3B). In contrast to these results, a protein–
protein interaction or colocalization, respectively, between
S100A11 and Rad54 was neither detectable in coIP experi-
ments nor in immunofluorescence experiments (Supplemen-
tal Figure S3).
Complex Formation between S100A11 and Rad54B Is
Stimulated by DNA Damage
It is supposed that Rad54B plays an unique role in homol-
ogous recombination (Miyagawa et al., 2002). Homologous
recombination is one of the major repair pathways when
DSBs occur as a consequence of application of DNA-
damaging agents (Wolner et al., 2003). We therefore deter-
mined whether BLM, a DNA-damaging agent, would influ-
ence the dynamics of the colocalization between S100A11
and Rad54B in HaCaT cells. First, we determined BLM treat-
ment conditions that induced the formation of DSBs but
would not kill the cells (Supplemental Figure 4). H2AX
becomes phosphorylated as one of the first cellular re-
sponses after DNA damage and forms foci at sites of DSBs
(Rogakou et al., 1998). Incubation of U2OS cells with 12.5
IU/ml for 30 min was sufficient to produce 30–40 gH2AX
foci 3 h after drug application. After 24 h the number of
gH2AX foci dropped to control levels, indicating successful
repair of most, if not all, DNA DSBs. A colony-forming assay
of cells treated with increasing amounts of BLM confirmed
that cells treated with 12.5 IU/ml BLM are viable, prolifer-
ate, and had therefore successfully repaired their DSBs. Sim-
ilar results were obtained with both U2OS and HaCaT cells.
Qualitatively, the induction of DNA DSBs in HaCaT cells
by BLM treatment caused an obvious increase of colocaliza-
tion between S100A11 and Rad54B during the repair pro-
cess, as indicated by an increase in yellow signals over time
(Figure 3A). This up-regulation was accompanied by an
increase of coprecipitated Rad54B/S100A11 complexes (Fig-
ure 3B). The degree of colocalization in the nucleus was
therefore quantitated during the complete repair cycle (Fig-
ure 3C). A significant increase in colocalization between
nuclear S100A11 and Rad54B foci was already observed 30
min after BLM application. Colocalization persisted at that
high level for 3 h, after which it decreased again to pretreat-
ment levels (Figure 3C). Interestingly, the kinetics of colo-
calization between S100A11 and Rad54B perfectly mirrored
the kinetics of the DNA DSB repair based on gH2AX foci
formation (compare Figure 3C and Supplemental Figure S4).
The colocalization of S100A11 and Rad54B at sites of DNA
DSB repair appears to be specific and not coincidental be-
cause the degree of colocalization between either S100A11 or
Rad54B with foci containing the functionally unrelated splic-
ing factor SC-35 (speckles) was significantly smaller after
BLM treatment (Figure 3C).
To assess if this protein complex is specifically linked to
DNA damage sites, we next carried out three-color confocal
immunostaining to simultaneously detect S100A11, Rad54B,
Figure 2. Colocalization of S100A11 and
Rad54B in the nucleoplasmic foci. Fixed Ha-
CaT cells were coimmunostained with anti-
S100A11 (green) and anti-Rad54B antibody
(red). The merged image reveals significant
colocalization between S100A11 and Rad54B
in a dot-like pattern throughout the nucleo-
plasm of HaCaT cells. A colocalized S100A11/
Rad54B complex is labeled by an arrow.
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Figure 3. DNA DSBs induce an increase in S100A11/Rad54B foci formation. (A) HaCaT cells were treated with bleomycin (BLM; 12.5 mg
ml21) and analyzed by two-color immunostaining followed by laser scanning microscopy for S100A11 (green) and for Rad54B (red) or
U. Murzik et al.
Molecular Biology of the Cell2930
and gH2AX. We detected focal colocalization of S100A11,
Rad54B, and gH2AX in the nucleoplasm of HaCaT cells
(Figure 3D). This result indicates that a significant subfrac-
tion of S100A11 and Rad54B is colocalized directly at sites of
DNA damage. Many, but not all gH2AX foci colocalized
with S100A11/Rad54B, clearly indicating that at any given
time during the DSB repair process only a subpopulation of
repair sites is associated with S100A11/Rad54B foci. Re-
cently, an induction of p21 after transfer of S100A11 into the
nucleus has been shown (Sakaguchi et al., 2003). Therefore,
we also assessed the dynamics of p21 protein expression in
HaCaT cells treated with BLM (Figure 3E). Hereby, we were
able to detect an increased expression of p21 already 30 min
after BLM treatment by immunoblotting.
Additionally, we asked whether the S100A11/Rad54B
complex is associated both, with other DNA repair processes
such the nonhomologous end joining (NHEJ) or sites of
DNA damage induced by stalled replication forks. To this
end, we assessed the distribution of S100A11, Rad54B, and
Ku80 in HaCaT cells treated with BLM. No or very little
colocalization was detectable between S100A11, Rad54B,
and Ku80 (Supplemental Figure S5). Interestingly, a colocal-
ization between S100A11 and Rad54B was also detectable
here. To assess if the S100A11/Rad54B complex is involved
in repair processes triggered by arrested replication, we
carried out three-color confocal immunostaining to simulta-
neously detect S100A11, Rad54B, and PCNA. This allowed
investigation of HaCaT cells at different cell cycle phases.
Because PCNA redistributes throughout S phase with the
same dynamic pattern of endogenous replication factories,
its localization pattern discriminates between early, mid-
and late replication (Somanathan et al., 2001). Neither in G1
or G2, nor at any stage of S phase did we observe a colocal-
ization between S100A11/Rad54B and PCNA (Supplemen-
tal Figure S6). The S100A11/Rad54B complex was again
detectable, above all in cells that are in G2 phase.
Appearance of Rad54B Foci Is Dependent on the S100A11
Protein Status
To assess whether S100A11 has an effect on Rad54B target-
ing to DNA damage sites, we used RNA interference to
down-regulate S100A11 protein levels. A significant reduc-
tion of the S100A11 protein level was detectable 72 h after
transfection. S100A11 down-regulated HaCaT cells that
were treated for 1 h with BLM to induce DSBs demonstrated
a diffuse nucleoplasmatic localization pattern of Rad54B that
was clearly different from the foci-like pattern in untreated
cells or cells treated with control siRNA (Figure 4A). In
HaCaT cells transfected with control siRNA the colocaliza-
tion between the S100A11/Rad54B foci at sites of DNA
damage repair was indistinguishable from nontreated cells
(compare Figures 4A and 3C). Most strikingly, colocalization
between Rad54B and gH2AX was abolished in cells with
down-regulated S100A11 levels. Thus, the appearance of
Rad54B foci at DSB repair sites depends on the S100A11
protein status and not on the induction of DNA damages by
BLM. Quantitation of the Rad54B nuclear localization pat-
tern in S100A11 down-regulated versus control-treated cells
confirmed the above observations (Figure 4B).
We finally assessed the impact of reduced S100A11 levels
on p21 expression in HaCaT cells by Western blotting. Sur-
prisingly, this analysis revealed a significant reduction in
p21 protein levels when S100A11 expression was down-
regulated by siRNA. This reduction of p21 was independent
of BLM treatment of HaCaT cells (Figure 4C). The level
of Rad54B persisted unaffected by down-regulation of
S100A11. These observations demonstrate that S100A11 is
required for both Rad54B accumulation at sites of DNA DSB
repair and for maintenance of p21 levels during the DNA
damage response.
Depletion of S100A11 Influenced the Proliferation
Capacity of HaCaT Cells
To analyze a possible impairment of DNA repair by abol-
ishing the S100A11–Rad54B interaction, we quantified the
repair of DNA DSBs by immunofluorescence-based detec-
tion of gH2AX foci (Rogakou et al., 1999; Kegel et al.,
2007). HaCaT cells were transfected with a specific
S100A11 siRNA and gH2AX foci appearance was assessed
after 1 or 3 h after BLM treatment. DSB repair by homol-
ogous recombination is nearly completed after 3 h (Chai et
al., 2005). Only minor or no differences in the number of
gH2AX foci were detectable at the different time points in
S100A11 down-regulated HaCaT cells compared with
cells transfected with a control siRNA (Figure 5A). Be-
cause there is a correlation between gH2AX loss and DSB
repair activity at low, but not high, cytotoxic doses (Bou-
quet et al., 2006; Markova et al., 2007), we analyzed the
proliferation capacity of S100A11 down-regulated HaCaT
cells compared with control cells. First, we assessed Ha-
CaT cells transfected with control or S100A11-specific
siRNA in colony-forming assays (Figure 5B). Thereby, we
detected a significant decrease of colony formation of
S100A11 down-regulated HaCaT cells compared with the
control. This decrease of colony formation was even rein-
forced when HaCaT cells were treated with BLM for 30
min. When S100A11 was down-regulated in HaCaT cells,
the proliferation capacity and thus the number of these
cells was limited. Hence, we also investigated if the re-
stricted proliferation capacity of S100A11 down-regulated
cells is reflected in a change of cell cycle transition or
increased apoptosis rate. Flow-cytometric analysis of
S100A11 down-regulated HaCaT cells that were treated
Figure 3 (cont). merged at different time points as indicated. (B)
CoIP of Rad54B by a specific anti-S100A11 antibody from HaCaT
cell extracts. HaCaT cells were treated with BLM for 3 h (lane 2) or
8 h (lane 3) or as a control, cells were untreated (lane 1). As a control
for equal protein loading corresponding actin levels were shown by
immunoblot. (C) Quantification of the increase in colocalization
between S100A11 and Rad54B in HaCaT cells after DNA DSB in-
duction. The colocalization coefficient was determined as described
in Materials and Methods in nuclei of cells treated as described in A.
At least 20 nuclei were analyzed per time point. Data are displayed
as mean values (6SD). The colocalization coefficient was also de-
termined from SC-35/S100A11 and SC-35/Rad54B colocalization
experiments of cells after 3 h of BLM treatment. (D) Examples of
fixed HaCaT cells that were analyzed by three-color immunostain-
ing followed by laser scanning microscopy for S100A11 (green),
Rad54B (blue), and gH2AX (red) at DNA damage sites 1 h after
BLM treatment. The intensities of the immunofluorescences in one
cell derived from the Rad54B signal (blue), the gH2AX signal (red)
and the S100A11 signal (green) are shown in a linescan (left panel;
bottom side of the overlay). In the other example cell (right panel),
multiple colocalizations of S100A11/Rad54B complexes with
gH2AX foci corresponding to DNA damage sites are labeled by
arrows (yellow); Bar, 5 mm. (E) Increased expression of p21 was
already detectable after 30 min (lane 2) in HaCaT cells treated by
BLM. As a control for equal protein loading corresponding actin
levels were shown below. Lane 1, control; lane 2, 0.5 h after BLM
treatment; lane 3, 1 h after BLM treatment; lane 4, 3 h after BLM
treatment; lane 5, 8 h after BLM treatment.
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with BLM revealed a significant increase of the sub-G1/
apoptotic cell fraction compared with BLM treated control
HaCaT cells (Figure 5C). The sub-G1/apoptotic cell frac-
tion of control HaCaT cells was similar to those of wild-
type HaCaT cells without BLM treatment. The simultaneous
down-regulation of p21 in S100A11 down-regulated Ha-
CaT cells might explain an accelerated transition in the
cell cycle from G1 to S phase and thus a smaller G1 cell
fraction compared with cells transfected with the control
siRNA.
Figure 4. S100A11 is required for Rad54B foci formation. (A) HaCaT cells were transfected with specific siRNA for depletion of S100A11
(siRNA S100A11) or, as a control, nonsilencing siRNA (siRNA control), respectively, and treated by BLM for 1 h followed by immunostaining
against S100A11 (green), Rad54B (blue), and gH2AX (red) using specific antibodies. The overlay image (merge) shows that S100A11/Rad54B
foci formation significantly overlaps with sites of DNA damage repair in experiments using cells transfected with control siRNA (bottom
panel). HaCaT cells transfected with specific S100A11 siRNA oligos show a diffuse nucleoplasmatic localization pattern of Rad54B and no
colocalization with gH2AX (top panel). In the image derived from the control experiment, a merged signal with complete overlap between
S100A11, Rad54B and gH2AX is indicated in a linescan (bottom panel). Bar, 5 mm. (B) Quantitation of alterations in the Rad54B nuclear
distribution pattern after S100A11 knockdown. HaCaT cells were treated as in A and the nuclear distribution pattern of Rad54B was assessed
in cells transfected with control siRNA (n 5 70) or oligos specific for S100A11 (n 5 65). (C) Down-regulation of p21 after knockdown of
S100A11. Protein extracts of HaCaT cells transfected with specific S100A11 siRNA (lane 2) or, as a control, nonsilencing siRNA (lane 1),
respectively, as well as HaCaT cells treated as in A (lanes 3 and 4) were subjected to immunoblotting against S100A11, p21, and Rad54B using
specific antibodies. As a control for equal protein loading corresponding actin levels were shown by immunoblot.
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DISCUSSION
In this study we used a proteomic approach comprising
SELDI mass spectrometry and immunological techniques to
identify in vivo interacting partners of S100A11. In this way,
we detected a protein complex between endogenously ex-
pressed S100A11 and Rad54B in the human keratinocyte cell
line HaCaT. A possible functional connection between
S100A11 and Rad54B was further characterized by immu-
nofluorescence experiments followed by confocal micros-
copy. It is believed that this phosphorylation of S100A11
causes dissociation of S100A11 from actin filaments as a
prerequisite for its nuclear translocation (Sakaguchi et al.,
2000). To simulate physiological conditions, we relinquished
at additional Ca21 in our protein–protein interaction detec-
tion approach. Previously, we showed that the detection of
protein interactions of S100 proteins is not dependent on
additional Ca21 (Lehmann et al., 2005). In addition, an in-
crease of the Ca21 concentration may result in an at least
transient destabilization of protein complexes containing
S100 proteins (Rosenberger et al., 2007). The specific
S100A11–Rad54B protein complex formation was further
consistent with our two-color immunofluorescence experi-
ments. Hereby, we detected extensive colocalization be-
tween S100A11 and Rad54B in small and discrete focal sites
throughout the nucleoplasm of several cell lines. Rad54B
plays an unique role in homologous recombination-medi-
ated DNA damage repair and appears in complexes after
replication arrest resulting from stalled replication forks
(Otterlei et al., 2006; Wesoly et al., 2006). Collapsed replica-
tion forks can lead to DSBs that are repaired predominantly
by homologous recombination (Amaudeau et al., 2001). Af-
ter induction of DNA damages one of the first cellular
responses is phosphorylation of H2AX at the sites of DSB
(Rogakou et al., 1998). The subsequent time- and space-
regulated accumulation of specific repair factors appears to
be essential during DSB repair and signaling (Bekker-Jensen
et al., 2006). The accumulation of gH2AX foci has also been
found in both apoptotic and senescent human cells
Figure 5. S100A11 down-regulated HaCaT cells possesses a restricted proliferation capacity. (A) Quantification of DNA DSB repair by
immunofluorescence-based detection of gH2AX foci in HaCaT cells transfected with a specific S100A11 siRNA (white bars) or, as a control,
with a nonsilencing control siRNA (gray bars). Transfected cells were treated with BLM for 30 min and number of gH2AX foci was counted
1 h and 3 h after BLM treatment as well as in untreated cells (control). (B) For analysis of the proliferation capacity of HaCaT cells colony
forming assays were carried out. HaCaT cells were transfected as in A, treated by BLM 72 h after transfection and grown for a further 7 d
(1BLM). As a control, transfected cells grown without BLM treatment (2BLM). For quantification, the colonies in 10 representative areas
(0.5-cm diameter) of Petri dishes with transfected HaCaT cells with (1BLM) or without (2BLM) BLM treatment were counted. M, cells
transfected with specific S100A11 siRNA; u, cells transfected with a nonsilencing control siRNA. (C) Flow-cytometric analysis of cell cycle
phases of HaCaT cells transfected as in A, which were treated by BLM for 30 min. Additionally, the flow-cytometric analysis of wild-type
HaCaT keratinocytes (HaCaT control [-BLM]) without BLM treatment is shown as a control. Percentage (6SD) of cells in cell cycle phases
is displayed in the diagrams.
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(Rogakou et al., 2000; Sedelnikova et al., 2004). Previously, it
was described that gH2AX colocalizes with specific repair
factors, for instance Rad51, at nuclear foci after DNA dam-
age (Paull et al., 2000). From our observations we conclude
that both, Rad54B and S100A11 share this feature with other
DNA repair factors. In this context we propose a novel
function for S100A11 in the DNA double-strand process that
likely involves DNA repair activity and/or signaling.
Rad54B is able to stimulate homologous recombination by
interaction with both Dmc1 and Rad51 (Sehorn et al., 2004;
Wesoly et al., 2006). We show here that formation of the
S100A11–Rad54B protein complex is stimulated by DNA
damage and that the kinetics of complex formation appears
to be directly correlated with the activity of the DSB repair
machinery during successful repair cycles. Moreover, the
focal colocalization pattern of S100A11/Rad54B was exten-
sively, albeit not exclusively, spatially associated with sites
of DSB repair as detected by gH2AX foci formation. The
stimulation of the complex formation between S100A11 and
Rad54B is obviously time dependent, with the highest num-
ber of S100A11–Rad54B complexes after approx. 3 h. These
kinetics are also similar to the temporal stimulation of the
Dmc1 recombinase-mediated DNA strand exchange activity
by Rad54B (Sarai et al., 2006). As reported, after transfer of
S100A11 into the nucleus, an induction of the CDK inhibitor
p21WAF1/CIP1 is initiated (Sakaguchi et al., 2003). In the
present study, we were able to detect elevated p21 protein
levels after treatment of HaCaT cells with BLM. The activa-
tion of p21 must be p53 independent because HaCaT cells
possess only a mutated inactive form of p53 that is not able
to induce p21 (Lehman et al., 1993; Yoon and Smart, 2004). A
Chk2-induced cellular senescence was associated with p21
expression that was also p53-independent (Chen et al., 2005).
The Chk2-induced senescence in HaCaT cells is dependent
on a Chk2-mediated up-regulation of p21 (Aliouat-Denis et
al., 2005). A functional link between p21-mediated cell cycle
regulation and Rad51 is suggested in mammalian cells be-
cause Rad51 expression, Rad51 foci formation, and p21 ex-
pression are interrelated. Furthermore, increase of p21 levels
can be induced by Rad51 overexpression independent of p53
(Raderschall et al., 2002).
As reported here, the S100A11–Rad54B complex occurred
in discrete foci in the nucleoplasm of untreated cells as well
as in cells treated by BLM where this complex was detect-
able directly at sites of DNA damages. This specific pattern
changed completely when S100A11 was down-regulated by
RNA interference. In this case, Rad54B appeared in a more
diffuse nucleoplasmatic localization pattern and, most strik-
ingly, Rad54B targeting to DSBs was abolished. An alter-
ation of the Rad54B distribution pattern from a diffuse lo-
calization pattern to discrete foci representing stalled
replication forks was also observed in HeLa cells treated
with mitomycin (Otterlei et al., 2006) at concentrations that
induce DNA DSBs at such sites (Mogi and Oh, 2006). Our
observations therefore indicate that S100A11 may be re-
quired to dynamically relocate Rad54B to or from sites of
DSBs. We also demonstrated that elimination of Rad54B
from sites of DSB repair after S100A11 depletion caused no
significant differences in the number of gH2AX foci in com-
pare to control cells. These data correlate with a report that
demonstrated very little sensitivity of Rad54B knockout
HCT116 cells to ionizing radiation (IR) and mitomycin C
(MMC) compared with wild-type cells (Miyagawa et al.,
2002). When Rad54B targeting to DSB is abolished, the ho-
molog protein Rad54 might adopt this task in the repair
processes. It was recently shown that Rad54B-deficient mice
ES cells possess only slight sensitivity to IR and MMC and a
more pronounced phenotype in response to MMC in the
additional absence of Rad54 (Wesoly et al., 2006). Interest-
ingly, p21 protein levels were also reduced in repairing cells
when S100A11 was down-regulated. This observation sug-
gests that S100A11, besides its Rad54B targeting function, is
also involved in the regulation of p21 protein levels. In this
context, we report here that S100A11 down-regulation
caused a restriction of the proliferation capacity of HaCaT
keratinocytes. Concurrently, an increase of the apoptotic cell
fraction of S100A11 down-regulated HaCaT cells was detect-
able. This is not surprising as p21 can act, beside its function
in the DNA damage response, as an inhibitor of apoptosis in
a number of systems (Gartel and Tyner, 2002). On the basis
of these observations we speculate that S100A11 provides a
direct link between the repair machinery at DNA DSBs and
the signaling machinery that controls cell cycle progression.
We currently investigate this possible connection.
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Supplemental Figure legends 
Suppl. Figure S1. The result of the database quest (profound) using PMF derived from actin 
detected in a protein-protein complex detection assay using an anti-S100A11 antibody as 
described in Materials and Methods is shown. 
 
Suppl. Figure S2. S100A11 and Rad54B sites do not overlap with SC-35 speckles. 
Colocalization experiments were performed to detect simultaneously the spilicing factor 
compartment (SC-35, red), S100A11 (green), and Rad54B (blue), respectively. Bar: 5 µm. 
 
Suppl. Figure S3. S100A11 and Rad54 do neither interact nor colocalize in the nucleus. (A) In 
coimmunoprecipitation experiments, the specific antibody against S100A11 was not able to 
precipitate Rad54 (lane 3). The specific anti-Rad54 antibody precipitated his antigen (lane 2) 
in a positive control. As a negative control (lane 1), rabbit IgG which was used as an 
unspecific antibody was not able to co-precipitate Rad54 similar to the S100A11 antibody. 
(B) No colocalization between S100A11 and Rad54 was detectable in a co-immunostaining 
with anti-S100A11 (green) and anti-Rad54 (red) antibody in fixed HaCaT cells treated with 
BLM. Bar: 5 µm. 
 
Suppl. Figure S4. Induction of DNA double-strand breaks in U2OS cells by bleomycin 
treatment. (A) U2OS cells were cultured in the presence of 12.5 IU/ml bleomycin for 30 min 
on cover slips. After different time intervals, cells were analyzed for the formation of DNA 
double-strand break repair foci by immunofluorescence detection of !H2AX epitopes. (B) 
Quantitation of !H2AX formation/nucleus over time in U2OS cells treated for 30 min with 
 1
12.5 IU/ml bleomycin. At each time point foci numbers of at least 100 cells were determined. 
(C) Colony forming assay of U2OS cells treated with increasing concentrations of bleomycin. 
 
Suppl. Figure S5. No to very little colocalzation between the S100A11/Rad54B complex and 
Ku80. HaCaT cells were treated with bleomycin (BLM) (12.5 µg ml
-1
) and analyzed by three-
colour immunostaining followed by laser scaning microscopy for S100A11 (green), Rad54B 
(blue), Ku80 (red) or merged as indicated. Bar: 5 µm. 
 
Suppl. Figure S6. No colocalization between the S100A11/Rad54B complex and PCNA in 
different cell cycle phases. HaCaT cells in G1 (a), early S (b), mid S (c), late S (d), or G2 (e), 
respectively, were immunostained against S100A11 (green), Rad54B (blue), and PCNA (red) 
and analyzed by laser scaning microscopy. Bar: 5 µm. 
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 Protein Candidates for search B796FF1A-03C4-6F18B9E5 [94820 sequences searched]  
Rank  Probability Est'd Z Protein Information and Sequence Analyse Tools (T) % pI kDa ®
+1  9.9e-001 1.17 T T gi|15277503|gb|AAH12854.1|  ACTB protein [Homo sapiens]  34 5.6 40.63 ®
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 Details for rank 1 candidate in search B796FF1A-03C4-6F18B9E5 </TD< TR>  
gi|7441428|pir||JC5818 gamma-actin - human 
 Sample ID :   [Pass:0] 
 Measured peptides     : 9 
 Matched peptides      : 5 
 Min. sequence coverage: 33% 
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 3287.254   A  3286.842  0.412   118   146    0   MTQIMFETFNTPAMYVAIQAVLSLYASGR 
                                                   (2)+O@M; 
 
     Murzik et al.  Supplemental Figure S1 
M
u
rz
ik
e
t a
l.
Su
pp
le
m
en
ta
lF
ig
u
re
S2
S1
00
A1
1
R
ad
54
B
a
S1
00
A1
1
SC
-
35
b
R
ad
54
B
SC
-
35
c
!
-
R
ad
54
IP
:
Ig
G
!
-
R
ad
54
!
-
S1
00
A
11
IB
:
1
2
3
A B
M
u
rz
ik
e
t a
l.
S1
00
A
11
R
ad
54
B
R
ad
54
m
er
ge
Su
pp
le
m
en
ta
lF
ig
u
re
S3
R
ad
54
!-H2AX fociper nucleus
tim
e
 
[hr
s]
B
cloningefficiency
Bl
e
o
m
yc
in
[IU
/m
l]
C
A
!-H2AX
0 
hr
s
1 
hr
3 
hr
s
8 
hr
s
24
 
hr
s
Su
pp
le
m
en
ta
l F
ig
u
re
 
S4
M
u
rz
ik
e
t a
l.
S1
00
A
11
R
ad
54
B
K
u
80
m
er
ge
M
u
rz
ik
e
t a
l.
Su
pp
le
m
en
ta
lF
ig
u
re
S5
M
u
rz
ik
e
t a
l.
G
1
a
ea
rly
S
b
m
id
S
c
la
te
S
d
e
G
2
S1
00
A
11
R
ad
54
B
PC
N
A
Su
pp
le
m
en
ta
lF
ig
u
re
S6
